Clinical Development
BKM120
Protocol CBKM120Z2402 / [STUDY_ID_REMOVED]
An open -label phase II study of BKM120 in patients w ith 
relapsed and refractor y diffuse large B -cell l ymphoma, 
mantle cell ly mphoma and follicular ly mphoma
Authors  
Document type Amended Protocol Version
EUDRACT number 2012 -002208 -41
Version number 04 (Clean )
Development phase II
Document status Final
Release date 09-Aug-2016
Property of [COMPANY_001]
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of [COMPANY_001]

[COMPANY_001] Confidential Page 2
Amended Protocol Version 04 ( Clean ) Protocol No. C BKM120Z2402
Table of contents
Table of contents ................................................................................................................. [ADDRESS_736094] of abbreviations ............................................................................................................ 8
Glossary  of terms ............................................................................................................... 10
Amendment 4 (09-Aug-2016) ........................................................................................... 11
Summary  of previous amendments ................................................................................... 13
Protocol summary :
............................................................................................................. [ADDRESS_736095] ................................................................................. 27
1.1.5 The PI 3K/mTOR/Akt pathway  and NHL ............................................. 29
1.2
Introduction to investigational treatment(s) and other study  treatment(s) ............. 32
1.2.1 Overview of BKM120 ........................................................................... 32
2Rationale ............................................................................................................................ 40
2.1 Study  rationale and 
purpose ................................................................................... 40
2.2 Rationale for the stud y design ............................................................................... 41
2.3 Rationale for d ose and regimen selection .............................................................. 41
2.4
Rationale for choice of combination drugs............................................................ 41
2.5 Rationale for choice of comparators drugs ............................................................ 41
3Objectives and endpoints ................................................................................................... 41
4Study  design ................................ ................................ ................................ ...................... 43
4.1 Description of stud y design ................................................................................... 43
4.2 Timing of interim anal yses and design adaptations ............................................... 44
4.3 Definition of completion of the study .................................................................... 44
4.4 Early study termination .......................................................................................... 44
5Population .......................................................................................................................... 45
5.1 Patient population .................................................................................................. 45
5.2 Inclusion criteria .................................................................................................... 45
5.3 Exclusion criteria ................................................................................................... 46
6Treatment ................................ ................................ ................................ ........................... 49
6.1 Study  treatment ...................................................................................................... 49

[COMPANY_001] Confidential Page 3
Amended Protocol Version 04 ( Clean ) Protocol No. C BKM120Z2402
6.1.1 Dosing regimen ..................................................................................... 49
6.1.2 Ancillary  treatments .............................................................................. 50
6.1.3
Rescue medication ................................................................................ 50
6.1.4 Guidelines for continuation of treatment .............................................. 50
6.1.5 Treatment duration ................................................................................ 50
6.2 Dose escalation guidelines ..................................................................................... 50
6.3 Dose modification .................................................................................................. 50
6.3.1 Dose modification and dose delay ........................................................ 50
6.3.2 Treatment interruption and treatment discontinuation .......................... 51
6.4
Concomitant medications ...................................................................................... 61
6.4.1 Permitted concomitant therap y
............................................................. 62
6.4.2 Prohibited concomitant therap y
............................................................ 63
6.5 Patient numbering, treatment assignment or randomization ................................. 65
6.5.1
Patient numbering ................................................................................. 65
6.5.2
Treatment assignment or randomization............................................... 65
6.5.3 Treatment blinding ................................................................................ 65
6.6 Study  drug supply .................................................................................................. 66
6.6.1 Study  drug preparation and dispensation .............................................. 66
6.6.2 Study  drug packaging and labeling ....................................................... 66
6.6.3 Drug supply  and storage ........................................................................ 66
6.6.4 Study  drug compliance and accountabil
ity........................................... 67
6.6.5 Disposal and destruction ....................................................................... 67
7Visit schedule and assessments ......................................................................................... 68
7.1 Study  flow and visit schedule ................................................................................ 68
7.1.1 Molecular p
re-screening ........................................................................ 74
7.1.2 Screening ............................................................................................... 74
7.1.3 Run-in period ........................................................................................ 75
7.1.4 Treatment period ................................................................................... 75
7.1.5
End of treatment visit including study  completion and premature 
withdrawal ............................................................................................. 75
7.1.6 Follow up period ................................................................................... 76
7.2 Assessmen
t types................................................................................................... 78
7.2.1 Efficacy  assessments ............................................................................. 78
7.2.2 Safety  and tolerabili ty assessments ....................................................... 80
88
7.2.4 Other assessments ................................................................................. 90

[COMPANY_001] Confidential Page 4
Amended Protocol Version 04 ( Clean ) Protocol No. C BKM120Z2402
8Safety  monitoring and reporting ................................ ................................ ........................ [ADDRESS_736096] abnormalities ................................................................ 92
8.2 Serious adverse events ........................................................................................... 92
8.2.1
Definitions............................................................................................. 92
8.2.2
Reporting............................................................................................... 93
8.3 Emergency  unblinding of treatment assignment ................................................... 94
8.4 Pregnancies ............................................................................................................ 94
8.5 Warnings and precautions ...................................................................................... 94
8.6 Data Monitoring Committee .................................................................................. 94
8.7 Steering Committee ............................................................................................... 94
9Data collection and management ................................ ................................ ....................... 95
9.1 Data confidentiality ............................................................................................... 95
9.2 Site monitoring ...................................................................................................... 95
9.3
Data collection....................................................................................................... 96
9.4 Database management and quality  control ............................................................ 96
10Statistical methods and data anal ysis................................................................................ 96
10.1 Analy sis sets .......................................................................................................... 97
10.1.1 Full Anal ysis Set ................................................................................... 97
10.1.2 Safety  Set
.............................................................................................. 97
10.1.3 Per Protocol Set ..................................................................................... 97
10.1.4 Dose -
determining anal ysis set............................................................... 97
10.1.5 Pharmacokinetic anal ysis set
................................................................. 97
10.2 Patient demographics/other baseline characteristics ............................................. 98
10.3 Treatments (stud y treatment, con comitant therapi[INVESTIGATOR_014], compliance)
....................... 98
10.4 Primary  objective ................................................................................................... 98
10.4.1 Variable ................................................................................................. 98
10.4.2 Statistical hy pothesis, model, and method of analy sis.......................... 98
10.4.3 Handling of missing values/censoring/discontinuations ....................... 98
10.4.4 Supportive analy ses............................................................................... 99
10.5 Secondary  objectives ............................................................................................. 99
10.5.1 Key secondary  objective(s) ................................................................... 99
10.5.2 Other secondary  efficacy objectives ..................................................... 99
10.5.3 Safety  objectives ................................................................................... 99
10.5.4 Pharmacokinetics ................................................................................ 101

[COMPANY_001] Confidential Page 5
Amended Protocol Version 04 ( Clean ) Protocol No. C BKM120Z2402
101
102
102
102
10.7 Interim anal ysis.................................................................................................... 103
10.8
Sample size calculation........................................................................................ 103
10.9 Power for anal ysis of key secondary  variables
.................................................... 104
11Ethical considerations and administrative procedures .................................................... 104
11.1 Regulatory
 and ethical compliance ...................................................................... 104
11.2 Responsibilities of the investigator and IRB/ IEC/REB ....................................... [ADDRESS_736097] keepi[INVESTIGATOR_79556] ..................... 105
11.7 Confidentiality  of study  documents and patient records ..................................... 106
11.8
Audits and inspections......................................................................................... 106
11.9 Financial disclosures ............................................................................................ 106
12Protocol adherence .......................................................................................................... 106
12.1 Amendments to the protocol ................................................................................ 107
13References (available upon request) ................................................................................ [ADDRESS_736098] of QT prolonging drugs to be used with caution.................... 114
14.5 Appendix 5 - Guideline for efficacy  evaluation in ly mphoma studies (based 
on Cheson response criteria)................................................................................ 116
14.5.1 Introduction ......................................................................................... 116
14.5.2 Definitions and criteria for normalization ........................................... 116
14.5.3 Efficacy  assessments ........................................................................... 117
14.5.4 Efficacy  anal ysis definitions ............................................................... 125
14.5.5 Data handling and programming conventions .................................... 131
14.5.6 References (available upon request )
................................................... 133
14.5.7 Appendices .......................................................................................... 134

[COMPANY_001] Confidential Page 6
Amended Protocol Version 04 ( Clean ) Protocol No. C BKM120Z2402
List of figures
Figure [ADDRESS_736099] frequent AEs (at least 15%) related to study  drug in stud y 
CBKM120X2101 (n=81): ..................................................................... 35
Table 1
-2 Numbers of patients with mood disorders occurred at 100 mg/day  
in ongoing BKM120 studies ................................................................. 37
Table 1
-3 Number of patients with hy pergly cemia occurred at 100 mg/day  in 
ongoing BKM studies ........................................................................... [ADDRESS_736100] of QT prolonging drugs to be used with caution ......................... 114

[COMPANY_001] Confidential Page 7
Amended Protocol Version 04 ( Clean ) Protocol No. C BKM120Z2402
Table 14-5 Radiological status based on SPD calculation for all index lesions ....121
Table 14-6 Radiological response criteria for index extranodal lesions in case 
of CR in index nodal lesions ............................................................... 122
Table 14
-7 Radiological response for index lesions .............................................. 122
Table 14
-8 Response criteria for non -index lesions (nodal, splenic and/or 
hepatic nodules and other extranodal lesions) ................................ ....123
Table 14
-9 Overall radiological response at each assessment ............................... 124
Table 14-10 Censoring reasons ............................................................................... 129
Table 14
-11 Options for event dates used in PFS, TTP, duration of response ........ 130

[COMPANY_001] Confidential Page 8
Amended Protocol Version 04 ( Clean ) Protocol No. C BKM120Z2402
List of abbreviations
AE Adverse Event
ALP Alkaline phosphatase
ALT Alanine aminotransferase/glutamic pyruvic transaminase/GPT
ANC Absolute neutrophil count
AST Aspartate aminotransferase/glutamic oxaloacetic transaminase/GOT
b.i.d. bis in diem/twice a day
BLRM Bayesian Logistic Regression Model
CPK Creatine Phosphokinase
CR Complete Response
CRF Case Report/Record Form; the term CRF can be applied to either EDC or Paper
CRO Contract Research Organization
CSP Clinical study protocol
CSR Clinical study report
CTCAE Common Terminology Criteria for Adverse Events
DILI Drug -induced liver injury
DLBCL Diffuse large B- cell lymphoma
DLT Dose Limiting Toxicity
DS&E Drug Safety and Epi[INVESTIGATOR_111744] -Barr Virus
ECG Electrocardiogram
ECOG Eastern Cooperative Oncology Group
EOT End of Treatment
FAS Full Analysis Set
FL Follicular lymphoma
FPFV First Patient First Visit
FPG Fasting plasma glucose
GABA Gamma amino -butyric acid
GI Gastrointestinal
HbA1c Glycosylated Hemoglobin
HBsAg Hepatitis B surface Antigen
HBV Hepatitis B Virus
HCV Hepatitis C Virus
HER2 Human epi[INVESTIGATOR_3506] 2
Hgb hemoglobin
HIAA Hydroxyindoleacetic acid
HIV Human immunodeficiency virus
HSV Herpes Simplex Virus
i.v. intravenous(ly)
ICH International Conference on Harmonization
IEC Independent Ethics Committee
IgG Immunoglobulin G
IgM Immunoglobulin M
INR International Normalized Ratio
IRB Institutional Review Board

[COMPANY_001] Confidential Page 9
Amended Protocol Version 04 ( Clean ) Protocol No. C BKM120Z2402
IRT Interactive Response Technology that includes Interactive Voice Response System and 
Interactive W eb Response System
LPFV Last Patient First Visit
MAP Master Analysis Plan documents project standards in the statistical meth ods which will be 
used within the individual clinical trial RAP documentation
MCL Mantle cell lymphoma
MTD Maximum Tolerated Dose
mTOR Mammalian target of rapamycin
NHL Non-Hodgkin lymphomas
o.d. omnia die /once a day
ORR Overall response rate
OS Overall Survival
p.o. Per os /by [CONTACT_1966]/orally
PD Progressive Disease
PFS Progression free survival
PHI Protected Health Information
PI3K Phosphatidylinositol -3-Kinase
PPS Per-Protocol Set
PR Partial Response
RAP The Report and Analysis Plan (RAP) is a regulatory document which provides evidence of 
preplanned analyses
SAE Serious Adverse Event
SEC Safety Event Categories
SOP Standard Operating Procedure
TBL Total bilirubin
TLS Tumor lysis syndrome
ULN Upper limit of normal
VAP Validation Analysis Plan

[COMPANY_001] Confidential Page 10
Amended Protocol Version 04 ( Clean ) Protocol No. C BKM120Z2402
Glossary  of terms
Assessment A procedure used to generate data required by [CONTACT_560046] a specific dose and regimen (i.e. 
treatment group) at the same time
Cycles Number and timing or recommended repetitions of therapy are usually 
expressed as number of days (e .g.: q28 days)
Dose level The dose of drug given to the patient (total daily or weekly etc .) 
Enrollment Point/time of patient entry into the study; the point at which informed consent 
must be obtained (i.e. prior to starting any of the procedures described in the 
protocol)
Investigational drug The study treatment whose properties are being tested in the study; this 
definition is consistent with US CFR 21 Section 312.3 and is sy nonymous with 
“investigational new drug.”
Investigational treatment Drug whose properties are being test ed in the study as well as their 
associated placebo and active treatment controls (when applicable). This also 
includes approved drugs used outside of their indication/approved dosage, or 
that are tested in a fixed combination. Investigational treatment generally does 
not include other study treatments administered as concomitant background 
therapy required or allowed by [CONTACT_79583]/dosage
Medication number A unique identifier on the label of each study treatment package which is 
linked to one of the treatment groups of a study
Other study treatment Any drug administered to the patient as part of the required stu dy procedures 
that was not included in the investigational treatment
Patient Number A unique identifying number assigned to each patient /subject /healthy 
volunteer who enrolls in the study
Premature patient withdrawal Point/time when the patient exits from the study prior to the planned 
completion of all study treatment administration and/or assessments; at this 
time all study treatment administration is discontinued and no further 
assessments are planned, unless the patient will be followed for progres sion 
and/or survival
Stage related to study timeline A major subdivision of the study timeline; begins and ends with major study 
milestones such as enrollment, randomization, completion of treatment, etc.
Stage in cancer The extent of a cancer in the body. Staging is usually based on the size of the 
tumor, whether lymph nodes contain cancer, and whether the cancer has 
spread from the original site to other parts of the body
Stop study participation Point/time at which the patient came in for a final evaluation visit or when 
study treatment was discontinued whichever is later
Study treatment Includes any drug or combination of drugs in any study arm administered to 
the patient (subject) as part of the required study procedures, including 
placebo and activ e drug run -ins.
In specific examples, it is important to judge investigational treatment 
component relationship relative to a study treatment combination; study 
treatment in this case refers to the investigational and non -investigational 
treatments in com bination.
Study treatment discontinuation Point/time when patient permanently stops taking study treatment for any 
reason; may or may not also be the point/time of premature patient withdrawal
Treatment group A treatment group defines the dose and regimen or the combination , and may 
consist of 1 or more cohorts. Cohorts are not expanded, new cohorts are 
enrolled.
Variable Identifier used in the data analysis; derived directly or indirectly from data 
collected using specified assessments at specified timepoints

[COMPANY_001] Confidential Page 11
Amended Protocol Version 04 ( Clean ) Protocol No. C BKM120Z2402
Amendment 4 (09-Aug-2016 )
Amendment rationale
The main purpose of this protocol amendment is to:
Provide a c larification on the m easures to follow when a patie nt exhibits sui cidal ide a tion 
regardless of the response to qu estion 9 of thePHQ-9 que sti onna ire(as has been 
described in the BKM120 Investigator’s Brochure Ed. 9.0).
Rationale: Patient Health Questionnaire -9 (PHQ -9) is used to increase the sensitivity  of 
identify ing potential depression and suicidal thoughts via positive response to “question 9”. 
However, it has not been consistently  predictive for suicidal ideation or attempt in BKM120 
trials, as some patients who exhibited suicidal ideation or attempt, reported as an adverse 
event, either had a negative response to question [ADDRESS_736101] been specified in the Investigator’s Brochure Ed. 9.0/dated 29-
Apr-2016.
A prospective suicid a lity assessment inclinicaltrialswith BKM120 is important and is 
facilita tedusing questi on 9 of thePHQ-9 questionnaire. A ti melyinterview with the
patient a fter thequestionnairecompletion is recommend ed. Patien ts with aposit ive response
toquesti on 9 (as indicated by [CONTACT_560047]“1”, “2” or “3” ),o rotherwise exhibitingany suicid al
ideation must immedi atelyinterru pt theBKM120/placebo treatme nt and must be assess ed by
a psychia tris t. This is regardless ofthe response or lack of response to question 9 or total 
PHQ-9 scoreor CTCAE gradin g of the suicidal ideation.
Additional changes
Update to the guidelines for BKM120 admini stration related to food intake
Rationale: A clinical pharmacology  study  [CBKM120C2108] investigating the food effect 
of both a low fat low calorie meal (LFLC) or a high fat, high calorie meal (HFHC) on the 
pharmacokinetics of BKM120 in healthy  volunteers showed that intake of food 
concomitantly  with BKM120 led to a delay ed and reduced Cm ax without a meaningful 
impact on exposure (AUCinf) compared to fasting administration ( BKM120 Investigator’s 
Brochure Ed. 9.0). Based on these findings, BKM120 can be administered with or without 
food and accordingl y the guidelines had been updated.
Update to the section on BKM120 dosing, without regard to food intake:
Removal of the requirement that BKM120/placebo be taken with regard to food intake.
Changes in the section on management and follow -up for mood alteration:
Clarification on measures to be followed (interruption of BKM120 and ps ychiatric 
consultation) for an y patient who presents with suicide ideation of an y grade

[COMPANY_001] Confidential Page 12
Amended Protocol Version 04 ( Clean ) Protocol No. C BKM120Z2402
Changes to the study assessments:
The inclusion of a statement that regardless of grade or respon se to question number [ADDRESS_736102] interrupt 
BKM120 and be referred for a psychiatric consultation.
Adding a statement to require the investigator to assess the patient for suicidal ideation 
regardless of the answer to question [ADDRESS_736103] been changed in the amended protocol:
Section 6.1.1 Dosing regimen: removal of the requirement that BKM120 be t aken with 
regard to food intake
Table 6- 3 Criteria for interruption and re -initiation of BKM120 treatment / Mood 
alteration (depression, anxiety ): for grade [ADDRESS_736104] be referred for a ps ychiatric consultation
Section [IP_ADDRESS].[ADDRESS_736105] interrupt 
BKM120/placebo and be referred for a ps ychiatric consultation regardless of grade or 
respon se to question 9 in the PHQ -9 questionnaire
Section [IP_ADDRESS] GAD- 7 and PHQ - 9 Questionnaires:
Adding a statement that any  patient who presents with suicide ideation must interrupt 
BKM120 and be referred for a ps ychiatric consultation regardless of grade or 
response to question 9 in the PHQ- 9 questionnaire
Adding a statement requiring assessment of suicidal ideation for an y patient who does 
not answer question 9 or the whole PHQ -9.
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation.
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.

[COMPANY_001] Confidential Page 13
Amended Protocol Version 04 ( Clean ) Protocol No. C BKM120Z2402
Summary  of previous amendments
Amendment 3
Amendment rationale
The purpose of this protocol amendment is to provide additional guidance to investigators 
around management of liver toxicities.
Alterations in liver function tests (LFTs) have been commonl y observed in clinical trials with 
BKM120 as an investigational agent. These include mostly transient increases in transaminase 
enzymes (ALT and/or AST), which often occur during the first 6 to 8 weeks of BKM120 
(buparlisib) treatment, and rarely are associated with signs/s ymptoms of impaired liver 
function. Current BKM120 protocols have conservative inclusion criteria for baseline LFTs 
with close monitoring guidelines to be followed during the treatment and stringent dose 
modification/interruption criteria.
In March 2015, a search for potential drug-induced liver injury  (DILI) cases in BKM120 
[COMPANY_001] -sponsored trials using conservati ve biochemical criteria (e.g. AST/AL T >3.0x ULN 
and total bilirubin (TBL) >2.0xUL N at any time during the treatment period, regardless of 
causality ) has been conducted. Upon medical review, most of these occurred in the context of 
disease progression in advanced cancer patients and/or were confounded by [CONTACT_22714]. 
However, six of these DILI candidates were consistent with Hy’s law criteria (e.g. 
AST/AL T >3.0x ULN and TBL >2.0xUL N in the absence of cholestasis and other 
explanatory  causes). Five of these cases were in combination with fulvestrant in study  
CBKM120F2302, and one in combination with the investigational drug LDE225 (sonidegib) 
in study  CLDE225X2114. All patients have recovered upon treatment discontinuation except 
one patient for whom the outcome is not available because the patient refused to return for 
safet y follow -up. Of note, with the exception of the first case reported as Investigator 
notification (IN) back in April 2014, it is unknown at this stage whether the remaining 
patients receive d BKM120 or placebo as the trial remains blinded. Updated liver safet y 
including the identified DILI/Hy ’s law candidates for the randomized, blinded studies 
CBKM120F2302 and CBKM120F2303 were further presented to the Data Monitoring 
Committee (DMC) in April-2015; the DMC noted no change or additional liver safet y 
concerns and recommended continuing the respective studies as planned.
An Aggregated Safet y Finding Report was submitted to Health Authorities and all 
investigators participating in BKM120 studies in May 2015 informing them about the liver 
findings including a brief summary  of the six Hy ’s law cases. In addition, [COMPANY_001] decided to 
update the current liver-related safet y measures in ongoing protocols to enhance patient safety . 
Therefore, the purpos e of this protocol amendment is to provide additional guidance to 
investigators around management of liver toxicities as outlined below.
Changes to the background section:
Update of the clinical background section on liver toxicity  to align with the protoc ol 
amendment rationale.

[COMPANY_001] Confidential Page 14
Amended Protocol Version 04 ( Clean ) Protocol No. C BKM120Z2402
Changes to the exclusion criteria:
Exclusion of patients with an acute viral hepatitis or with a history of chronic or active 
HBV or HCV infection (testing not mandatory )
Changes in the section on management and follow -up for select ed toxicities:
Addition of hepatotoxicity management guidelines
Changes to the visit schedule and assessments:
Clarification of laboratory  parameters collection plan and viral hepatitis testing.
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
The following sections have been changed in the amended protocol:
Section [IP_ADDRESS] Clinical experience: addition of the outcome from a recent medical review for 
the liver toxicity .
Section 
5.3 Exclusion criteria: Addition of exclusion Criteria #24to exclude patients with an 
acute viral hepatitis or a history  of chronic or active HBV or HCV infection.
Section 
6.2 - Table 6-3(Criteria for interruption and re-initiation of BKM120 treatment): 
Clarification of the management of AST or ALT side effects.
Section 
[IP_ADDRESS] (Additional management and follow - up for selected toxicities): New section 
added “Management of hepatotox icity (ALT and/or AST >3.0x UL N and total bilirubin >2.0x 
ULN) in patients receiving BKM120 ” including detailed liver event follow -up assessments 
and close monitoring measures.
Section 7.1 Study  flow and visit schedule -Table 7-1(Visit evaluation schedul e):addition of 
hepatotoxicity  follow -
up testing/procedures.
Section [IP_ADDRESS] (Patient demographics and other baseline characteristics): addition of viral 
hepatitis serology .
Section 
[IP_ADDRESS] (Laboratory  evaluations) and Table 7-4 (Clinical laboratory  parame ters 
collection plan): addition of hepatotoxicity  follow -up testing and procedures (Note: testing not 
mandatory ).
Section 
[IP_ADDRESS].8: New section added “Viral hepatitis serology  and other tests for 
hepatotoxicity  follow -up”.
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.

[COMPANY_001] Confidential Page 15
Amended Protocol Version 04 ( Clean ) Protocol No. C BKM120Z2402
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation.
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.
Amendment [ADDRESS_736106] [Investigator’s 
Brochure version 6], specificall y psychiatric disorders, hypergl ycemia grade 2, skin rash and 
stomatitis (details outlined below).
In addition, a cap of N=28 patients has been added for each cohort to limit over enrollme nt. 
Despi[INVESTIGATOR_560003], rapid enrollment into the DLBCL cohort 
resulted in several additional patients in screening who then ethically  had to be enrolled on 
trial. A similar situation might arise for MCL and FL cohorts. Hence, maximum number of 
patients per cohort will be capped at N = 28 patients, in case of over enrollment. The method 
of statistical analy sis remains the same, knowing that the power and rejection rule may  change 
with the final number of patients enr olled as described in Table 10-1.
Modification in the BKM120 interruption period to recover from an adverse event is extended 
from 21 to 28 days before the patient has to be permanentl y discontinued from study  
treatment. The maximum allowed treatment interruption for BKM120 after which the 
treatment has to be permanently  discontinued will be increased from 21 to 28 days since the 
recovery  to ≤ grade 1 has been reported to take longer for some of the side effects (e.g. skin 
rash, transaminase increase). This will allow sufficient time for recovery, implementation of 
appropriate clinical management and/or external consultation (e.g. involvement of a 
psychiatrist for psychiatric disorders, etc.) should this be needed. Grade [ADDRESS_736107] AEs (irrespective of recovery  time). 
Patients who experience treatment interruptions because of an adverse event will further 
resume treatment with a reduced dose after recovery  in most cases (see specific tables for dose 
adjustment guidelines). In addition, the investigator may decide to discontinue the patient at 
any time if this is in the best interest of the patient.
Moreover , t
o improve clarit y, changes have been implemented to the inclusion/exclusion 
criteria, definition of post-menopausal status, collection of outcomes from pregnant partners 
of male study  participants, as well as editorial changes.

[COMPANY_001] Confidential Page 16
Amended Protocol Version 04 ( Clean ) Protocol No. C BKM120Z2402
Changes to the inclusion/exclusion criteria:
Clarification that inclusion of patients with total bilirubin values below the lower limit of 
normal is allowed as such values are considered not clinically  relevant for the purpose of 
entry  into the study  [inclusion criterion #8].
Patients with active severe personalit y disorders will be excluded to align with changes 
within the program b ased on clinical experience from ongoing BKM trials as reflected in 
the updated information in the current IB version 6.0 issued on 13 -Nov-2013 , and with 
additional feedback from earlier advisory  boards [exclusion criterion #8] .
Postmenopausal status defin ition has been clarified and aligned with the NCCN guidelines 
[National Comprehensive Cancer Network 2012 -www.nccn.com]. Postmenopausal range 
for hormone levels is either serum FSH >40 mIU/mL  and estradiol <20 pg/mL , or 
according to the respective postmen opausal range definition used by  [CONTACT_560048] [exclusion criterion #26].
Changes to the management of psychiatric disorders, hypergl ycemia grade 2, skin rash and 
stomatitis:
To align with changes within the program based on clinical experience f rom ongoing 
BKM trials as reflected in the updated information in the current IB version 6.[ADDRESS_736108] be based on clinical assessment only , according to NCI -CTC 4.03; 
independentl y from patient self -reported mood questionnaires.
Patients with active severe personality disorders will now be excluded, and Section 
6.3.2 ha s been revised to clarify  the dose modification and interruption for mood 
alterations. In addition, specific guidelines for the treatment of study  drug induced 
psychiatric disorders has been added ( Section [IP_ADDRESS].5).
Section [IP_ADDRESS] is revised to clarify  that the grading of ps ychiatric disorders must be 
based on clinical assessment only , according to NCI -CTC 4.03, independently  from 
patient self -reported mood questionnaires .
Section [IP_ADDRESS] is revised to clarify  that patients who answer positivel y to question 9 
of PHQ -9 (suicidal risk) must omit treatment with BKM120 and must be referred for 
psychiatric consultation to mitigate potential suicide risk . Psy chiatric consultation will 
confirm if study drug should be interrupted or permane ntly discontinued. Moreover, 
psychiatric consultation is further required for patients who develop CTC AE g rade 3 
or 4 psy chiatric disorders
Hypergl ycemia is a common side effect of BKM120 treatment. However, there is no 
immediate or subacute safety  
risk f or patients experiencing g rade 2 h yperglycemia. 
Therefore, the management guideline for grade 2 hy pergly cemia has been amended and 
closer aligned with the recently  published NCI task force guidelines on hy pergly cemia and 
metabolic disorders associated with mTOR/PI 3K inhibitors ( Busaidy  et al 2012 ). This will 
better allow installing appropriate anti -glycemic therap y. No change s are made for 
symptomatic, or g rade 3 or 4 hy pergl ycemia, which are still managed conservatively .

[COMPANY_001] Confidential Page 17
Amended Protocol Version 04 ( Clean ) Protocol No. C BKM120Z2402
Skin rash is a common side effect associated with BKM120 treatment which can be severe 
and potentially  lead to treatment interruption or discontinuation. Thus, more conservative 
dose interruption/modification guidelines are instituted for g rade 2 and 3 skin rash.
Stomatitis is occurring in up to 25% of patients receiving BKM120 monotherap y 
[Investigator B rochure version 6 ]. Guidelines are added to support investigators in the 
management of this adverse event.
Update to prohibited con comitant medications:
Wording added in the prohibited concomitant therap y section to clarify the wash -out 
period for prohibited concomitant therapi[INVESTIGATOR_014] (e.g. prohibited concomitant therapy  should be 
stopped at least 5 half -lives or 7 day s before start of stu dy treatment (Cycle 1Day 1).
As of December 11, 2013, [ADDRESS_736109] been enrolled in the study  CBKM120Z2402.
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike throug
h red font for deletions and red underlined for insertions.
Protocol Summary Exclusion criteria: mTOR inhibitors was removed from the first exclusion 
criterion listed. This should have been removed in Amendment 1 when the change was made.
Protocol Summary  Efficacy  Assessments : “Objective response rate” updated to “Overall
response rate”. Overall response rate is the proportion of patients with best overall response of 
CR or PR. This is also referred to as “Objective response rate”. All instances of “objecti ve 
response rate” have been updated to “overall response rate” for consistency .
Protocol Summary  Data analysis: updated to clarify  that maximum number of patients per 
cohort will be capped at N = 28 patients, in case of over enrollment.
Table 3-1: Updated to include definitions of endpoints as per protocol.
Figure 4-1: Note added that maximum number of patients per cohort will be capped at N = 28 
patients, in case of over enrollment.
Section 
5.2: Inclusion # 8 was updated to clarify that calcium levels should be corrected for 
albumin . The lower normal limit constraint for total bilirubin was removed and further 
clarification was provided regarding Gilbert Sy ndrome .
Section 5.2: Exclusion criteria #8: Addition to specify  that patients with active severe 
personality  disorders (defined according to DSM -IV) are not eligible.
Section 5.2: Exclusion criteria #20: Additional examples, including immunocompromised, 
chronic pulmonary  disease including dyspnea at rest or interstitial lung disease, uncontrolled 
hypertension
, have been added for clarification.
Section 5.2 Exclusion criteria #26: Clarification on the definition of postmenopausal status to 
align with NCCN guidelines.
Section [IP_ADDRESS]
:To limit the potential impact of H2 antagonists, in this study  BKM120 will be 
administered at least one hour before or 10 hours after H2 antagonists (or proton pump 
inhibitor, antacid, etc.) administration.

[COMPANY_001] Confidential Page 18
Amended Protocol Version 04 ( Clean ) Protocol No. C BKM120Z2402
Section 6.3.2: Clarifications provided related to additional exams in Table 6-3. Updated
number of day s permitted for 
study  treatment interruption.
Section [IP_ADDRESS]: Criteria for BKM120 dose modification and Table 6 - 2modification
Section [IP_ADDRESS]: Table 6 -3 : Criteria for interruption and re-initiation ofBKM120 treatment. 
Modification for FPG, Mood alteration, Fatigue, Rash and addition of criteria for 
Stomatitis/Oral mucositis.
Section [IP_ADDRESS].3 :Guidelines for the treatment of study  drug induced stomatitis/oral mucositis:
Addition of Section [IP_ADDRESS].5 :Guidelines for the treatment of study  drug induced psychiatric 
disorders.
Addition of Section [IP_ADDRESS].6 : Minor changes in wording on guidelines for the treatment of 
study  drug induced skin toxicity .
Section 6.4.2: Clarified that prohibited concomitant therapy should be stopped at least [ADDRESS_736110] not be used while the patient is on study .
Section 
[IP_ADDRESS], Table 14-3 and Table 14-4 updated to include website 
(http://crediblemeds.org/) for a comprehensive list of agen ts that prolong the QT interval
Section [IP_ADDRESS]: Updated number of day s permitted for study  treatment interruption.
Section 
[IP_ADDRESS]: Updated maximum number of days from tumor assessment to first dose of 
study  drug to be consistent with Visit Schedule. Chan ged from 21 day s to 28 day s.
Section 
[IP_ADDRESS].7: Updated the definition of postmenopausal status to align with NCCN 
guidelines.
Section [IP_ADDRESS]: Description of mood alteration questionnaires and their administration.
Management of mood 
alterations: Toxicity grading table was deleted to add the severit y 
classification table instead. Specification that for patients who indicate a positive response by 
[CONTACT_20683] “1, 2, or 3” to the question number [ADDRESS_736111] be referred for psychiatric consultation. Clarification of severit y 
based on mood questionnaire score Table 7 -5updated.
Section 8.1.1: Updated Death form to EOT/SEC/Survival Information eCRF pages.
Section 
8.4: Included guidelines for the collection of pregnancy  outcomes for the female 
partners of an y males who took study drug in this study.
Section 10 :Updated to clarify  that the maximum number of patients per cohort will capped at 
N = 28 patie nts, in case of over enrollment and removed pharmacokinetic measurements.

[COMPANY_001] Confidential Page 19
Amended Protocol Version 04 ( Clean ) Protocol No. C BKM120Z2402
Section 10.5.2 :Updated to clarify  that duration of response is defined as the time from the 
date of first occurrence of CR or PR to the date of the first documented progressive disease 
(PD) or death due to ly mphoma per Cheson criteria .
Secti on [IP_ADDRESS]: Updated to include safet y anal ysis of mood questionnaires.
Section 
10.8: Updated to include the over enrollment scenario. In addition, a cap of N=28 
patients has been added for each cohort to account for over enrollment. Due to the rapid 
enrol lment into the DLBCL cohort and despi[INVESTIGATOR_560004], the study  
team encountered too many  additional patients already  in screening who could not be declined 
enrollment due to ethical reason. Also similar situation might arise for MCL and FL cohorts. 
Hence, maximum number of patients per cohort will be capped at N = 28 patients, in case of 
over enrollment. The method of statistical analysis remains the same, knowing that the power 
and rejection rule may  change with the final number of pa tients enrolled as described in Table 
10-1.
Table 14
-1:Reference was mentioned twice. Ty po was corrected.
Table 14 -2:First asterisk in footer was removed since it did not correspond to any thing within 
the table.
Section 
14.5.1: Updated to clarify  that Appendix 5consists ofgeneral guidelines some of 
which 
have been modified for this protocol:
Only  patients with measurable disease at baseline are being considered for this study
Randomization is not applicable to the study  since it is a non -randomized trial. All 
responses will be calculated from start of treatment.
If a lesion splits during the study , the sub -lesions will not be measured separatel y. Instead, 
such lesion swhich have split into sub -lesions will be measured as one lesion with all sub -
lesions contributing to the overall SPD.
Central Blinded Review of radiological response will not be used for this study . 
Responses will be assessed by  [CONTACT_737].
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. In addition, if the changes herein affect the Informed Consent, sites are 
required to update a nd submit for approval a revised Informed Consent that takes into account 
the changes described in this amended protocol.
Amendment 1
Amendment rationale
The primary  purpose for amending the protocol is to include monitoring for evidence of tumor 
lysis syndrome during treatment with BKM 120. Tumor lysis syndrome (TLS)may occur 
during treatment for diffuse large B-cell lymphoma ; therefore the protocol and visit schedule 

[COMPANY_001] Confidential Page 20
Amended Protocol Version 04 ( Clean ) Protocol No. C BKM120Z2402
are being amended to include appropriate monitoring for evidence ofTLS during the first [ADDRESS_736112] been modified to provide further information or 
clarification. O ne additional exclusion criterion has been added to exclude patients who are
currentl y receiving warfarin or other coumarin derived anti -coagulant for prophy laxis .
In addition, this amendment includes other administrative corrections and clarifications.
The study  has not y et opened and is not currentl y enrolling pat ients.
Changes to the protocol
Section 4.1: End of treatment visit will occur within 7 days following discontinuation of 
BKM120.
Section 5.2: The upper limit of normal (ULN) associated with International Normalized Ratio 
(INR) has been removed from inclusion criterion #[ADDRESS_736113] isspecified for INR.
Section 5.3
Previous treatment with mTOR inhibitors has been removed from exclusion criterion #1. 
Patient s who have had previous treatment with mTOR inhibitors may  be enrolled.
Exclusion criterion #19 has been clarified to exclude patients receiving increasing or 
chronic treatment (> 5 day s) with corticosteroids or another immunosuppressive agent, as 
chronic administration of corticosteroids (> 5 day s) can induce CYP3A4.
Exclusion crit erion #21 has been updated to exclude patients unable to grant consent.

[COMPANY_001] Confidential Page 21
Amended Protocol Version 04 ( Clean ) Protocol No. C BKM120Z2402
Exclusion criterion #[ADDRESS_736114] 
discontinued strong inhibitors before the start of treat ment
An additional exclusion criterion (#23) has been added to exclude p atients who are
currentl y receiving warfarin or other coumarin derived anti -coagulant, for treatment, 
prophy laxis or otherwise . Therap y with heparin, low molecular weight heparin (L MWH ), 
or fondaparinux is allowed.
The use of hormonal contraception has been removed from the list of acceptable forms of 
effective contraception provided in exclusion criterion #26. Hormonal contraception must 
not be used during BKM treatment as stated in Se ction [IP_ADDRESS] .The criterion has also been 
updated to clarify  that female partners of male study  subjects should use contraception 
through [ADDRESS_736115].
Exclusion criterion #27 has bee nclarified to exclude patients with a know n 
hypersensitivity  to an
y of the excipi[INVESTIGATOR_560005]120 .
Section 6.4: Paclitaxel has been removed as the study involves onl y one treatment (BKM120).
Section [IP_ADDRESS] (Bisphosphonates) has been removed since these are not part of the standard 
management of NHL patients.
Section [IP_ADDRESS]: Allopurinol or rasburicase have been added as p ermitted concomitant therap y. 
Allopurinol and rasburicase may be used at the physician’s discretion in DLBCL patients at 
risk for tumor ly sis sy ndrome.
Section 
6.5.[ADDRESS_736116] No.
Re-screening of patients is only  allowed once per patient.
Section 7.1: Safety  follow -up visit wind ow has been updated to +7 day s.
Section 7.1.5: The window 
for the end of treatment visit has been updated. The end of 
treatment visit and evaluations must occur wit hin 7 day s from treatment discontinuation.
Table 7-1 and Section [IP_ADDRESS].2 :The visit evaluation schedule (Table 7-1) and section have
been revised to include assessments forTLS during the initial [ADDRESS_736117] cy cle in DLBCL patients only.
Section 
[IP_ADDRESS].2 has also been updated to include further details regarding the frequency  of 
laboratory  evaluations.
Section [IP_ADDRESS].7 has been updated to clarify  that only serum pregnancy  testing will be 
performed throughout the study . Urine preg nancy testing is not permitted.
Section [IP_ADDRESS] has been made consi stent with the visit evaluation schedule. The mood 
questionnaires (PHQ -9 and GAD- 7) must be completed at all study  visits. This section has 
also been updated with ad ditional details and clarifications regarding the questionnaires.

[COMPANY_001] Confidential Page 22
Amended Protocol Version 04 ( Clean ) Protocol No. C BKM120Z2402
Section 8.[ADDRESS_736118] been made throughout the protocol.
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Aut horities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. In addition, if the changes herein affect the Informed Consent, sites are 
required to update and submit for approval a revised Informed Consent that takes into account 
the changes described in this amended protocol.

[COMPANY_001] Confidential Page 23
Amended Protocol Version 04 ( Clean ) Protocol No. C BKM120Z2402
Protocol summary :
Protocol number CBKM120Z2402
Title An open -label phase II study of BKM120 in patients with relapsed and refractory 
diffuse large B-cell lymphoma, mantle cell lymphoma and follicular lymphoma
Brief title Study of BKM120 in relapsed and refractory NHL
Sponsor and
Clinical Phase[COMPANY_001]
Phase II
Investigation ty pe Drug
Study  type Interventional
Purpose and rationale The purpose of this study is to explore therapeutic efficacy of BKM120 in three 
selected types of NHL, including DLBCL, MCL and FL, and the safety/tolerability of 
patients.
Inhibitors of the PI3K/mTOR/Akt pathway, including BKM120, may be 
therapeutically effective in NHL patients based on the observations from both pre -
clinical and early phase clinical trials with either selective or non -selective inhibitors 
of the PI3K/mTOR/Akt pathway. As pan class I PI3K inhibitors demonstrate 
evidence of efficacy in solid tumor patients and since there are several p110 
isoforms detected in B cell NHLs, this presents an intriguing opportunity fo r further 
evaluation of BKM120.
Primary  Objective(s) and 
Key Secondary  ObjectiveTo determine the efficacy of BKM120 in patients with relapsed/refractory Non -
Hodgkin Lymphoma in t he three different histological subgroups
Secondary  Objectives To evaluate the safety and tolerability in the three different histological subgroups
To assess progression free survival in the three different histological subgroups
To assess the duration of response in the three different histological subgroups
To assess overall survival in the three different histological subgroups
Study  design This is an open label phase II study in patients with relapsed and refractory Non -
Hodgkin Lymphoma including 3 histological subgroups (cohorts): diffuse large B -
cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and follicular lymphoma 
(FL). The primary eff icacy and safety analysis for each cohort will be performed 
when all patients included in the corresponding cohort experienced progression, 
discontinued early or [ADDRESS_736119] completed the study.
Population Patients with histologically confirmed relapsed or refractory diffuse large B cell 
lymphoma, mantle cell lymphoma and follicular lymphoma.

[COMPANY_001] Confidential Page 24
Amended Protocol Version 04 ( Clean ) Protocol No. C BKM120Z2402
Inclusion criteria 1.Patient has a histologically confirmed diagnosis of mantle cell lymphoma, 
follicular lymphoma, or diffuse large B cell lymphoma.
2.Patient has relapsed or refractory disease and received at least one prior 
therapy
3.Patient with diffuse large B cell lymp homa has received or is ineligible for 
autologous or allogeneic stem cell transplant. This does not apply to patients with 
mantle cell lymphoma and follicular lymphoma .
4.Patient has at least one measurable nodal lesion (≥2 cm) according to Cheson 
criteri a (Cheson et al 2007 ). In case where the patient has no measurable nodal 
lesions ≥ [ADDRESS_736120] one 
measurable extra -nodal lesion.
5.Patient ha s an Eastern Cooperative Oncology Group (ECOG) performance 
status ≤ [ADDRESS_736121] disease (GVHD)
3.Patient has active or history of central n ervous system (CNS) disease
4.Patient has a concurrent malignancy or has a malignancy within 3 years of 
study enrollment (with the exception of adequately treated basal or squamous c ell 
carcinoma or no n-melanomatous skin cancer)
5.Patient has a score ≥ 12 on the PHQ -9 questionnaire.
6.Patient has a GAD -7 mood scale score ≥ 15.
7.Patients with an acute viral hepatitis or a history of chronic or active HBV or 
HCV infection
Investigational and 
reference therapyBKM120
Efficacy  assessments -Overall Response rate (ORR)
-Progression Free Survival (PFS)
-Duration of Response
-Overall Survival (OS)
Safety  assessments - Frequency and severity of adverse events; other safety data as considered 
appropriate
Other assessments
Data analy sis The primary endpoint of the study is Overall Response Rate (ORR) defined the 
proportion of patients with a best overall response of CR or PR according to 
Cheson criteria (Cheson et al 2007). The analysis for each cohort will be based on 
an exact binomial test comparing the ORR to the reference level of 10%. The test 
for each cohort will use a significance level of 5%. A significant test r esult is 
achieved when at least 6 responses are observed among the 22 patients in each 
cohort. Maximum number of patients per cohort will be capped at N = [ADDRESS_736122] 95% 
Clopper -Pearson confidence interval.
Key words PI3K inhibitor, BKM120, Non -Hodgkin lymphoma, diffuse large B -cell lymphoma, 
mantle cell lymphoma, follicular lymphoma

[COMPANY_001] Confidential Page 25
Amended Protocol Version 04 ( Clean ) Protocol No. C BKM120Z2402
1 Background
1.1 Overview of disease pathogenesis, epi[INVESTIGATOR_560006]-Hodgkin lymphomas (NHL) are a heterogeneous group of lymphoproliferative 
malignancies with differing patterns of behavior and responses to treatment (Armitage 1993 ). 
Like Hodgkin ly mphoma, NHL usually  originat es in lymphoid tissues and can spread to other 
organs. NHL, however, is much less predictable than Hodgkin lymphoma and has a far 
greater predilection to d isseminate to extranodal sites.
NHL  represents 4% of all types of cancer. The risk of NHL  during a person’s life time is one 
in 50 people (about 2%). Men have slightl y higher chance sthan women to have NHL 
(American Cancer Society  2012). There are estimated 70,130 new cases of NHL and about 
18,940 deat hs in the [LOCATION_002] in 201 2 (National Cancer Institute 2012). NHL can occur at 
any age and isoften marked by [CONTACT_560049], fever, and weight 
loss. NHL  is now the 5th leading cause of cancer in both men and women. NHL  is a disease 
of aging; for unclear reasons, the incidence of NHL continues to increase. With the increasing 
age of the population, NHL  is an important cause of morbidity  and mortality  in adults.
NHL  can 
be divided into aggressive (fast-growing) and indolent (slow- growing) types, and 
can arise from either B-cells or T-cells. B-cell NHL represents 85% of all NHL , andinclude 
Burkitt lymphoma, chronic lymphocy tic leukemia/small lymphocy tic lymphoma (CLL/SLL), 
diffuse large B -cell lymphoma (DLBCL), follicular ly mphoma (FL), immunoblastic large cell 
lymphoma, precursor B -lymphoblastic l ymphoma, and mantle cell l ymphoma (MCL).
Though considered a curable disease, about 50% of NHL  patients are not cured with availab le 
therap y, and this remains an important cause of morbidity  and mortality  in adults. Novel 
therapi[INVESTIGATOR_560007]. The current 5-year and 10-
year survival rates for lymphoma are 63-67% and 51-55%, respectivel y (American Cancer 
Society  2012).
The diffuse large B
-cell lymphoma, mantle cell lymphoma and follicular lymphoma are 
among of those most commonly  seen NHLs, and are the malignancies targeted in this study .
1.1.1 Overview  of diffuse large B cell ly mphoma
DLBCL comprises more than 30% of all newly  diagnosed NHL  cases. Majority  (over 80%) 
are aggressive lymphomas, and more than half of these patients are older than [ADDRESS_736123] decade and around 
50% of DLBCL patients can be cured with rituximab and chemotherap y. The other 50% of 
DLBCL  patients, especially  the poor risk patients (International Prognostic Index of 3, 4 or 5 
factors), will relapse or progress despi[INVESTIGATOR_040] a good initial response to the front line immuno -
chemotherap y. High-dose chemotherap y with autologous stem -cell transplantation (ASCT) is 
an established treatment option for poor
-prognosis patients who are 65 or younger and 
refractory  to front line therap y. Nevertheless, more than half of these patients will relapse 

[COMPANY_001] Confidential Page 26
Amended Protocol Version 04 ( Clean ) Protocol No. C BKM120Z2402
following ASCT/high dose chemotherap y and die of the disease. The prognosis among 
patients who are not transplant candidates is even more dismal.
Novel drug therapy  with different mechanisms to prolong duration of disease remission in 
poor risk patients and eventually  to improve long term survival among these patients is a 
pressing need.
Single agent everolimus (AFINITOR®, RAD001), an inhibitor of the mammalian target of 
rapam ycin (mTOR) has demonstrated substantial anti-tumor activity  in relapsed aggressive 
NHL  and other t ypes of relapsed or refractory  lymphomas, including MCL , indolent and other 
uncommon ly mphomas.
1.1.2 Overview  of mantle cell ly mphoma
MCL has been classified as a subgroup of aggressive diffuse low grade B cell lymphomas. 
MCL  is a unique subtype of NHL  characteristic with the t(11;14) (q13;q32) balanced 
chromosomal translocation of the cyclin D1 gene (bcl-
1) on chromosome 11 to the 
immunoglobulin heav y chain (IGH) enhancer region on chromosome 14, which results in 
Cyclin D1 over expression and increased cell proliferation of the tumor cells (Witzig et 
al 
2005). With a prevalence of 5% to 6% of all NHL , MCL accounts for up to [ADDRESS_736124] MCL  patients are treated with rituximab 
(Rituxan®/Mabthera®), directed against CD20 (a B lymphocy te specific antigen), in 
combination with different chemot herap y regimens. The initial treatment usually  yields a high 
response rate, however, most patients relapse following initial therapy  and their 
median 
survival is about 1-2 years (Fisher et al 2006). As there is no standard therap y for newl y 
diagnosed or relapsed patients with MCL  and the treatment remains suboptimal, new agents 
are beginning to emerge.
Bortezomib (Velcade®) is an intravenous proteasome inhibitor that was approved in the US in 
2006 for treatment of MCL  in patients with a history  of one prior treatment. The response rate 
to Velcade®therapy  was 33%, including 8% complete responses. The median time to 
progression (TTP) was 6.2 months. With an average follow -
up of 13.4 months, the median 
overall survival (OS) was not reached (Fisher et al 2006). Velcade®has not been approved for 
treatment of MCL  in the EU, however it is approved by [CONTACT_560050].
Data on the efficacy  and safety of temsirolimus (Torisel®, CCI-779), an intravenous mTOR 
inhibitor, as a single agent in patients with relapsed or refractory  MCL have been published 
by (Witzig et al 2005). Thirty -five patients were treated in this study  with temsirolimus 250 
mg intravenously  every  week as a single agent. Patients had previousl y received a median of 3 
prior therapi[INVESTIGATOR_13265] 54% had been refractory  to the last therap y. The overall response rate was 
38% (95% CI: 22% to 56%), with one complete response and 12 partial responses. Median 
time to progression was 6.5 months (95% CI: 2.9 to 8.3 months). The authors concluded that 
single -agent temsirolimus has substantial 
antitumor activity  in relapsed MCL . A similar 

[COMPANY_001] Confidential Page 27
Amended Protocol Version 04 ( Clean ) Protocol No. C BKM120Z2402
response rate of 29% (4 out of 14) has been observed in a phase II trial of 10 mg daily 
everolimus in patients with MCL  (Reeder & Gornet ASH 2007 ). In a multicenter phase II trial 
of single -agent everolimus in patie nts with relapsed or refractory  mantle cell lymphoma, 
complete response (CR) was achieved in two 
patients and partial response (PR) in five 
patients, resulting in an objective response of 20% (95% CI 8-37%) and an additional 17 
patients (49%) achieved disease stabilization (SD) (Renner et al 2012). A large international 
trial (PI[INVESTIGATOR_383078] -1) with everolimus in 
relapsed/refractory  MCL has completed enrollment and 
data are awaited.
1.1.[ADDRESS_736125] patients tend to relapse after treatment with 
shorter intervals of remission in between. In approximately  30% of patients, the disease 
progresses more rapi[INVESTIGATOR_2478] y with transformation into DLBCL and early death. The molecular 
biology  underl ying this phenomenon and the factors associated with the risk of transfo rmation 
are not entirely  known.
The incorporation of effective and well- tolerated monoclonal antibodies, such as rituximab, 
into chemo -immunoth erapeutic strategies provided the first evidence that survival of these 
patients could be prolonged. Arelatively  small pi[INVESTIGATOR_560008] [ADDRESS_736126] FDA approved monoclonal antibody  for the 
treatment of cancer. The combination of rituximab and chemotherapy  (R-Chemo) has resulted 
in greatly  improved response rates, progression free survival and also overall survival, to such 
an extent that R -Chemo is now worldwide the standard induction treatme nt in first line as well 
as for relapsed advanced stage FL.
Nevertheless, FLremains incurable and characterized by [CONTACT_560051]. An increasing number of effective drugs are now being evaluated either 
alone or in combin ations including the chemotherap y drugs bendamustine and bortezomib. 
More targeted agents include monoclonal antibodies and their derivatives such as drug-
antibody  conjugates and small modular immunopharmaceuticals. Other agents inhibit various 
cellular pathway s including those triggered by [CONTACT_941] B-cell receptor, including spleen tyrosine 
kinase (Sy k) and Bruton’s ty rosine kinase, and other intracellular pathway s such as the mTOR, 
Phosphatidy linositol-3- Kinase (PI3K), and apoptosis, and drugs that target the tumor 
microenvironment. This abundance stresses the unremitting need for clinical trials aimed at 
answering the many open questions as to optimal treatment strategies in advanced FL 
(Cheson 2011).
1.1.[ADDRESS_736127]
The phosphatidy linositol -
3-kinase (PI3K) signaling regulates diverse cellular functions, 
including cell proliferation, survival, translational regulation of protein synthesis, glucose 
metabolism, cell migration, and angiogenesis (Katso et al2001). PI3K signaling also serves a 
central role in the pathogenesis of numerous forms of neoplasia. At the structural level, the 
enzy me PI3K is composed of a 110 -kDa catal ytic subunit and an 85 -kDa adaptor subunit. The 

[COMPANY_001] Confidential Page 28
Amended Protocol Version 04 ( Clean ) Protocol No. C BKM120Z2402
PI3K signaling is modulated by [CONTACT_236019], including growth factors (such as EGF, 
IGF-1, and FGF), hormones (such as estrogen and thyroid hormone), integrins, intracellular 
calcium levels, and RAS signaling. PI3K signaling is negatively  regulated at the level of PI P3 
clearance by [CONTACT_236020], such as the phosphatase and tensin homologue 
(PTEN) protein and the inositol 5 -phosphatase -2 (SHI P2) protein.
Constitutive activation of PI3K signaling is known to be a critical step in mediating the 
transforming potential of oncogenes and tumor suppressors and in many  tumor ty pes ( Liuet al 
2009). Resistance to a variety  of therapeutic interventions, including chemotherapy , hormonal 
therap y and anti-HER2 therapi[INVESTIGATOR_014], can also be linke d to constitutive activation of the PI3K 
pathway  (McCubrey et al2006 ). Moreover, preliminary  data suggest that activation of the 
PI3K pathway  may  be a predictor of poor prognostic outcome in many cance rs.
Molecular changes leading to constitutive activation of the PI3K pathway  are diverse and 
include, but are not limited to,
a.Gain -of-function mutations of PI 3K subunits ( PIK3CA encoding the PI 3K cataly tic 
subunit p110α; genes encoding the p85 regulatory  subunit) or oncogenes encoding 
positive regulators of PI3K (e.g., HER2, EGF R, RAS, Src -famil y proteins) or
b.Loss -of-function mutations or epi[INVESTIGATOR_539362] 3K 
signaling (e.g., loss of PTEN expression or function) ( Chow & Baker 2006 ,Cully  et al 
2006)
Together these observations suggest that PI3K pathway  could be a critical
therapeutic target 
for the treatment of p atients with advanced solid malignancies whooften have limited 
therapeutic options beyond institutional standard of care. Hence, the pan-PI3K inhibitor 
BKM120 treatment potentially addresses an unmet medical need in such patients
A schematic representation of these PI3K components is shown in Figure 1 -1.

[COMPANY_001] Confidential Page 29
Amended Protocol Version 04 ( Clean ) Protocol No. C BKM120Z2402
Figure 1-[ADDRESS_736128]
1.1.5 The PI3K /mTOR/A ktpathw ay and NHL
Pre-clinical and early-phase clinical studies support the rationale of inhib iting the PI3K 
pathway  for NHL.
[IP_ADDRESS] Observations from pre- clinical studies
The PI3K pathway  is an intracellular component of the B-cell receptor signaling pathway  that 
regulates the cell cycle and is implicated in the development of many  malignancies, including 
lymphoma, leukemia, and many  solid tumor malignancies. Unregulated activation of Akt has 
been demonstrated in MCL , both in cell lines and in patient samples. Also, PI3K inhibition 
decreased expression of NF-κB and CyclinD1, and induced apoptosis (Rudelius et al2006 ). 
Additionally , overexpression of phosphory lated Akt by [CONTACT_560052] . There was decreased expression of downstream 
targets of Akt and increased apoptosis when these cells were exposed to a PI 3K inhibitor ( Dal 
Col et al2008 ). Akt upregulation is also demonstrated in tissue samples of follicular 
lymphoma (FL) ( Zhaet al 2004 ), while expression of pAKT was observed in 52 -72% primar y 
DLBCL samples, indicating activation of the pathway  in these histological subty pes of NHL. 
Reduction, or loss of PTEN expression was also reported in 76/215 (37%) primary  DLBCL 
samples ( Baohua 
et al 2008, Abubaker et al 2007, Uddin et al 2006).

[COMPANY_001] Confidential Page 30
Amended Protocol Version 04 ( Clean ) Protocol No. C BKM120Z2402
Preclinical data suggests that targeting any of the PI3K/Akt/mTOR components can induce 
tumor cell death in a variet y of lymphoid malignancies. BKM120, the investigational 
compound in this study , is a pan class I oral PI3K inhibitor, including the p110α, β, γ, and δ 
isoforms. It has demonstrated its activity  in lymphoma cell lines, including mantle cell 
lymphoma, w here it resulted in at least a 2-fold down -regulation of the myc -dependent 
proliferation, measured by [CONTACT_306238] ( Walsh et al 2009).
Thepan-PI3K inhibitor, SF1126 exhibited >90% decrease in pAkt and p[COMPANY_004] -3 beta. SF1126 
induced apoptosis in a dose and time dependent manner confirmed by [CONTACT_4133]. 
SF1126 induced G1 cell cycle to suppression of cell proliferation. The cell cycle protein 
cyclin D1, a hallmark of MCL  was significantly  decreased by [CONTACT_67307]1126 demonstrating that 
SF1126 potently  inhibits the constitutively  activated PI3K/mTORC/Akt pathway  in 
aggressive B- cell NHL cell lines with consequent suppressive effects on cell cycle 
progression, cell proliferation and induction of apoptosis in aggressive B-cell NHL 
(Mahadvan et al 2011 ).
CAL -101, a selective inhibitor of the p110δ isoform of PI3K, has shown activit y in vitro 
against B-cell malignancies. Treatment of cell lines from CLL and MCL also demonstrated 
significant reduction in Akt, indicative of inhibition of the pathway . In addition, in FL cell 
lines demonstrating increased pAkt at baseline, there was a concentration- dependent reduction 
in pAkt and the downstream target pS6 when treate d with CAL -101 ( Lannutti et al 2011). 
CAL -101 could disrupt signals from the microenvironment, induce apo
ptosis, and enhance the 
antitumor activity  of everolimus in MCL . The pAkt decrease was associated with growth 
suppression and induction of apoptosis in all MCL cell lines. CAL -101 decreased cyclin D1 
levels in MCL  cell lines ( Meadows et al 2011 ) .
While the p110δ isoform of PI3K is found in B cells, it could become a suitable target for a 
selective PI3K inhibitor (i.e. CAL -101). As additional isoforms such as p110α and p110β are 
also found in B cells, given their association with the B cell receptor signaling pathway , these 
isoforms would potentially be additional targets for B-cell lymphoma therap y. In fact, 
treatment of MCL  cell lines with a selective inhibitor of p110α as well as with a non -selective 
PI3K inhibitor induced tumor cell growth inhibition, while a selective inhibitor of p110δ did 
not (Zhou et al 2010).
[IP_ADDRESS] Observations from early  phase clinical trials
CAL -[ADDRESS_736129] hematologic 
malignancies including relapsed/refractory  CLL or select B-cell NHL. Approximately  [ADDRESS_736130] 4 weeks, consisting of 17 patients with CLL 9 
patie nts with indolent NHL , 10 patients with aggressive NHL and 7 patients with AML . The 
demographic and disease characteristics were 33% female, mean age 65 (60% over age 65), 
49% had refractory  disease and the median number of prior regimens was 5. The median
duration of treatment at data cutoff was 3 cycles (range 1 to 10). Two patients discontinued 
early due to adverse events, one for acute on chronic renal failure and one for abnormal liver 

[COMPANY_001] Confidential Page 31
Amended Protocol Version 04 ( Clean ) Protocol No. C BKM120Z2402
function tests (LFTs). DLTs were observed in [ADDRESS_736131] 
frequent. 41 patients were evaluable for clinical response . At data cutoff, the response rate in 
NHL was 10/18 (56%); all were partial responses (PR). Of the 9 patients with indolent NHL, 
5 patients had PR and 2 patients had stable disease (SD) and remained oil study . Of the 9 
patients with aggressive NHL, 5 patients had PR (all with mantle cell lymphoma) and [ADDRESS_736132] duration of response was 9 months in a 
patient with follicular lymphoma. Enrollment is continuing (Flinn et al 2009). Kahl and 
colleagues reported clinical safet y and activity  in a Phase 1 study  of CAL -101 in patients with 
relapsed or refractory  NHL. 
At data cutoff, the study  had enrolled 55 patients with NHL ; 28 
patients had indolent NHL : FLn=15, small lymphocy tic lymphoma n=6, Waldenstrom's 
macroglobulinemia n=4, marginal zone lymphoma n=3, and 27 had aggressive NHL : MCL 
n=18, DLBCL n=9. Patient characteristics included 69% males (38 vs.17 females); median 
age [range] of 68 [32-82] years, 44% with refractory disease and 56% with relapsed disease.
Symptomatic adverse events were infrequent, usually  low-grade, and not clearl y CAL -101-
related. Grade >= 3 hematological laboratory  abnormalities included neutropenia n= 5 (9%); 
lymphopenia n=3 (5%), and thrombocy topenia n=3 (5%) with uncertain relationship to CAL -
101. Grade >= 3 ALT/AST elevations occurred in 18 (33%) patients with onset 2-8 weeks 
after CAL -
101 initiation and resolution 2- 4 weeks after CAL -101 interruption . Partial 
responses were observed at all dose levels, with respective overall n/N (response rates) in 
evaluable patients of 15/24 (63%) for indolent NHL , 10/16 (62%) for MCL  and 0/9 (0%) for 
DLBCL. Respective response rates, by  [CONTACT_560053] 9/13 (69%) and 6/11
(55%) for indolent NHL and 8/11 (73%) and 2/5 (40%) for MCL. [ADDRESS_736133] had 
response durations of >= 6 months with response durations ranging to >16 months. The 
median [range] duration of response was 3 month s [1 month to 8 months] in MCL  
(Kahl et al 
2010).
SAR245409 (S09) was another potent orallyadministered inhibitor of pan class I PI3K 
isoforms (alpha, beta, gamma, and delta) and mTOR. In a
 Phase I dose expansion cohort 
study , patients with refractory  or relapsed lymphomas were enrolled in a lymphoma -specific 
expansion cohort to receive SAR245409 orally. The duration of each cycle was 28 days. 
Tumor response was assessed every  8 weeks. Sixteen patients with NHL  were enrolled: MCL 
n=6, FL n=5. DLBC L n=2, HD n=1, follicular transformed lymphoma n=1, and anaplastic T-
cell/null cell lymphoma n=1. There were 12 males/4 females with a median age of 69 years 
(range, 20-90). Among 15 patients, 10 (66.7%) had received [ADDRESS_736134] common related adverse events (> 10% of patients) were nausea (25%), diarrhea 
(12.5%), and elevated liver enzymes (ALT 18.8% and AST 18.8%). Drug -related grade >= 3 
ALT elevation occurred during the second cycle in 2 patients (12.5%) and resolved with drug 
discontinuation. This study  is ongoing (Papadopoulos et al 2011 ).
Additionally , pan class I PI3K inhibitors have been evaluated in Phase I trials with several 
demonstrating an acceptable safety  profile while stabilizing the disease, even in patients 
whose disease has been refractory  to multiple lines of treatment ( Bendell et al 2012, Von Hoff 
et al 2011, Chiorean et al 2009).

[COMPANY_001] Confidential Page 32
Amended Protocol Version 04 ( Clean ) Protocol No. C BKM120Z2402
mTOR, a kinase downstream of PI3K, has emerged as important therapeutic target for cancer 
treatment. The mTOR inhibitors, temsirolimus and everolimus, have been extensively  tested 
as single agents and found to have activity  in lymphoma. A phase -II study  of temsirolimus 
(CCI -779) in patients with relapsed mantle cell lymphoma showed a 44% response rate and 
demonstrated clinical activity  in a variet y of NHL subtypes (Smith et al 2010). Similarly , a 
phase -II study  with the oral mTOR inhibitor everolimus has demonstrated activity  in NHL , 
reporting an overall response rate of 30% (range from 30 to 38% depending on NHL types), 
with a median duration of response 5.7 months (Witzig et al 2011 )
.
1.2 Introduction to investigational treatment(s) and other study  
treatment(s)
1.2.1 Overview  of BKM120
NVP -BKM120 (BKM120) is a potent and highl y specific oral pan-class I PI3K inhibitor that 
is a 2,6-dimorpholino pyrimidine derivatives. This compound has been studied extensively  in 
non-clinical models and is currentl y being evaluated in clinical trials.
[IP_ADDRESS] Non
-clinical experience
[IP_ADDRESS].1 Pharmacodynamics
BKM12 0 inhibits wild-type PI3K(IC 50: 35 nM), with at least 50-fold selectivity  towards 
this target compared to other protein kinases as well as against somatic PI3Kactivating 
mutants (H1047R -
, E542K -, and E545K -p110 ), the other three PI3K paralogs as well as the 
direct downstream effector AKT. BKM120 does not inhibit the related kinases ,mTOR ,or 
Vps34, nor does it inhibit other receptors and ion channels profiled (I C50>10 M).
BKM120 demonstrates significant tumor growth inhibition in relevant tumor xenog rafts in 
mice and rats when administered orally, including models of renal cell cancer (RENCA, 786-
0, Caki -1), glioblastoma multiforme (U87MG), prostate cancer (PC3M), lung cancer (A549, 
NCI-H1975), ovarian cancer (A2780), colorectal cancer (HCT116, HCT -
15) and melanoma 
(A2058, A375). In vivo PK/PD 
analy ses of tumor tissues shows a good correlation between 
exposure, PI 3K pathway  blockade (S473P -Akt levels), and anti- tumor activity .
[IP_ADDRESS].2 Nonclinical pharmacokinetics and metabolism
BKM120 showed favorable pharmaco kinetic properties in all animal species tested. The 
absorption of [14C]-BKM120 -related radioactivity  was >84% in the rat. Oral bioavailability  
was high in rats (73%), was complete in dogs, and was moderate in monkey s (42%). The 
estimated steady  state plasma volume of distribution (Vss) was high (3.0-
3.5 L/kg) in all 
species tested, suggesting a wide tissue distribution. BKM120 was found to cross the blood 
brain barrier in rats with a tissue -to-plasma ratio of approximately  2 ([COMPANY_001] internal data). 
BKM12 0 is moderately  bound to plasma protein in all species examined (about 80%).
In vitro metabolism studies using human liver microsomes showed that oxidative phase I 
metabolism of BKM120 was predominantl y mediated by [CONTACT_097]3A4 (estimated fm >0.9). 
Formation of a BKM120 N-glucuronide conjugate (Phase II metabolism) via the UDP -
glucuronosy ltransferase -1 family , polypeptide A4 (UGT1A4) was also observed in human 

[COMPANY_001] Confidential Page 33
Amended Protocol Version 04 ( Clean ) Protocol No. C BKM120Z2402
liver microsomes supplemented with uridine 5'-diphospho -glucuronic acid (UDPGA). 
BKM [ADDRESS_736135] a low potential for covalent binding to protein.
BKM120 was determined to be a weak reversible inhibitor of CYP3A4 (IC50 = 8 µM, Ki = 
13.4 µM unbound) at concentrations reached in the clinic. BKM120 very  weakly inhibited the 
CYP2C family  (2C8, 2C9 and 2C19) with IC50 values ranging from 35-65 μM (34-59 μM 
unbound). BKM120 did not show time-dependent inhibition of CYP450 enzymes. In GLP 
toxicology  studies, BKM120 exposure in terms of AUC0 -24h and Cmax increased in a dose 
proportional manner in rat and dog. Results from the rat ADME study  showed that 
radioactivity  was mainly excreted into the feces. Renal excretion was minor. There was no 
noticeable drug accumulation in dog or male rats after 13 weeks of daily dosing. There was a 
sligh t accumulation in female rat (< 2 fold).
Further information concerning the pharmacokinetic and pharmacod ynamics properties of 
BKM120 may  be found in the [Investigator ’sBrochure ].
[IP_ADDRESS].3 Safety pharmacology and toxicology
Safety  pharmacology  studies in rats revealed no effects on neuronal (behavior) or respi[INVESTIGATOR_13521] y 
functions. Cardiac safety studies, conducted in vitro and in vivo did not indicate a prominent 
electroph ysiological risk. No relevant electroph ysiological effect was seen in dogs. The only 
effect considered relevant was a trend towards an increase in systolic and diastolic blood 
pressure, which was observed in two dog telemetry  studies. In rats and dogs, clinical 
pathology  and histopathology  findings showed quantitative reductions of lymphoid and 
erythroid counts and l ymphoid tissue hy poplasia.
The pancreas was seen to be affected by [CONTACT_540813]120, particularly  in dog s, where 
acinar cell toxicity  was seen in the exocrine part of this organ. At higher doses in the 2-week 
dose-range -finding study inrats, there were histopathological findings in both the endocrine 
as well as the exocrine pancreas.
Male sexual organs and associated tissues were found to be targets of toxicity  in both rats and 
dogs. Changes included minimal to slight germ cell depletio n, formation of spermatic giant 
cells and abnormal spermatids, and cellular debris in epi[INVESTIGATOR_560009]. Testicular toxicit y 
did 
not fully  reverse after the 4-week treatment -free period in rats (highest dose), although a 
clear trend towards recovery  was seen. In individual female rats, minimal to slight cyst 
formation occurred in the Graafian follicles. In dogs, there was no effect on female sexual 
organs.
Glucose homeostasis was affected in various species (mice, rats, dogs), as expected from the 
mode of action of BKM120. However, these effects were minimal in both rats and dogs at the 
doses used in the 4- week studies.
Other safety considerations include:
After up to 2 weeks of treatment with up to 2.5 mg/kg/day  of BKM120, alterations in the 
levels of multiple brain neurotransmitters were seen in rats.
No evidence for a direct DNA interaction was found in an Ames test and two chromosome 
aberration tests in vitro with BKM120. However, evidence of a genotoxic potential with 
BKM120 has been seen in vitro a nd in vivo and is likely  due to an aneugenic effect.

[COMPANY_001] Confidential Page 34
Amended Protocol Version 04 ( Clean ) Protocol No. C BKM120Z2402
No phototoxic potential or any effect on wound healing has been identified with BKM120 
in pre -clinical studies.
In conclusion, the majority  of the observed effects were related to the pharmacological 
activity of BKM120 as an inhibitor of PI3K, such as a potential influence on glucose 
homeostasis and the risk of increased blood pressure.
Please refer to the [Investigator’s Brochure ]for additional information on the preclinical 
testing of BKM120.
[IP_ADDRESS] Clinical experience
As of September 2011, a total of 251 patients were enrolled into eight [COMPANY_001] sponsored 
clinical studies of BKM120 for oncology  indications other than NHL :
Phase I single agent studies [CBKM120X2101] (First in man dose e scalation in solid 
tumors) and [CBKM120X1101] (Japanese dose escalation in solid tumors)
Phase II single agent studies [CBKM120C2201] (endometrial cancer) and 
[CBKM120D2201] (non-small cell lung cancer)
Phase I combination studies [CBKM120B2101] (BKM120 plus [COMPANY_004]1120212), 
[CBKM120X2107] (BKM120 plus trastuzumab), [CBEZ235A2118] (BKM120 plus 
paclitaxel), and [CMEK 162X2101] (BKM120 plus MEK162).
[IP_ADDRESS].1 Human safety and tolerability data
Study  recruitment in study  [CBKM120X2101] has been completed with forty (40) patients 
included in the dose escalation phase at 6 dose levels (all once daily ) (12.5 mg (1 patient); 25 
mg (2), 50 mg (5), 80 mg (11), 100 mg (17), 150 mg (4)) (Bendell et al 2012 ). Dose limiti ng 
toxicities were hy pergl ycemia, skin rash, epi[INVESTIGATOR_50684], mood disorder, joint pain. The MTD 
for BKM120 given as single agent, once daily was established at 100 mg/day . Forty
-three 
additional patients were treated in the expansion cohort at 100 mg/day.At the cut-off date of 
4-Jul- 2011 patient characteristics of 82 patients analyzed were as follows: median age 55 
years (range 30–78); ECOG performance status 0/1/2 for 35/46/1 patients, respectivel y. The 
safet y experience for this single agent trial of BK M120 is described in Table 1 -
1.

[COMPANY_001] Confidential Page 35
Amended Protocol Version 04 ( Clean ) Protocol No. C BKM120Z2402
Table 1-[ADDRESS_736136] frequent A Es (at least 15%) related to study  drug in study 
CBKM120X2101 ( n=81):
Event All grades Grade 3/4
Fatigue/asthenia 31(38.3%) 3 (3.7%)
Decreased appetite 24 (29.6%) -
Diarrhea 24 (29.6%) 3 (3.7%)
Hyperglycemia 24 (29.6%) 4 (4.9%)
Nausea 24 (29.6%) -
Rash 22 (27.2%) 4 (4.9%)
Mood altered/emotio nal disorder/affective disorder 17 (21.0%) 4 (4.9%)
Transaminases increased 16 (19.8%) 9 (11.1%)
Anxiety 14 (17.3%) 1 (1.2%)
Depression 14 (17.3%) 1 (1.2%)
A second single agent trial, [CBKM120X1101] was a phase I dose escalation study  in 
Japanese patients with advanced solid tumors with dose levels ranging from 25 to 100 mg/day 
(Doi et al 2011 ). Enrolment of 15 patients has been completed, includi ng 9 patients at 100 
mg/day . One DLT (G4 hepatic function abnormal) was observed in the 100 mg/day  group. 
The most common G3 or G4adverse events occurring in at least 2 patients were hepatic 
function abnormal in 6 patients including transaminase increase in 2 patients, G3 anemia in 2 
patients, hypokalemia in 2 patients. The recommended phase 2 dose (RP2D) for Japanese has 
been determined at 100 mg/day , asin the western population.
BKM120 in combination with trastu
zumab is currentl y investigated in a phase Ib/II 
[CBKM120X2107] study  in patients with HER2 -positive MBC who acquired trastuzumab 
resistance. The phase Ib part of the study  has been presented (Saura et al2011). In this study  
trastuzumab is given at fixed dose of 2 mg/kg/week (with a 4 mg/kg/week loading dose). In 
the dose 
escalation phase, [ADDRESS_736137] been enrolled at the cut-off date of 
September 30th, 2011: 5 patients at 50 mg/day  and 12 patients at 100 mg/day . The 
recommended phase 2 dose for BKM120 was declared at 100 mg/day . The median age was 47 
years (range 28 - 70). Most of the patients have been heavily  treated (range of prior 
chemotherap y lines 1-8). With the completion of escalati on phase, BKM120 in combination 
with trastuzumab has shown an acceptable safety  profile. Grade 3 adverse events reported 
with a suspected relationship to BKM120 were asthenia, ALT increase, hypersensitivity 
hypergly cemia, mood altered, affective disorder, photosensitivity  reaction and rash in 1-2 
patients each. No drug related G4 toxicity  has been observed so far. The trial is currently 
recruiting the phase II part.
Details on liver toxicity , mood alterations, pneumonitis and hypergl ycemia as side effects of 
BKM120 are presented below.
Please refer to [BKM120 Investigator’s Brochure ]for more detailed information on specifics 
of clinical safety  and tolerability  of BKM120.

[COMPANY_001] Confidential Page 36
Amended Protocol Version 04 ( Clean ) Protocol No. C BKM120Z2402
Liver Toxicity
Approximately  25 to 45% of patients treated with single agent BKM120 reported liver 
toxicity  (all grades, regardless of study  drug relationship, 100 mg/d dose) based on a search of 
multiple MedDRA event terms (e.g. SMQ preferred terms). The incidence of grade 3 and 4 
events was approximately  10 to 30%. Liver function test (LFT ) alterations observed during 
ongoing and completed studies have been mostl y transaminase enzy me increases (ALT and/or 
AST). Data suggest a slightl y higher rate of grade 3 and 4 liver enz yme elevations in Japanese 
patients (44%) in the [CBKM120X1101] study , however, the number of patients treated at 
100 mg in this study  was limited (n=9). Transaminase elevations typi[INVESTIGATOR_560010] 6 to 8 weeks of treatment start.
Although transaminase increases are relativel y common, only a few of the patients had other 
simultaneous observations related to impaired liver function (e.g. bilirubin increase or clinical 
symptoms).
Based on these findings, conservative inclusion criteria and guidelines to monitor and follow 
patients with LFT alterations (including dose and schedule modifications) have been 
implemented. Please refer to the respective inclusion/exclusion criteria and Section 
5in this 
protocol for more detailed guidelines.
A recent liver safet y review across [COMPANY_001] -sponsored trials with BKM120 identified several 
potentially  drug-induced liver toxicity  (DILI) cases (e.g. AST/ALT >3.[ADDRESS_736138] and 
TBL >2.[ADDRESS_736139] of these cases occurred in the context of disease progression in terminally  ill, 
advanced cancer patients and/or were confounded by  [CONTACT_22714]. However, six of these DILI 
candidates were consistent with Hy’s law criteria (e.g. AST/ALT >3.0x ULN and 
TBL >2.0xULN in the absence of cholestasis and other explanatory  causes) with probable 
causal relationship to study  treatment. Five of these cases were enrolled in study  
[CBKM120F2302 ]in combination with fulvestrant, and one in combination w ith the 
investigational drug LDE225 (sonidegib). All patients have recovered upon treatment 
discontinuation except one patient for whom no data is available since the patient refused to 
return for safet y follow -up.
Mood alteration
Recently , a number of pub lications demonstrated that the modulation of AKT/[COMPANY_004]3 signaling 
pathway  by [CONTACT_560054] ( Beaulieu et al 2009). 
Preclinical studies conducted in rats to investigate the effect of BKM120 on different 
neurotransmitters have shown that repeated administration of BKM120 resulted in an 
enhanced decrease in glutamate, dopamine, serotonin and epi[INVESTIGATOR_560011].
Revers ible mild to moderate mood disorders observed at 100 mg/day , regardless of study  drug 
relationship, in ongoing BKM120 studies are summarized in Table 1
-2.

[COMPANY_001] Confidential Page 37
Amended Protocol Version 04 ( Clean ) Protocol No. C BKM120Z2402
Table 1-2 Numbers of patients with mood disorders occurred at 100 mg/day  in 
ongoing BKM120 studies
Study  Number
(N= patient treated with 100 mg/d BKM120)All grades Grade3/4
CBKM120X2101 (N = 55) 11 (20%) 2 (3%)
CBKM120X1101 (N = 9) 4 ( 44%) 0 (0%)
CBKM120C2201 (N = 50) 6 (12%) 0 (0%)
CBKM120X2107 (N = 12) 7 (58%) 2 (16.7%)
CBEZ235A2118 (N = 6, BKM120 treated only) 0 ( 0 %) 0 ( 0%)
These adverse events are currentl y under investigation. Nevertheless, until a more complete 
understanding of this AE is compi[INVESTIGATOR_560012], protocol guidelines 
disqualify  patients with an active and/or history of major psychiatric disorder. In addition, 
throughout the trial patients must be closely  monitored using self-rating questionnaires (i.e. 
PHQ -9 and GAD -7), when required a psy chiatrist should be consulted and the use of standard 
available medication should be considered as per investigator’s discretion. Detailed 
instructions are provided in Section 7.
Across the ongoing studies of BKM120, 4 patients experienced 
other psychiatric toxicities 
related to BKM120: confusional state in 3 patients (grade 3 in 1 patient) and mental status 
change in 1 patient (grade 3). With regards to the confusional state, in one case it has been 
considered as a symptom related to mood disorders, cholangitis and brain metastases, and in 
the remaining two cases, the confusional state occurred in a context of infection and 
gastroin testinal disorders. In two out of the three cases, the event improved/resolved after 
study  drug interruption. Further information is being collecte d for the latest reported case.
Lung Toxicity /Pneumonitis
Lung changes compatible with pneumonitis have not been observed in the preclinical setting. 
Among the current studies, lung toxicity  has been observed in 2 
patients and reported as 
pneumonitis, including a fatal outcome reported in one patient in a complex clinical context, 
combining progression of lung le sions and aspergillosis infection. The currently  available data 
do not enable a clear assessment about the causal relationship of pneumonitis with BKM120 
treatment. Newly  appearing or significant changes in pulmonary  symptoms (which cannot be 
explained by [CONTACT_560055]), should be carefully  followed with appropriate 
management as per institutional guidelines and the guidelines provided in the protocol.
Hyperglycemia events
The PI3K/Akt pathway  plays a significant role in regulating glucose metabolism, particularly 
by [CONTACT_560056]. Therefore, hypergly cemia 
is considered as an “on target” effect of BKM120. Regular monitoring ofinsulin C-peptide is 
implemented in BKM120 protocols to evaluate this pharmacod ynamics effect. Transient 
increases of plasma glucose levels have been reported commonly  in patients treated with 
BKM120. Hypergly cemia observed at 100 mg/day, regardless of study drug relationship, in 
ongoing BKM120 studies are summarized in Table 1 -3.

[COMPANY_001] Confidential Page 38
Amended Protocol Version 04 ( Clean ) Protocol No. C BKM120Z2402
Table 1-3 Number of patients with hy perglyce mia occurred at 100 mg/day  in 
ongoing BKM studies
Study  Number
(N= patient treated with 100 mg/d BKM120)All grades Grade3/4
CBKM120X2101 (N = 55) 17 (30.9%) 2 (3.6%)
CBKM120X1101 (N = 9) 2 (22.2%) 1 (11.1%)
CBKM120C2201 (N = 50) 31 (62.0%) 12 (24.0%)
CBKM120X2107 (N = 12) 4 (33.3%) 2 (16.7%)
CBEZ235A2118 (N = 6, BKM120 treated only) 2 (33.3%) 1 (16.7%)
The highest rate of hypergly cemia (62.0%) was reported in [CBKM120C2201] , a phase II 
study  conducted in patients with advanced endometrial carcinoma, as this was the only study 
among those listed allowing the enrollment of patients with controlled diabetes mellitus. 
However, so far, there were only two patients that experienced a grade [ADDRESS_736140] dose level (150mg/day ) in [CBKM120X2101] study .
Detailed guidelines to monitor and manage patients who develop hypergly cemia are provided 
in Table 6-3. Specifically , with regards to appropriate concomitant medic ation, considering 
that in vitro studies have shown that BKM120 may inhibit insulin -stimulated glucose uptake, 
the first recommended approach is to use oral anti-diabetics (e.g. metformin) who increases 
muscle and fat glucose uptake. The addition of insuli n can be considered based on the 
guidelines of American Diabetes Association included as reference i n the current protocol.
[IP_ADDRESS].[ADDRESS_736141]-in-human trial [CBKM120X2101]. BKM120 was administered as a 
capsule (doses ranging between 12.5 and 150 mg) and full pharmacokinetic profiles were 
collected on Day  1, Day  8 and Day  28 of C ycle 1.
BKM120 was rapi[INVESTIGATOR_2478] y absorbed, with the 
median time to reach the peak plasma concentration 
(Tmax) ranging from 1.0 to 1.75 hours following administration. Tmax was independent of 
dose and was not altered after multiple oral doses. Variability  in systemic drug exposure was 
moderate at all dose levels. At 100 mg the variability  in systemic drug exposure and Cmax 
(CV %) at stead y-state was moderate, about 36% and 25%, respectivel y.
During once daily dosing, plasma BKM120 concentrations were found to accumulate in 
reaching steady -state. Afte r one week of oral daily  dosing (day  8), both Cmax and AUC0 -24h 
were approximately  3-fold higher than after a single dose (day 1). The mean accumulation 
ratio (Racc) of BKM120 at 100 mg was 2.7 and 3.3 on day s 8 and 28, respectivel y, indicating 
the absence of significant drug accumulation after day  8.
The decay  in BKM120 plasma concentration over time was bi-exponential, with an apparent 
long terminal half-life. The mean T1/2,acc (effective half-life, obtained from drug 
accumulation) calculated from exposur e data at day 28 ranged between 38 and 49 hours 
across all dose levels. T1/2,acc was found to be independent of dose. Based on the effective 
half-life, stead y state BKM120 plasma levels can be expected to be reached after 1 week of 
daily  dosing.

[COMPANY_001] Confidential Page 39
Amended Protocol Version 04 ( Clean ) Protocol No. C BKM120Z2402
Furthermor e the preliminary  PK data within the Japanese population [CBKM120X1101]
show no significant differences in Cmax or AUC0 -24h with the Caucasian population 
[CBKM120X2101] . A preliminary  population PK analy sis, including data from studies 
[CBKM120X2101] and [ CBKM120X1101] confirmed those findings ([COMPANY_001] internal data).
[IP_ADDRESS].3 Clinical efficacy data
BKM120 has not been tested in patient swith NHL to date. The following information comes 
from the [COMPANY_001] sponsored clinical trials for soli d tumors.
Sixty  six patient s were evaluable for response in study  [CBKM120X2101] where all patients 
in the expansion cohort were required to have mutated and/or amplified PIK3CA and/or 
mutated PTEN or null/low PTEN protein expression: partial tumor responses (PR) were 
observed in [ADDRESS_736142] cancer and the other 2 not confirmed ([ADDRESS_736143] cancer 
and 1 patient with parotid carcinoma) ( Graña et al 2011).
The first 
patient was a  with poorly  differentiated ductal metastatic breast 
cancer assessed as triple negative (ER-, PgR-, HER2- ), PI3KCA wild type, PTEN IHC 
positive. Since  received many previous anticancer agents (cyclophosphamide, 
doxorubicin, gemcitabine, docetaxel, paclitaxel, vinorelbine, capecitabine, etoposide, 
anastrazole). As progressive disease developed (bulky  lymph node involvement and local 
breast relapse),  was enrolled  in the Phase I study  of BKM120 in the 
100mg/day  cohort. A metabolic response (
 decrease in SUV) was observed after [ADDRESS_736144] partial response (  tumor shrinkage) after [ADDRESS_736145] cancer, assessed as ER positive, HER2 negative, PI3KCA mutated (E545K & H1047Y), 
PTEN I HC positive. 
 had been previousl y treated with several antineoplastic agents. When 
 received BKM120 at 100 mg/day  ,  had measurable metastases in the 
brain, lung and liver. At the second radiological assessment after receiving 4cycles of 
BKM120 treatment, a  reduction of the sum of the lesions was recorded. The TTP for this 
patient was [ADDRESS_736146] patient was a  with grade 4 parotid gland ductal carcinoma, 
PI3KCA wild ty pe, PTEN IHC positive . had been previousl y treated with doxorubicin and 
adriam ycin. After disease progression was observed on this regimen  was enrolled in the 
100mg/day  cohort  in the [CBKM120X2101] study . At the first radiological 
assessment after receiving 2 cycles of BKM120 treatment, a  reduction of the sum of the 
lesions was recorded. The TTP for this patient was 16 weeks.
As of the data cut -off 4 -Jul-2011, preliminary  analy sis shows forty -five percent of patients (30 
of 66 evaluable) had stable disease as best response, with 20 patients (30%) with a disease 
stabiliza tion of 3 months or longer . A trend towards better activity  (long-term stabilizations) 
has been observed at the higher dose cohorts, also expressed in metabolic FDG -PET response. 
However, considering the impact of a PI3K inhibitor on glucose metabolism, further data 
needs to be acquired to understand whether the current FDG -PET assessment data can be used 
as a predictive factor for efficacy .

[COMPANY_001] Confidential Page 40
Amended Protocol Version 04 ( Clean ) Protocol No. C BKM120Z2402
With regards to pharmacod ynamic markers observed in study  [CBKM120X2101], down 
regulation of pS6 in skin by 30-80% was demonstrated in 28 out of the 38 evaluable patients 
at 100 and 150 mg/d and more than 25% FDG
-PET signal decrease in patients at doses greater 
than the MTD.
With regards to the PI3K pathway  activation, of the two responders described above, one had 
a tumor with the PIK3CA mutation. Moreover, [ADDRESS_736147]  is warranted.
Pharmacokinetic experience
Preliminary  PK data showed that at the low dose of 40 mg on both day s 8 and 22 of treatment, 
the PK of BKM120 in this study  was consistent with that seen following single agent 
administration of BKM120. At the 80 mg dose, observed profiles on days 8 and 22 were 
slightly  lower than expected (less than 10%). At the other 2 dose levels (60 mg and 100 mg) 
almost all of the profiles lie in the lower half of the expected distribution indicating a large 
reduction (around 30%) in exposure to BKM120 compared to expectations. Hypotheses 
explaining this observation are being evaluated. These include: a possible impact of H2 
antagonist administration as premedication for paclitaxel, which could limit BKM120 
solubility  (i.e., BKM120 exhibits pH-dependent solubility , with a significant increase in 
solubility  at low pH) or more likely  an interaction between this and the extremely  rapid 
absorption kinetics of BKM120 (half -life of 10 minutes) suggest ing a limited window for 
absorption in the upper part of the duodenum. To limit the potential impact of H2 antagonists, 
in this study  BKM120 will be administered at least one hour before H2 antagonists (or proton 
pump inhibitor, antacid, etc.) administrati on.
2 Rationale
2.1 Stud y rationale and purpose
The PI 3K/Akt/mTOR pathway  has become an important focus for cancer t herapeutics.
BKM120 is a potent and highly  specific oral pan-class I PI3K inhibitor and has been studied 
extensively  in non -clinical models and is currently being evaluated in clinical trials for several 
oncology  indications other than NHL to date (see details in Section 1.2).
As alread y stated in the previous sections, inhibitors of the PI3K/mTO R/Akt pathway , 
including BKM 120, may be therapeutically  effective in NHL patients based on the 
observations from both pre-clinical and early phase clinical trials with either selective or non
-
selective inhibitors of the PI3K/mTOR/Akt pathway . As pan class I PI3K inhibitors 
demonstrate evidence of efficacy  in solid tumor patients and since there are several p110 
isoforms detected in B cell NHL s, this presents an intriguing opportunity  for further 
evaluation of BKM120. Therefore, there is a stron g rationale to support this study of BKM 120 
for the selected t ypes of B -cell NHL .
The purpose of this study  is to explore therapeutic efficacy  of BKM 120 in three selected ty pes 
of NHL, including DLBCL , MCL and FL, and the s afety/tolerability  of patients.

[COMPANY_001] Confidential Page 41
Amended Protocol Version 04 ( Clean ) Protocol No. C BKM120Z2402
2.2 Rationale for the study  design
Anopen -label, multi- center, single arm phase II study  has been selected to explore the 
efficacy  and 
safet y of BKM120 in patients with three histologically  different 
relapsed/refractory  non-Hodgkin’s lymphomas, including diffu se large B-cell lymphoma ,
mantle cell ly mphoma and follicular ly mphoma .
No clear data exist on the effect of molecular alteration and data with PI3K/ mTOR inhibitor 
do not currently  support the notion of a specific target population. Thus, enrollment of 
patients with activated as well as non -activated PI3K pathway  is considered appropriate.
In the absence of a comparator arm and robust historical data, ORR is considered an 
appropriate primary  endpoint to objective ly measure anti -tumor activity .
A single arm study  will be performed due to the lack of approved agents as well as the small 
patient population.
The protocol specific assessments, treatment and follow -up are consistent with the standard 
procedures applied in this disease setting.
2.3 Rationale for dose a nd regimen selection
As described in details inSection [IP_ADDRESS].1, BKM120 100 mg once daily  has been established 
as the MTD/RP2D in two single agent trials ( [CBKM120X2101] and [CBKM120X1101] ) and 
one co mbination trial ( [CBKM120X2107] with trastuzumab).
Accordingl y, BKM120 will be dosed at 100 mg/day.
2.4 Rationale for choice of combination drugs
Not applicable.
2.5 Rationale for choice of comparators drugs
Not applicable.
3 Objectives and endpoints
Objectives and related endpoints are described in Table 3
-1below.

[COMPANY_001] Confidential Page 42
Amended Protocol Version 04 (Clean) Protocol No. C BKM120Z2402
Table 3-1 Objectives and related endpoints
Objective Endpoint Anal ysis
Primary
- To determine the efficacy of BKM120 in patients with 
relapsed/refractory Non -Hodgkin Lymphoma in the three 
different histological subgroups (cohorts)Overall Response rate (ORR) is defined as the proportion of patients 
with a best overall response of CR or PR according to Cheson criteria 
(Cheson et a l 2007 ).Refer to Section 10.4
Secondary
-To evaluate the safety and tolerability in the three different 
histological subgroupsFrequency and severity of adverse events; other safety data as 
considered appropriateRefer to Section 10.5
-To assess progression free survival in the three different 
histological subgroupsProgression Free Survival (PFS) is defined as the time from the date of 
treatment start to the date of the first documented progressive disease 
(PD) or death due to any cause per local investigator.
-To assess the duration of response in the three different 
histological subgroupsDuration of Response is defined as the time from the date of first 
occurrence of CR or PR to the date of the first documented progressive 
disease (PD) or death due to lymphoma.
-To assess overall survival in the three different histological 
subgroupsOverall Survival (OS) is defined as the time from treatment start to the 
date of death due to any cause.

[COMPANY_001] Confidential Page 43
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
4 Study  design
4.1 Description of study  design
This is a multi- center, open label, single arm phase II study  in patients with relapsed and 
refractory  Non-Hodgkin Lym phoma including 3 histological subgroups (cohorts): mantle cell 
lymphoma (MCL), follicular ly mphoma (FL) and diffuse large B -cell l ymphoma (DLBCL). A 
study  design overview is given in Figure 4 -
1.
Figure 4-1 Study  Design Overview
Note: Maximum number of patients per cohort will be capped at N = [ADDRESS_736148] provide a signed Informed Consent Form (ICF) prior to any study specific 
screening evaluations. Eligibility  will be determined according to the inclusion/exclusion 
criteria as detailed inSection 5. A list of procedures to be performed at screening is 
summarized inTable [ADDRESS_736149].
Patients will return to the clinic for regular safet y and efficacy  assessment as outlined in Table 
7-1.At each office visit, remaining study  drug should be accounted for to allow as sessment of 
patient treatment adherence.
Study  treatment duration is determined independently  for each cohort. Response to treatment 
will be determined locally  according to Cheson criteria (Cheson et al2007 ) every  [ADDRESS_736150]. All patients benefiting from treatment at the time of 

[COMPANY_001] Confidential Page 44
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
final anal ysis will be permitted to continu e study  drug at investigator’s discretion until disease 
progression, intolerable toxicity  or withdrawal of consent.
An end of treatment visit will occur within 7 day s following discontinuation of BKM120 .
Safety  follow -up
After discontinuation of study  treatment, patients will be followed for safet y (AEs and/or 
SAEs) for at least [ADDRESS_736151] dose of the study drug will be recorded on Case Report Forms (CRFs) designed to 
capture antineoplastic therapi[INVESTIGATOR_560013] .
Survival follow -up
All patients will be fol lowed for survival outcome after they discontinue from study  treatment 
and tumor evaluations (efficacy  follow -up). Survival follow -up assessments in each cohort 
will be performed once every  [ADDRESS_736152] completed the study .
4.4 Early study  termination
The study  can be terminated at any  time for any reason by  [CONTACT_5343]. Should this be necessary, 
the patients remaining in the study  should be seen as soon as possible and the same 
assessments should be performed as described in Section 7 for a prematurely  withdrawn 
patient. The investigator may be informed of additional procedures to be followed in order to 
ensure that adequate consideration is given to the protection of the patient’s interests. The 

[COMPANY_001] Confidential Page 45
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
investigator will be responsible for informing IRBs and/or ECs of the early termination of the 
trial.
[ADDRESS_736153] to meet all of the following criteria:
1.Patient has provided a signed stud y Informed Consent Form prior to an y screening 
procedure
2.Patient is ≥ [ADDRESS_736154] one measurable nodal lesion ( ≥2 cm) according to Cheson criteria
(Cheson et al 2007) . In case where the patient has no measurable nodal lesions ≥ 2cm in 
the long axis at baseline, then the patient must have at least one measurable extra -nodal 
lesion
7.Patient has an Eastern Cooperative Oncology  Group (ECOG) performance status score ≤ 2
8.Patient has adequate bone marrow and organ function shown by :
Absolute neutrophil count (ANC) ≥ 1.0 x 109/L
Platelets ≥ 75 x 109/L (no platelet transfusion within past 14 day s)
Hemoglobin (Hgb) ≥ 9.0 g/dL (no RBC transfusion within past 14 day s)
International Normalized Ratio ( INR)≤ 1.5
Potassium, calcium (corrected for albumin) , magnesium within normal limits for the 
institution
Serum Creatinine ≤ 1.[ADDRESS_736155]
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal 
range (or 
≤3.0 x UL N if liver metastases are present)
Serum bilirubin ≤ ULN(or ≤ 1.5 x UL N if liver metastases are present; or total 
bilirubin ≤ 3.[ADDRESS_736156] bilirubin within normal range in patients with well 
documented Gilbert Sy ndrome which is defined as presence of several epi[INVESTIGATOR_560014] (including 

[COMPANY_001] Confidential Page 46
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
normal reticulocy te count and blood smear), normal liver function test results, and 
absence of other contributing disease processes at the time of diagnosis . )
Fasting plasma glucose (FPG) ≤ 120 mg/dL or ≤ 6.7 mmol/L
9.
Patient is able to swallow and retain oral medication
5.[ADDRESS_736157] not meet anyof the following criteria:
1.Patient has received previous treatment with PI 3K inhibitors
2. Patient has evidence of graft versus host disease (GVHD)
3.Patient has active or history  of central nervous s ystem (CNS) disease
4.Patient has a concurrent malignancy  or has a malignancy  within 3 y ears of study  
enrollment (with the exception of adequately  treated basal or squamous cell carcinoma or 
non-melanomatous skin cancer)
5.Patient has a score 
≥ 12 on the PHQ -9 questionnaire
6. Patient selects a response of “1, 2 or 3” to question number 9 on the PHQ- 9 questionnaire 
regarding potential for suicidal thoughts or ideation (independent of the response to 
question 9 or the total score of the PHQ -
9)
7.Patient has a GAD- 7 mood scale score ≥ 15
8.Patient has a medicall y documented history  of or active major depressive epi[INVESTIGATOR_1865], bipolar 
disorder (I or II), obsessive -compulsive disorder, schizophrenia, a history  of suicidal 
attempt or ideation, or homicidal ideation (e.g. risk of doing harm to self or others) , or 
patients with active severe personalit y disorders (defined according to DSM -IV). For 
patients with psy chotropic treatments ong oing at baseline, the dose and the schedule 
should not be modified within the previous 6 weeks prior to start of study  drug.
9. Patient has ≥ CTCAE grade 3 anxiety
10.Patient is concurrentl y using other approved or investigational antineoplastic agent
11.Patient ha s received chemotherapy  or targeted anticancer therap y ≤ 4 weeks (6 weeks for 
nitrosourea, monoclonal antibodies or mitomy cin-C) prior to starting stud y drug or who 
have not recovered from side effects of such therapy
12.Patient has received pelvic and/or par a-aortic radiotherapy  ≤ 28 day s prior to enrollment in 
this study  or has not recovered from side effects of such therapy  at the time of initiation of 
screening procedures
13.Patient has had major surgery  within 28 day s prior to starting study  drug or has not 
recovered from major side effects of the surgery
14.Patient has poorly  controlled diabetes mellitus (HbA 1c> 8 %) at baseline
15.Patient has active cardiac disease including an y of the following:
Left Ventricular Ejection Fraction (LVEF) < 50% as determined b y Multiple Gated 
acquisition (MUGA) scan or echocardiogram (ECHO)
QTc > 480 msec on screening ECG (using the QTcF formula)
Angina pectoris that requires the use of anti- anginal medication
Ventricular arrh ythmias except for benign premature ventricular contrac tions

[COMPANY_001] Confidential Page 47
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
Supraventricular and nodal arr hythmias requiring a pacemaker or not controlled with 
medication
Conduction abnormality  requiring a pacemaker
Valvular disease with documented compromise in cardiac function
Symptomatic pericarditis
16.Patient has a history of cardiac dy sfunction including an y of the following;
Myocardial infarction within the last 6 months, documented by  [CONTACT_560057] L VEF 
function
History  of documented congestive heart failure ([LOCATION_001] Heart Association 
functional classification III -IV)
Documented cardiom yopathy
17.Patient is currently  receiving treatment with QT prolonging medication known to have a 
risk to induce Torsades de Pointes, and the treatment ca nnot be discontinued or switched 
to a different medicati on prior to starting study  drug
18.Patient has impairment of gastrointestinal (GI) function or GI disease that may  
significantl y alter the absorption of BKM120 (e.g., ulcerative diseases, uncontrolled 
nausea, vomiting, diarrhea, malabsorption sy ndrome, or small bowel resection)
19.Patient is currently  receiving increasing or chronic treatment (> 5 day s) with 
corticosteroids or another immunosuppressive agent, as chronic administration of 
corticosteroids (> 5 days) can induce CYP3A4. The following uses of corticosteroids are 
permitted: single dose, topi[INVESTIGATOR_14929] (e.g., rash), inhaled spray s (e.g., obstructive 
airway s diseases), ey e drops or local injections (e.g., intra -articular) .
20.Patient has other con current severe and/or uncontrolled medical condition that would, in 
the investigator’s judgment contraindicate his/her participation in the clinical study  (e.g. 
chronic pancreatitis, active chronic hepatitis , immunocompromised, chronic pulmonary  
disease including dy spnea at rest or interstitial lung disease, uncontrolled hypertension etc.)
21.Patient has a history  of non -compliance to medical regimen or inability  to grant consent.
22.Patient is currently  being treated with drugs known to be moderate orstrong inhibitors or 
inducers of isoenz yme CYP3A, and the treatment cannot be discontinued or switched to a 
different medication prior to starting stud y drug. Patients must have discontinued strong 
inducers for at least one week and must have discontinued strong inhibitors before the 
start of treatment. Note: the oral anti-diabetic drugs troglitazone and pi[INVESTIGATOR_560015]3A inducers . Refer to Table 14- 1 in Appendix 1 .
23.Patient is currently  receiving w arfarin or other coumarin derived anti -coagulant for 
prophy laxis. Therapy  with heparin, low molecular weight heparin (LMWH), or 
fondaparinux is allowed.
24.Patient has a known history  of HIV (testing not mandatory ) infection
25.Patient has acute viral hepatitis or a history  of chronic or active HBV or HCV infection, 
(typi[INVESTIGATOR_560016]/ALT (persistent or intermittent), high HBV DNA level, 
HBsAg positive, or high HCV RNA level (testing not mandatory , refer to 
Section [IP_ADDRESS].8)

[COMPANY_001] Confidential Page 48
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
26.Pregnant or nursing (lactating) women, where pregnancy  is defined as the state of a female 
after conception and until the termination of gestation, confirmed by  a positive serum hCG 
laboratory  test (> 5 mIU/mL )
27. Patient who does not apply  highly  effective contraception during the study  and through the 
duration as defined below after th e final dose of study  treatment
Female Patients
Women of child -bearing potential , defined as all women physiologicall y capable of 
becoming preg nant, must use highl y effective contraception during the study and 
through 4 weeks after the final dose of study  treatment
Highl y effective contraception is defin ed as either:
Total abstinence: When this is in line with the preferred and usual lifest yle ofthe 
subject. [Periodic abstinence (e.g., calendar, ovulation, sy mptothermal, post -ovulation 
methods) and withdrawal are not acceptable methods of contraception] .
Sterilization: have had surgical bilateral oophorectomy  (with or without hysterectom y) 
or tubal ligation at least six weeks before taking study  treatment. In case of 
oophorectom y alone, only when the reproductive status of the woman has been 
confirmed b y follow up hormone level assessment
Male partner sterilization (with the appropriate post -vasec tomy documentation of the 
absence of sperm in the ejaculate). [For female study  subjects, the vasectomized male 
partner should be the sole partner for that pat ient]
Use a combination of the following:
a.Placement of an intrauterine device (IU D) or intrauterine s ystem (IUS)
b. Barrier methods of contraception: Condom or Occlusive cap (diaphragm or 
cervical/vault caps) with spermicidal foam/gel /film/cream/vaginal suppository
Note: Hormonal contraception methods (e.g. oral, injected, implanted) are not 
allowed as it cannot be ruled out that BKM120 decreases the effectiveness of 
hormonal contraceptives.
Women are considered post -menopausal and not of child bearing potential if any  
of the following conditions is fulfilled:
Prior bilateral oophorectomy  (with or without hy sterectom y) or tubal ligation at 
least six weeks ago
Age ≥60
Age < 60 and amenorrhea for 12 or more months (in the absence of 
chemotherap y), and FSH and estradiol in the postmenopausal range (serum 
FSH > 40 mIU/mL and estradiol <20 pg/mL or ac cording to the postmenopausal 
range definition for the laboratory  involved).
Male Patients
Fertile males, defined as all males phy siologicall y capable of conceiving offspring 
must use a highl y effective contraception during dosing of the stud y agent -
contraception through [ADDRESS_736158]: highl y effective 

[COMPANY_001] Confidential Page 49
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
contraception during dosing of the stud y agent - contraception through [ADDRESS_736159] y, packaged in bottles. BKM120 will be dosed on a 
flat scale of mg/day  and not be adjusted to body  weight or body  surface area. The investigator 
needs to instruct the patient to take the study  drug as per the protocol. All dosages prescribed 
and dispensed to the patient and all dose changes during the study  must be recorded in the 
Dosage Administration Record eCRF.
6.1.1 Dosing regimen
BKM120 100 mg will be administered orally once daily  on a continuous dosing schedule. A 
complete treatment cycle is defined as 28 days of once daily  continuous treatment with 
BKM120.
Table 6-1 Dose and treatment schedule
Study  treatmentsPharmaceutical form and 
route of administration DoseFrequency  and/or 
Regimen
BKM120 Oral gelatin capsules 100 mg Daily (28 day cycles)
[IP_ADDRESS] BKM120 Administration
BKM120 will be administered on a continuous once daily  dosing schedule. There will be no 
breaks between dosing cycles.
The following general guidelines should be followed for BKM120 administration:
Patients should be instructed to take the dose of BKM120 once dail y in the morning, at 
approximate ly the same time each day.
BKM120 can be taken with or without food.
BKM120 should be taken with a glass of water. Patients should swallow the capsules as a 
whole and not chew them.
To limit the potential impact of H2 antagonists, in this study  BKM120 will be 
administered at least one hour before or 10 hours after H2 antagonists (or proton pump 
inhibitor, antacid, etc.) administration.
If vomiting occurs during the course of treatment , no re -dosing of the patient is allowed 
before the next scheduled dose. The occurrence and frequency  of any  vomiting during a 
treatment cy cle must be noted in the adverse events section of the eCRF.
If the patient forgets to take her dose before 18:00 (6:00 PM), then the dose should be 
withheld that day and BKM120 should be restarted the following day .

[COMPANY_001] Confidential Page 50
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
Patients must avoid consumption of Seville orange (and juice), grapefruit or grapefruit 
juice, grapefruit h ybrids, pummelos, starfruits and cranberry  juice from [ADDRESS_736160] dose of study  drug and during the entire study  treatment period due t o potential 
CYP3A interaction. Regular orange (Citrus X sinensis) juice is allowed.
Patients must avoid concomitant intake of strong and moderate CYP3A inhi bitors and 
inducers. Detailed information on potential drug interactions and a list of prohibited 
concomitant CYP3A interfering medications is provided in Table 14-1 in Appendix 1 .
6.1.2 Ancillary  treatments
For more information about handling diarrhea, rash, hypergly cemia and pneumonitis see
Section 6.3.
6.1.3 Rescue medication
Not applicable .
6.1.4 Guidelines for continuation of treatment
In general, patients will be treated until disease progression or unacceptable toxicity . 
Guidance for continuation of study  treatment in case of toxicity  (e.g. dose delay  and/or 
modification) is provided in Section 6.3.
6.1.[ADDRESS_736161] be recorded on the eCRF.
BKM120 dose modification guidelines are described in Section [IP_ADDRESS] . Any  planned variance 
from these guidelines in the view of the patient safet y must be previousl y discussed with the 
sponsor unless there is an urgent need for action.
All dose modifications, interruptions or discontinuations must be based on the worst 
preceding toxicity  as graded by  [CONTACT_560058] (NCI -CTCAE version 4.03). 
Once a dose has been reduced during a treatment cycle, re-escalation will not be permitt ed 
during an y subsequent cycle.
If the administration of BKM120 is interrupted for reasons other than toxicity , then treatment 
with the study  drug may be resumed at the same dose. The same applies if the patient 

[COMPANY_001] Confidential Page 51
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
experienced an unacceptable toxicity  not specifically  described in Table 6-3orSection 6.3.2, 
provided this toxicity  resolv ed to 
≤ CTCAE grade 1, unless otherwise specified.
6.3.2 Treatment interruption and treatment discontinuation
If the study  drug is being held due to toxicity , scheduled visits and all assessments should 
continue to be performed (with the exception of the dosing of the held study  drug), as 
described inTable 7-1. Additional exams may be required as outlined in Table 6-3, or as 
medically  indicated.
If treatment with the study  drug is held for ≥28days due to 
toxicity, then study  drug must be 
permanentl y discontinued. Patients who permanently  discontinue the study  drug should have 
weekl y follow -up for 30 days after discontinuation of all study  treatment or resolution of the 
AE to ≤ grade 1, whichever occurs first, that includes all study  assessments appropriate to 
monitor the event.
[IP_ADDRESS] Criteria for BKM120 dose modifications
For each patient, a maximum of 2 dose reductions (as outlined in Table 6-2) will be allowed . 
Patients requiring an additional dose reduction will be discontinued from treatment with
BKM120.
Table 6-2 Dose reduction steps for BKM120
BKM120 dose levels and dose reductions*
Starting dose level – 0 100 mg/day
Dose level – 1 80 mg/day
Dose level – 2 60 mg/day
*Dose reduction should be based on the worst preceding toxicity
Guidelines for dose modification and dose interruption for toxicities suspected to be related to
BKM120 are described in Table 6-3.
After treatment is resumed at a lower dose:
If the same toxicity  recurs with the same severit y, then the next treatment re -initiation 
must resume at a lower dose irrespective of duration.
These stipulations do not apply  to hy pergly cemia, as specific rules are stated in Table 6-3.

[COMPANY_001] Confidential Page 52
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
Table 6-[ADDRESS_736162] toxicity  (CTCAE 4.03 Grade)** Dose Modifications for BKM120
HEMATOLOGICAL
Neutropenia (ANC)
Grade 1 (ANC < LLN -1.5 x 109/L)
Grade 2 (ANC < 1.5 -1.0 x 109/L)Maintain dose level
Grade 3 (ANC < 1.0 -0.5 x 109/L)
Grade 4 (ANC < 0.5 x 109/L)Omit dose until resolved to ≤ Grade 1, then:
--If resolved in ≤ 7 days, then maintain dose level
-- If resolved in > 7 days, then 1 dose level
Febrile neutropenia 
(ANC < 1.0 x 109/L, with a single
temperature of ≥ 38.3 °C or a sustained 
temperature of ≥ 38 °C for more than one 
hour )Omit dose until resolved, then 1 dose level
Thrombocy topenia
Grade 1 (PLT < LLN -75 x 109/L)
Grade 2 (PLT < 75 -50 x 109/L)Maintain dose level
Grade 3 (PLT < 50 -25 x 109/L) Omit dose until resolved to ≤ Grade 1, then:
--If resolved in ≤ 7 days, then maintain dose level
-- If resolved in > 7 days, then 1 dose level
Grade 4 (PLT < 25 x 109/L) Omit dose until resolved to ≤ Grade 1, then 1 dose level
RENAL
Serum creatinine 
< [ADDRESS_736163] Maintain dose level 
2 –[ADDRESS_736164] Omit dose until resolved to ≤ grade 1, then:
--If resolved in ≤ 7 days, then maintain dose level
-- If resolved in > 7 days, then 1 dose level
Grade 3 (> 3.0 –6.[ADDRESS_736165]) Permanently d iscontinue patient from BKM120
Grade 4 ( > 6.[ADDRESS_736166]) Permanently discon tinue patient from BKM120
HEPATIC
Bilirubin
(*for patients with Gilbert Syndrome these dose modifications apply to changes in direct bilirubin only)
will be fractionated if elevated
Grade 1 (> ULN -1.[ADDRESS_736167]) Maintain dose level with LFTs* monitored as per protocol
Grade 2 (> 1.[ADDRESS_736168]) with ALT or 
AST ≤ 3.0 x ULNOmit dose until resolved to ≤ Grade 1, then:
--If resolved in ≤ 7 days, then maintain dose level
-- If resolved in > 7 days, then 1 dose level
Grade 3 (> 3.[ADDRESS_736169]) with ALT or 
AST ≤ 3.0 x ULNOmit dose until resolved to ≤ Grade 1, then:
--If resolved in ≤ 7 days, 1 dose level
--If resolved in 7 days discontinue patient from BKM120
Grade 4 (> 10.[ADDRESS_736170]) Permanently discontinue patient from BKM120

[COMPANY_001] Confidential Page 53
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
Dose Modifications for BKM120
Worst toxicity  (CTCAE 4.03 Grade)** Dose Modifications for BKM120
AST or ALT
AST or ALT without bilirubin elevation > 2ULN
Note: confounding factors and/or alternative causes for increased transaminases like concomitant medications, 
infection, hepato -biliary disorder, obstruction, liver metastasis, etc. should be excluded before dose 
interruption/reduction
Same grade as baseline (i.e. Grade 0 or 
Grade 1 (> ULN – 3.[ADDRESS_736171]) if presence 
of liver metastasis)Maintain dose level with LFTs* monitored per protocol
Increase from baseline Grade 0 to > 1.[ADDRESS_736172] or from baseline Grade 1 to Grade 2Can continue treatment at 1 dose level
Increase of two grades from baseline 
(from baseline Grade 0 to Grade 2 or from 
baseline Grade 1 to Grade 3)Omit dose until resolved to Grade 1 or less, then 1 dose level**
If no recovery in ≤ 28 days, discontinue permanently BKM120
Grade 4 (> 20.[ADDRESS_736173]) Discontinue BKM120 permanently
AST or ALT and concurrent Bilirubin
AST or ALT > 3.[ADDRESS_736174] and total 
bilirubin > 2.0 x ULNPermanently discontinue BKM120
*(LFTs include albumin, ALT, AST, total bilirubin (fractionated if total bilirubin > 2.[ADDRESS_736175]), alkaline phosphatase 
(fractionated if alkaline phosphatase is grade 2 or higher) and GGT)
** In case of recurring Grade 3 or higher toxicity after re-challenge, patients should be permanently discontinued
*** All patients with ALT or AST >3.0x ULN and total bilirubin > 2.0x ULN in the absence of cholestasis must 
immediately be withdrawn from BKM120 and every attempt should be made to carry out the liver event follow -up 
assessments as described below in Section [IP_ADDRESS] and Section [IP_ADDRESS].8 ).
Hepatic toxicity  monitoring (*for patients with Gilbert Syndrome: total and direct bilirubin must be monitored, 
intensified monitoring applies to changes in direct bilirubin only; the m onitoring includes the following LFTs: 
albumin, ALT, AST, total bilirubin (fractionated if total bilirubin > 2.[ADDRESS_736176]), alkaline phosphatase (fractionated if 
alkaline phosphatase is grade 2 or higher) and GGT):
-Cycle 1 and 2: every  other week (if visit schedule allows a more frequent monitoring this should be considered) 
or more frequently if clinically indicated especially for patients with borderline acceptable AST/ ALT , orbilirubin* 
values
-Cycle [ADDRESS_736177]: monthly or more fre quently i f clinically indicated
In case of any occurrence of ALT/AST , orbilirubin* increase ≥ grade [ADDRESS_736178] be monitored 
weekly or more frequently if clinically indicated until resolved to ≤ grade 1
In case of any occurrence of ALT/ AST orbilirubin* increase ≥ grade [ADDRESS_736179] be monitored 
weekly or more frequently if clinically indicated until resolved to ≤ grade 1 ; hereafter the monitoring should be 
continued every  other week or more frequently if clinically indicated until the end of treatment with study  
medication
Patients who discontinued study treatment should be monitored weekly, including LFTs* or more frequently if 
clinically indicated until resolved to ≤ grade [ADDRESS_736180] abilization (no CTCAE grade change over 4 weeks).

[COMPANY_001] Confidential Page 54
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
Dose Modifications for BKM120
Worst toxicity  (CTCAE 4.03 Grade)** Dose Modifications for BKM120
ENDOCRINE/METABOLIC
Fasting Plasma Glucose (FPG)
Grade 1 (> ULN -160 mg/dL) [> ULN -8.9 
mmol/L]Maintain dose level, check FPG every week
-initiate or intensify medication with appropriate anti-diabetic 
treatment as per investigator’s discretion
-instruct patient to follow dietary guidelines according to local and/or 
institutional standards for management of diabetes mellitus (such as 
those provided by [CONTACT_11026]) du ring the 
study
-consider use of oral anti -hyperglycemic therapy such as metformin 
(or intensify existing medications) 
-check FPG at least weekly for [ADDRESS_736181] every 2 weeks
Grade 2 (>160 - 250 mg/dL) [> 8.9 - 13.9 
mmol/L]- If signs or symptoms of hyperglycemia (for example, mental status 
changes, excessive thirst, polyuria), omit BKM120 immediately and 
manage as for Grade 3 hyperglycemia (below)
-If asymptomatic, maintain dose and re -check FPG within 24 hours. 
If grade worsens or improves then follow s pecific grade 
recommendations. If FPG remains at Grade 2:
--maintain dose level and monitor FPG at least weekly until FPG 
resolves to ≤ Grade 1
-- initiate or intensify medication with appro priate anti -diabetic 
treatment such as metformin; consider adding a second oral agent if 
no improvement after several days.
---instruct patient to follow dietary guidelines according to local 
and/or institutional standards for management of diabetes mellitus 
(such as those pro vided by [CONTACT_11026]) 
during the study
-If FPG does not resolve to ≤ Grade 1 within 14days after 
initiation/intens ifying of appropriate anti-diabetic treatment , reduce 
BKM120 by [ADDRESS_736182] every 2 weeks.
Grade 3 (> 250 -500 mg/dL) [> 13.9 -
27.8 mmol/L]- Immediately omit BKM120 , initiate or intensify medication with 
appropriate anti -diabetic treatment, re -check FPG within 24hours. If 
grade worsens or improves then follow s pecific grade 
recommendations. If FPG remains at Grade 3:
--administer intravenous hydration and interven tion for 
electrolyte/ketoacidosis/hyperosmolar disturbances as clinically 
appropriate
--continue to omit BKM120
--monitor FPG at least twice weekly until FPG resolves to ≤Grade 1
--If FPG resolves to ≤ Grade 1 in 7 days or less, then re- start 
BKM120 an d 1 dose level
--If FPG remains greater than Grade 1 severity for more than 7 
days, then discontinue patient from BKM120

[COMPANY_001] Confidential Page 55
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
Dose Modifications for BKM120
Worst toxicity  (CTCAE 4.03 Grade)** Dose Modifications for BKM120
--initiate or continue anti-diabetic treatment as appropriate
---instruct patient to follow dietary guidelines according to local
and/or institutional standards for management of diabetes mellitus 
(such as those provided by [CONTACT_11026]) 
during the study
---consider use of oral anti -hyperglycemic therapy such as 
metformin
--check FPG at least weekly for [ADDRESS_736183] every 2 weeks
For non -fasting plasma glucose >250 -500 mg/dL (> 13.9 -27.8 
mmol/L) accompanied by [CONTACT_23804]/symptoms of hyperglycemia (for 
example, mental status changes, excessive thirst, polyuria), or 
presence of blood or urine ketones, omit BKM120 and following 
guidance for management of Grade 3 fasting plasma glucose (FPG)
Grade 4 (> 500 mg/dL) [ ≥ 27.8 mmol/L] -immediately omit BKM120 , initiate or intensify medication with 
appropriate anti -diabetic treatment, re -check within 24 hours. If 
grade improves then follow s pecific grade recommendations. If FPG 
is confirmed at Grade 4:
--administer intravenous hydration and intervention for 
electrolyte/ketoacidosis/hyperosmolar disturbances as clinically 
appropriate
--discont inue patient from BKM120
--instruct patient to follow dietary guidelines according to local 
and/or institutional standards for management of diabetes mellitus 
(such as those provided by [CONTACT_11026]) 
during the study
--consider use o f oral anti -hyperglycemic therapy such as metformin
--check FPG at least weekly for [ADDRESS_736184] every 2 weeks if clinically indicated
For non -fasting plasma glucose >500 mg/dL (> 27.8 mmol/L) 
accompanied by [CONTACT_23804]/symptoms of hyperglycemia (for example, 
mental status changes, excessive thirst, polyuria), or presence of 
blood or urine ketones, discontinue BKM120 and following guidance 
for management of Grade 4 fasting plasma glucose (FPG).
CARDIAC
Cardiac - Left Ventricular sy stolic dy sfunction
Asymptomatic, 
resting ejection fraction 40 -50%;
or 10 -20% drop from baselineMaintain dose level, and continue BKM120 with caution
Repeat LVEF within 4 weeks or as clinically appropriate
Symptomatic, 
responsive to intervention, 
ejection fraction 20 -39%
or > 20% drop from baseline-Omit BKM120 until resolved* (as defined below), then 1 dose 
level
-LVEF measurement to be repeated, if not resolved* within 28 days , 
permanently discontinue patient from BKM120 treatment
Refractory or poorly controlled,
ejection fraction < 20%-Permanently discont inue patient from BKM120
*the event is considered resolved when the patient is asymptomatic, has a resting ejection fraction ≥ 40% and 
≤20% decrease from baseline.

[COMPANY_001] Confidential Page 56
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
Dose Modifications for BKM120
Worst toxicity  (CTCAE 4.03 Grade)** Dose Modifications for BKM120
Cardiac –QTc prolongation
QTcF > 500 ms ( ≥ Grade 3) 
or > [ADDRESS_736185] Occurrence:
-omit BKM120
-Perform an analysis of serum potassium and magnesium, and if 
below lower limit of normal, correct with supplements to within 
normal limits. Concomitant medication usage must be reviewed.
-Perform a repeat ECG within one hour of the first QTcF of > 500 
ms or >60ms from baseline
-If QTcF remains > 500 ms or >60ms from baseline, repeat ECG as 
clinically indicated, but a t least once a day until the QTcF returns to 
< [ADDRESS_736186] input.
-Once QTcF prolongat ion has resolved, BKM120 may be restarted 
at a one lower dose level
Second Occurrence:
-Permanently discont inue patient from BKM120
Other Cardiac Events
Grade 1 or 2 Maintain dose level
Grade 3 Omit dose until resolved to ≤ Grade 1, then 1 dose level
Grade 4 Permanently discontinue patient from BKM120
OTHER
Mood alteration
* Note: For all grades, if question 9 on the PHQ -9 has a positive response (as indicated by [CONTACT_20683] "1", "2", or 
"3"), omit study drug and refer patient for psychiatric consult regardless of the total questionnaire score or CTCAE 
grading to confirm if study drug should be interrupted or permanently discontinued.
Grade 1* ●Maintain dose level
Consider psychiatric consultation at the investigator’s discretion and 
introduce appropriate psychotropic management except in presence 
of suicidal ideation where dose must be interrupted and psychiatric 
consultation is required t o provide optimal management
Grade 2 * ●Omit dose until resolved to ≤ Grade 1 or baseline status
●Consider psychiatric consultation at the investigator’s discretion 
and introduce appropriate optimal psychotropic management except 
in presence of suicidal ideation where dose must be interrupted and 
psychiatric consultation is required to provide optimal management
●First event: if the condition resolved to Grade ≤ 1 or to baseline 
status, continue psychotropic treatment and reinitiate study drug at 
the same dose level
●Second and further events: if the condition resolved to Grade ≤ 1 
or to baseline status, continue psychotropic treatment andreinitiate 
study drug ↓ 1 dose level
Grade 3 * ●Omit dose until resolved to ≤ Grade 1or baseline status
●Psychiatric consultation is required
Introduce appropriate psychotropic management
● If the condition resolved to Grade ≤ 1 or to baseline status, 
continue psychotropic treatment and reinitiate study drug ↓ 1 dose 
level

[COMPANY_001] Confidential Page 57
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
Dose Modifications for BKM120
Worst toxicity  (CTCAE 4.03 Grade)** Dose Modifications for BKM120
Grade 4 * ●Permanently discontinue patient from BKM 120
●Psychiatric consultation is required.
Introduce appropriate psychotropic management
* A timely interview with the patient after the questionnaire completion is recommended. For all grades, if question 
9 on the PHQ -9 has a positive response (as indicated by [CONTACT_20683] “1”, “2”, or “3”) and/or the patient presents with 
suicidal ideation, interrupt study drug and refer patient for psychiatric consultation regardless of the total 
questionnaire score or CTCAE grading for optimal management and to confirm if study drug should be interrupted 
or permanently discontinued. If the patient does not respond to question [ADDRESS_736187] be interrupted and the patient referred for psychiatric consultation for 
assessment.
Rash
Grade 1 Maintain dose level. Consider to initiate appropriate skin toxicity 
therapy (such as antihistamines, topi[INVESTIGATOR_11930]) 
Grade [ADDRESS_736188] occurrence: Omit dose until resolved to grade ≤ 1 then:
●If resolved in ≤ 2 weeks, maintain dose level.
●If reso lved in more than 2 weeks, 1 dose level.
Second occurrence: 1 dose level.
Initiate/intensify appropriate skin toxicity therapy (such as 
antihistamines, topi[INVESTIGATOR_11930])
Grade [ADDRESS_736189] occurrence: Omit does until resolved to CTCAE Grade ≤ Grade 
1, then re -start at ↓ dose level.
Second occurrence: permanently discontinue patient from
BKM120/placebo. If skin rash is readily manageable, re-introduction
at a reduced dose level might be considered at the discretion of the
investigator.
According to the investigators discretion, a paired skin biopsy could 
be obtained (from both an affected and an unaffected skin area for 
local histopathology assessment) if clinical appropriate.
Grade 4 Permanently discont inue patient from BKM120
According to the investigators discretion, a paired skin biopsy could 
be obtained (from both an affected and an unaffected skin area for 
local histopathology assessment) if clinical appropriate.
Fatigue (asthenia)
Grade 1 or 2 Maintain dose level
Grade 3 Omit dose until resolved to ≤ Grade 1, then:
-If resolved in ≤ 7 days, maintain dose level
-If resolved in 7 days, 1 dose level
Grade 4 Permanently discont inue patient from BKM120
Pneumonitis please see Section [IP_ADDRESS].2
Other non -hematological adverse events
Grade 1 or 2 Maintain dose level
Grade 3 Omit dose until resolved to ≤ Grade 1, then 1 dose level
Grade 4 Permanently discont inue patient from BKM120
Note: Omit dose for ≥ Grade 3 vomiting or Grade 3 nausea only if 
the vomiting or nausea cannot be controlled with optimal antiemetic

[COMPANY_001] Confidential Page 58
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
Dose Modifications for BKM120
Worst toxicity  (CTCAE 4.03 Grade)** Dose Modifications for BKM120
Stomatitis/Oral mucositis
Grade 1 / Tolerable Grade 2 Maintain dose level.
Non-alcoholic or salt water mouth wash (see also Section [IP_ADDRESS].3 )
Intolerable Grade [ADDRESS_736190] occurrence: hold until resolved to grade ≤ G1 and 1 dose 
level (if stomatitis is readily manageable with optimal management, 
re-introduction at t he same level might be considered at the 
discretion of the investigator).
Second occurrence: hold until resolved to grade ≤ G1 and 1 dose 
level.
Grade 4 Permanently discontinue patient from BKM120
** Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
[IP_ADDRESS].1 Additional follow -up for selected toxicities
[IP_ADDRESS].2 Management of Pneumonitis in patients receiving BKM120
All patients participating in clinical trials with BKM120 will be routinely asked about and 
observed for the occurrence of adverse events which could include new or changed 
pulmonary  symptoms (consistent with lung abnormalities). CT scans and pulmonary  function 
tests should be done, as clinically  indicated, or if there are symptoms that indicate that the 
patient has 
developed Pneumonitis. In case of a documented Pneumonitis, the guidelines 
(including dose modifications) in Table 6-[ADDRESS_736191] every 8 weeks until return to 
within normal limits.No specific 
therapy is 
requiredAdminister 100% of BKM120 dose.
Grade 2 CT scan with lung windows. Consider 
pulmonary function testing includes: 
spi[INVESTIGATOR_038], DLCO, and room air O2 
saturation at rest. Repeat at least 
every 8 weeks until return to within 
normal limits. Consider a 
broncho scopy with biopsy and / or 
BAL.Symptomatic 
only. Consider 
corticosteroids if 
symptoms are 
troublesome.Reduce BKM120 dose by 1 dose 
level (see Table 6 -3) until recovery 
to <Grade 1. Study treatment may 
also be interrupted if symptoms are 
troublesome. Patients will 
discontinue study treatment if they 
fail to recover to < Grade [ADDRESS_736192] scan with lung windows and 
pulmonary function testing includes: 
spi[INVESTIGATOR_247190], DLCO, and room air O2 
saturation at rest. Repeat at least 
every 6 weeks until return to within 
normal limits. Bronchoscopy with 
biopsy and / or BAL is recommended.Consider 
corticosteroids if 
infective origin is 
ruled out. Taper 
as medically 
indicate d.Hold treatment with BKM120 until 
recovery to < Grade 1. May restart 
study treatment within 28 days at a 
reduced dose (by [CONTACT_12691]) if 
evidence of clinical benefit.

[COMPANY_001] Confidential Page 59
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
Worst Grade 
Pneumonitis Required InvestigationsManagement of 
Pneumonitis BKM120 Dose Adjustment
Grade 4 CT scan with lung windows and 
required pulmonary function testing, if 
possible, includes: spi[INVESTIGATOR_038], DLCO, 
and room air O2 saturation at rest. 
Repeat at least every 6 weeks until 
return to within normal limits. 
Bronchoscopy with biopsy and / or 
BAL is recommended if possible.Consider 
corticosteroids if 
infective origin is 
ruled out . Taper 
as medically 
indicated.Discontin ue treatment with 
BKM120 .
[IP_ADDRESS].3 Guidelines for the treatment of study drug induced stomatitis/oral mucositis
General guidance and management include patient awareness and early intervention. 
Evaluation for herpes virus o r fungal infection should be considered.
Patients should be informed about the possibility of developi[INVESTIGATOR_235968]/ oral mucositis 
and instructed to report promptly  any signs or s ymptoms to their phy sician,
Patients should be educated about good oral hygiene, instructed to avoid spi[INVESTIGATOR_70329] /acidic/salt y 
foods, and should follow the following guidelines:
For mild toxicity  (grade 1), use conservative measures such as non- alcoholic mouth wash 
or salt water (0.9%) mouth wash several times a day  until resolution.
For more severe toxicity  (grade [ADDRESS_736193] pain but are able to maintain 
adequate oral alimentation, or grade 3 in which case patients cannot maintain adequate 
oral alimentation), the suggested treatments are topi[INVESTIGATOR_560017] (i.e., 
local anesthetics such as benzocaine, but yl aminobenzoate, tetracaine hy drochloride, 
menthol, or phenol) with or without topi[INVESTIGATOR_11930], such as triamcinolone oral 
paste 0.1% (Kenalog in Orabase®).
Agents containing alcohol, hy drogen peroxide, iodine, and thy me derivatives may  tend to 
worsen mouth ulcers. It is preferable to avoid these agents.
Antifungal agents should be avoided unless a fungal infection is diagnosed as they may 
interfere with BKM120 metabolism (see Section 6.3 ).
[IP_ADDRESS].4 Guidelines for the treatment of study drug induced diarrhea
The investigator should consider/investigate potential concomitant medication, food or 
comorbidity  driven causes of diarrhea (including infectious causes) and remedy  these causes 
if possible (e.g. discontinuation of concomitant medication, dietary  modificati on, treatment of 
comorbidity ).
The patient should be monitored for signs of dehy dration and instructed to take preventive 
measures against dehydrati on as soon as diarrhea occurs. Concomitant medication for the 
treatment of diarrhea should be considered, as per local practice and best investigator’s 
judgment and may consist for example, as per “the recommended guidelines for the treatment 
of cancer treatment -induced diarrhea” ( Benson et al 2004), of loperamide given at a standard 
dose (e.g. initial administration of 4mg, then 2mg every  4
 hours, maximum of 16 mg/day), 
along with oral hydration and dietetic measures could be considered for grade 1-2 diarrhea. 
More severe diarrhea should be treated appropriately  according to investigator discretion, 
including for example IV fluids.

[COMPANY_001] Confidential Page 60
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
Dose adaptations of BKM120 in case of treatment related diarrhea should follow the 
guidelines presented above for other non- hematological adverse events.
[IP_ADDRESS].5 Guidelines for the treatment of study drug induced psychiatric disorders
Psychiatric adverse events will be closel y monitored and evaluated at each planned visit until 
recovery  to Grade ≤ 1 or baseline status. The grading of psychiatric adverse events/mood 
alterations must be based on the clinical interpretation of severit y according to the NCI-
CTCAE (v 4.03) guidelines.
For patie nts who experience new or worsening of existing psychiatric AEs of Grade ≥1, 
psychiatric consultation should be considered as described in Table 6 -3.
Patient self -reported mood questionnaires (GAD -7 and PHQ -9) will be used for screening and 
during the study  treatment phase to aid 
the investigator in identify ing new or worsening of 
events. For additional information regarding safety  assessments based on patient self-reported 
mood questionnaires, please re fer to Section [IP_ADDRESS].
If question 9 in the PHQ -9 has a positive response (as indicated by [CONTACT_20683] "1", "2", or "3"), 
or patient exhibits suicidal idealation, interrupt treatment with study  drug and refer the patient 
for psychiatric consultation for optimal management regardless of the total questionnaire 
score or CTCAE grading and to confirm if study  drug should be interrupted or permanently 
discontinued. In this specific case, the psychiatric advice can overrule the patient’s PHQ -9 
self-assessment.
During the study , subjects will be monitored at regular scheduled visits (eg, Day 1 of each 
cycle and at the End of Treatment visit) by [CONTACT_093]/site staff through personal 
interaction and the two self-reported questionnaires. Additional assessments may be done 
according to the clinical judgment of the investigator if desired.
[IP_ADDRESS].[ADDRESS_736194] exposure to 
sunlight, including the wearing of sunglasses as well as the use of hats, long-sleeve shirts and
long pants when outdoors.
[IP_ADDRESS] Management of hepatotoxicity  (ALT and/or A ST >3.0x ULN and total 
bilirubin >2.0x ULN) in patients receiving BKM120
Criteria for interruption and re-initiation of BKM120 treatment in case of the occurrence of 
AST, AL T or b ilirubin increase are detailed in Section 6.3 , Dose Modification ( Table 6-3 ).
Patients with clinically  significant liver test abnormalities should perform liver-directed 
medical history , physical examination and other tests as medically  indicated to assess 
potential relationship with study  treatment and rule out other underl ying causes (e.g. disease

[COMPANY_001] Confidential Page 61
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
progression/obstruction, infection/hepatitis or other liver diseases, sepsis, metabolic diseases 
including diabetes, concomitant medications including herbals, alcohol, drug -drug interaction, 
cardiovascular disease/ischemia, other organ injuries, etc.). Any pre-existing liver conditions 
or risk factors should be reported in the respective medical history and concomitant 
medication CRF pages (if not done alread y).
All patients with ALT or AST >3.[ADDRESS_736195] and total bilirubin > 2.[ADDRESS_736196] in the absence of 
cholestasis (elevation of ALP in patients without bone metastasis or if bone metastasis are 
present elevation of 5’-nucleotidase and ALP liver fraction) must be immediatel y withdrawn 
from BKM120, and every  attempt should be made to carry out locall y the liver event follow -
up assessments as described below:
Inform the sponsor about the event immediatel y after its occurrence b y reporting the event 
immediately  in the clinical database if it meets the criteria for an AE or SAE.
Evaluate if associated with the appearance or worsening of clinical s ymptoms of hepatitis
or hy persensitivity  such as fatigue, nausea, vomiting, right upper quadrant pain or 
tenderness, fever, rash or eosinophilia, or other organ involvement.
Obtain fractionated bilirubin, serum Alkaline Phosphatase (ALP), creatine phosphokinase 
(CPK), lactate dehydrogenase (LDH), and blood count with differential to assess 
eosinophilia.
Perform liver imaging (ultrasound, magnetic resonance, or computerized tomography ) to 
evaluate liver disease including metastasis or new lesions, obstruction/compression, etc.
Perform viral hepatitis and other serology  tests:
Hepatitis C (HCV) serology  and viral RNA, Hepatitis B (HBV) serology  and viral 
DNA, Hepatitis A (HAV) I mmunoglobulin M (IgM) and HAV total
Hepatitis E (HEV) serology : IgM and IgG, viral RNA
Herpes Simplex V irus (HSV), Cy tomegalovirus (CMV), Ep stein- Barr viral (EBV) 
serology
Verify  and record the use of concomitant medications, acetaminophen, herbal remedies, 
and other over the counter medications, or putative hepatotoxins, on the concomitant 
medications repo rt form.
Consultation with a specialist(s) or a hepatologist(s) is recommended.
Liver biopsy  as clinicall y indicated to assess pathological change and degree of potential 
liver injury
LFTs should be followed -up weekl y until resolve to ≤ grade 1, baseline o r stabilization 
(no CTCAE grade change over 4 weeks) and outcome documented on the respective AE 
and lab chemistry  pages.
6.4 Concomitant medications
In general, the use of any concomitant medication/therapi[INVESTIGATOR_560018] (see Section 6.4.1), except as specifically  prohibited (see Section 
6.4.2).
All medications (excluding study  treatment and prior antineoplastic treatments), procedures 
and significant non-drug therapi[INVESTIGATOR_014] (including physical therapy  and blood transfusions) 

[COMPANY_001] Confidential Page 62
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
administered within [ADDRESS_736197] dose of stud y treatment will be recorded in the Concomitant Medications/Significant Non -
Drug Therapi[INVESTIGATOR_144924] . Medications include not only physician prescribed medications, 
but also all over-the counter medications, herbal medications (prohibited, see Section [IP_ADDRESS]) 
and food or vitamin supplements. The investigator should instruct the patient to notify  the 
investigational site about any  new medications she takes after the start of the study  drug.
The patient must be told 
to notify  the investigational site about any new medications he/she 
takes after the start of the study  drug. All medications (other than study  drug) and significant 
non-drug therapi[INVESTIGATOR_014] (including physical therap y and blood transfusions) administered during 
the study  mustbe listed on the Concomitant Medications /Significant Non-Drug Therapi[INVESTIGATOR_560019].
6.4.1 Permitted concomitant therapy
[IP_ADDRESS] Corticosteroids
Chronic dosing of corticosteroids such as dexamethasone and prednisone is known to induce 
CYP3A enzymes, thereby  [CONTACT_560059]120 drug exposure to sub
-
therapeutic levels. Systemic corticosteroid treatment must not be given during the study , 
except for:
topi[INVESTIGATOR_14929] (e.g., rash), inhaled spray s (e.g., obstructive airway s diseases), ey e 
drops or local injections (e.g., intra -articular);
a short duration (< 5 days) of sy stemic corticosteroids ≤ to the anti- inflammatory  potency  
of 4 mg dexamethasone (e.g. for chronic obstructive pulmonary  disease, or as an 
antiemetic);
[IP_ADDRESS] Drugs that are metabolized by  [CONTACT_097]450 enzymes
In vitro metabolism studies performed to examine the reversible and metabolism- dependent 
inhibition of CYPP450 enzy mes showed that BKM120 is a weak, reversible inhibitor of 
CYP3A4/5, CYP2C8, CYP2C9 and CPY2C19. Note that with the data available, it is not 
possible to confirm whether such interactions will occur in patients. Therefore, investigators, 
at their discretion, may administer concomitant medications known to be metabolized by 
[CONTACT_097]3A4/5, CYP2C8, CYP2C9 and CYP2C19. Patients receiving such medications must be 
monitored for potentiation of toxicity  due to any individual concomitant medications, and 
may require dose titration or r eduction of the drug substrate.
Refer to Table 14-[ADDRESS_736198] of CYP3A and CYP2C substrates to be used with 
caution. Particularly , caution is advised when BKM120 is co -administered with drugs that are 
sensitive substrates and/or have a narrow therapeutic index (e.g., SSRI).
Concomitant treatment of BKM120 with weak inducers of CYP3A4 is permitted, however, 
duration of concomitant treatment should be kept as short as possible (e.g., less than 1 week), 
or fully  avoided whenever possible. Note thatcoadministration of BKM120 with strong and 
moderate inducers is prohibited (refer to Section [IP_ADDRESS]).

[COMPANY_001] Confidential Page 63
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
[IP_ADDRESS] Non- enzy me Inducing A nti-epi[INVESTIGATOR_111767]-enzy me inducing anti-epi[INVESTIGATOR_7377] (Non -EIAED) is allowed, except for those 
listed in Table 14-1 inAppendix 1 .
[IP_ADDRESS] Palliative radiotherapy
Local radiotherapy  for analgesic purposes or for lytic lesions at risk of fracture may  be carried 
out if required. Whenever possible, these patients should have a tumor assessment of the 
lesion(s) before receiving the radiotherapy  in order to rule out progression of disease. No dose 
modification of study  treatmen t is needed during radiotherap y.
[IP_ADDRESS] Drugs with a conditional or possible risk to induce Torsades de 
Pointes
If a patient, after enrollment in the study , requires the concomitant use of any QT prolonging 
medication with a possible or conditional risk for Torsa des de Pointes included in Table 14-[ADDRESS_736199] however be closely  monitored.
[IP_ADDRESS] Gastric protection agents
BKM120 is characterized by a pH-dependent solubility . Medicinal products that alter the pH 
of the upper Gastro -Intestinal (GI) tract may alter the solubility  of BKM120 and hence its 
bioavailability . These agents include, but are not limited to, proton- pump inhibitors (e.g., 
omeprazole), H2-antagonists (e.g., ranitidine) and antacids. BKM120 should be dosed in a 
staggered manner at least [ADDRESS_736200] .
[IP_ADDRESS] Allopurinol and rasburicase
Allopurinol or rasburicase may  be used at the physician’s discretion in DLBCL patients at risk 
for tumor ly sis sy ndrome.
6.4.[ADDRESS_736201] before start of study treatment (C1D1) and must not be used while the patient is on 
study .
[IP_ADDRESS] Other anticancer therapy
Anticancer therapy  (chemotherapy , biologic orradiation therap y, and surgery ) other than the 
study  treatments must not be given to patients while the patient is enrolled in the treatment 
portion of the trial. If such agents are required for a patient then the patient must be 
permanentl y discontinued from the treatment portion of the study .
[IP_ADDRESS] Other investigational therapi[INVESTIGATOR_560020] .

[COMPANY_001] Confidential Page 64
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
[IP_ADDRESS] Hematopoietic growth factors
Prophy lactic use of hematopoietic growth factors (e.g. erythropoietins, granulocy te colon y-
stimulating factor (G -CSF) and granulocy te macrophage colony -stimulating factor (GM -CSF)) 
are not permitted. However, in the event of an emergency  (e.g. acute myelosuppression with 
infection), a patient may  be given hematopoietic growt h factors according to the investigator’s 
judgment, and the sponsor should be notified as soon as possible. Subsequent secondary 
prevention use is permitted at investigator’s discretion.
Patients who begin erythropoietin or darbepoetin therap y before rando mization, may continue 
this treatment at the discretion of the investigator.
[IP_ADDRESS] Warfarin and coumarin derivatives
Therapeutic doses of warfarin sodium or any  other coumarin -derivative anticoagulants are not 
permitted.
BKM120 is a weak inhibitor of CYP2C8 and 2C9, the major metabolizing enzyme of 
warfarin. Despi[INVESTIGATOR_560021], an increase of 40-50% of 
warfarin exposure is possible and for a drug like warfarin, thi s might be clinically  relevant.
[IP_ADDRESS] Enzy me-inducing anti -epi[INVESTIGATOR_32551] (EIA ED)
Use of enz yme
-inducing anti- epi[INVESTIGATOR_32551] (EIAED) is not permitted. Refer to Table [ADDRESS_736202] two weeks prior to starting stud y drug.
If a patient is previously  on a non-EIAED and needs to permanently  change the 
anticonvulsant agent, but cannot change to another non-EIAED, the patient will be taken off 
BKM120.
[IP_ADDRESS] Drugs w ith a kno wn risk for Torsades de Pointes
If a patient requires the concomitant use of any medication included in Table 14-3 in 
Appendix 3entitled “List of Prohibited QT prolonging drugs” (i.e., drugs that are generally 
accepted by [CONTACT_236054].org Advisory  Board of the Arizona CERT 
to have a risk of causing 
Torsade de Pointes), study  treatment must be delay ed. Note that Table 14-3 lists drugs with a 
known risk for Torsades de Pointes (TdP) as well as sensitive CYP3A substrates (with narrow 
TI) with a possible or conditional 
risk for TdP. Study  treatment administration must be 
interrupted as long as the patient requires therap y with the QT prolonging ag ent.
Please also refer to http://crediblemeds.org/ for a comprehensive list of agents that prolong the 
QT interval.
[IP_ADDRESS] Moderate and strong CYP3A  inhibitors and inducers
In vitro metabolism studies suggest that oxidative metabolism of BKM120 is predominantl y 
mediated by [CONTACT_097]3A4 and UGT1A4. Coadministration of BKM120 with strong and moderate 
CYP3A4 inhibitors and inducers is predicted to respectively  increase or decrease t he systemic 
exposure to BKM120.

[COMPANY_001] Confidential Page 65
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
Please refer to Table [ADDRESS_736203] 
may not be comprehensive.
[IP_ADDRESS] Herbal medications
Herbal preparations/medications are not allowed throughout the study , as a potential drug-
drug interaction is always possible. These herbal medications include, but are not limited to: 
St. John’s wort, Kava, ephedra (ma huang), gingko biloba, dehy droepi[INVESTIGATOR_2119] (DHEA), 
yohimbe, saw palmetto, and ginseng.
Patients should stop using these herbal medications at least [ADDRESS_736204] dose of study  
treatment.
[IP_ADDRESS] Hormonal contraception
Hormonal contraceptives may be affected by [CONTACT_9058] P450 interactions, and are therefore 
not considered effective for this study , since induction of CYP3A4 may not be excluded in 
patients receiving BKM120.
6.[ADDRESS_736205] Number (Subject No.), that is assigned 
when the patient is first enrolled for screening and is retained as the primary  identifier for the 
patient throughout his/her entire participation in the trial. The Subject No. consists of the 
Center Number (Center No.) (as assigned by [CONTACT_5359]) with a 
sequential patient number suffixed to it, so that each subject is numbered uniquely  across the 
entire database. Upon signing the informed consent form, the patient is assigned to the next 
sequential Subject No. available at the site .
Once assigned, the Subject No. must not be reused for any other subject and the Subject No. 
for that individual must not be changed, even if the patient is re -screened.
Re-screening is permitted for patients as long as all screening procedures are performed 
within the specific time window. Any re-screened patient must retain the same Subject No.
Re-screening of patients is only  allowed once per patient .
If the patient fails to be assigned to treatment for any reason, the reason will be entered into 
the Screening log eCRF page.
6.5.2 Treatment assignment or randomization
Not applicable .
6.5.3 Treatment blinding
This is an open -label study .

[COMPANY_001] Confidential Page 66
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
6.6 Stud y drug supply
6.6.1 Study drug preparation and dispensation
Study  medication will be dispensed by [CONTACT_263606]’s site. 
Investigator staff will add the patient number on thelabel. Immediatel y before dispensing the 
package to the patient, investigator staff will detach the outer part of the label from the 
packaging and affix it to the source document (Drug Label Form) for that patient’s unique 
patient number.
Patients will be provided with an adequate supply  of study  drug for self-administration at 
home, including instructions for administration, until at least their next scheduled study  visit. 
Patients will receive BKM120 on an outpatient basis. The investigator shall provide the 
patient with instructions for BKM120 administration according to the protocol.
All dosages prescribed to the patient and all dose changes during the study  must be recorded 
on the Dosage Admini stration Record CRF.
6.6.[ADDRESS_736206] gelatin capsules, packaged in bottles, and 
will be given orally on a flat scale of mg/day. The capsules are packaged in HDPE bottles 
with a plastic child resistant closure.
Medication labels will comply  with the legal requirements of each country  and printed in the 
local langu age for each specific country . The storage conditions for study  drug will be 
described on the medication label.
Immediately  before dispensing the study  drug to the patient, the investigator or his/her 
designee will detach the outer part of the label from the packaging and affix it to the source 
document containing that patient’s unique patient number.
Table 6
-5 Packaging and labeling
Study  treatments Packaging Labeling (and dosing frequency )
BKM120 Capsules in bottle
10 mg
50 mgLabeled as “BKM120”
Once daily dosing
6.6.[ADDRESS_736207] access. Upon receipt, the study  treatment should be stored 
according to the instructions specified on the drug labels and in the [Investigator’s Brochure]. 
These instructions should also be made clear to the patient for storage and self-administration 
of BKM120 at home.

[COMPANY_001] Confidential Page 67
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
6.6.4 Study drug compliance and a ccountability
[IP_ADDRESS] Study drug compliance
Compliance will be assessed and verified by [CONTACT_1755]/or study personnel at each 
patient visit by [CONTACT_560060]120 capsules consumed between visits and 
information provided by [CONTACT_5363]/or caregiver will be captured in the Drug 
Accountability  Form. This information must be captured in the source document at each 
patient visit.
Any overdose must be recorded in the dosage administration record of the eCRF. An overdose 
is defined as any dose greater than the daily  dose level at which the patient is being treated. If 
the subject has taken a higher dose than stated in the protocol, then the patient should also be 
monitored for potential adverse reactions. In case of an overdose that needs to be treated, the 
investigator should use his or her clinical judgment for the management of this overdose and 
apply  adequate supportive care and follow up until recovery .
[IP_ADDRESS] Study drug accountability
The investigator or designee must maintain an accurate record of t he shipment and dispensing 
of study  treatment in a drug accountability  log. Drug accountability  will be noted by [CONTACT_5364] . Patients will be asked to return 
all unused study  treatment and packag ing on a regular basis, at the end of the study  or at the 
time of study  treatment discontinuation.
At study  close-out, and, as appropriate during the course of the study , the investigator will 
return all used and unused study  treatment, packaging, drug labels, and a copy  of the 
completed drug accountability  logto the [COMPANY_001] monitor or to the [COMPANY_001] address provided 
in the investigator folder at each site.
[IP_ADDRESS] Handling of other study  treatment
Not applicable.
6.6.[ADDRESS_736208] party, as appropriate . Study  drug destruction at the investigational site will only be 
permitted if authorized by [CONTACT_15024] a prior agreement and if permitted by [CONTACT_427] .

[COMPANY_001] Confidential Page 68
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
7 Visit schedule and assessments
7.1 Stud y flow and visit schedule
Table 7-1lists all of the assessments and indicates with an “X”, the visits when they are 
performed. All data obtained from these assessments must be supported in the patient’s source 
documentation. The table indicates which assessments produce data to be entered into the 
database (D) or remain in source documents only  (S) (“Category ” column).
All visits can take place 3 day s before or 3 day s after the specified study  visit (total window of 
7 days) except for the time window for the end of treatment and safet y follow
-up visit which 
is +7days.

[COMPANY_001] Confidential Page 69
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
Table 7-1 Visit evaluation scheduleCategoryReferenc
e to 
Section
ScreeningCycl
e 1
(28 
days
)Cycl
e 1Cycl
e 1Cycl
e 1Cycl
e 2
(28 
days
)Cycl
e 3
(28 
days
)Subsequen
t cycles
(28 day s)End of 
study  
treatmen
t (EOT)Safety  
follow
-upEfficac
y 
follow -
up (FU)Completio
n of Study
(end of 
Efficacy  
FU)Overall 
Surviva
l 
follow -
up
Visit Number 1 2 601 602 603 3 4 5 777 501 778
Day of cycle-28 
to-
1
1 2 3 4 1 1 1EOT + 
30
(+7)
days
Obtain Informed 
ConsentD 4.1& 11.3 X
Patient history
Demography D [IP_ADDRESS] X
Inclusion/exclusio
n criteriaD 5.2&5.3 X
Relevant medical 
history/current 
medical 
conditionsD [IP_ADDRESS] X
Diagnosis and 
extent of cancerD [IP_ADDRESS] X
Prior 
antineoplastic 
therapyD [IP_ADDRESS] X
Prior/concomitant 
medicationsD [IP_ADDRESS] &
6.4X Continuous
Antineoplastic 
therapi[INVESTIGATOR_560022] 7.1.5 & 
7.1.6.3X X X X

[COMPANY_001] Confidential Page 70
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402CategoryReferenc
e to 
Section
ScreeningCycl
e 1
(28 
days
)Cycl
e 1Cycl
e 1Cycl
e 1Cycl
e 2
(28 
days
)Cycl
e 3
(28 
days
)Subsequen
t cycles
(28 day s)End of 
study  
treatmen
t (EOT)Safety  
follow
-upEfficac
y 
follow -
up (FU)Completio
n of Study
(end of 
Efficacy  
FU)Overall 
Surviva
l 
follow -
up
Visit Number 1 2 601 602 603 3 4 5 777 501 778
Day of cycle-28 
to-
1
1 2 3 4 1 1 1EOT + 
30
(+7)
days
Physical 
examinationS [IP_ADDRESS] X X* X X X X
ECOG 
Performance 
statusD [IP_ADDRESS] X X* X X X X
Height D [IP_ADDRESS] X
Weight D [IP_ADDRESS] X X* X X X X
Vital signs D [IP_ADDRESS] X X* X X X X
PHQ -9 Patient 
self-rating mood 
scaleD [IP_ADDRESS] X X* X X X X
GAD7 Patient 
self-rating mood 
scaleD [IP_ADDRESS] X X* X X X X
Laboratory  assessments
Hematology D [IP_ADDRESS].1 X X* X X X X
Biochemistry (full) D [IP_ADDRESS].2 X X* X X X X
Hepatotoxicity 
follow -up 
testing/procedure
sD [IP_ADDRESS] As clinically indicated

[COMPANY_001] Confidential Page 71
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402CategoryReferenc
e to 
Section
ScreeningCycl
e 1
(28 
days
)Cycl
e 1Cycl
e 1Cycl
e 1Cycl
e 2
(28 
days
)Cycl
e 3
(28 
days
)Subsequen
t cycles
(28 day s)End of 
study  
treatmen
t (EOT)Safety  
follow
-upEfficac
y 
follow -
up (FU)Completio
n of Study
(end of 
Efficacy  
FU)Overall 
Surviva
l 
follow -
up
Visit Number 1 2 601 602 603 3 4 5 777 501 778
Day of cycle-28 
to-
1
1 2 3 4 1 1 1EOT + 
30
(+7)
days
DLBCL arm only: 
Chemistry specific
to tumor lysis 
syndromeD [IP_ADDRESS].2 X X X
Lipid profile D [IP_ADDRESS].4 X X* X X (every 2nd
cycle)X
Fasting plasma 
glucoseD [IP_ADDRESS].2 X X* X X X X
HbA1c D [IP_ADDRESS].5 X X* X X (every 2nd
cycle)X
Coagulation D [IP_ADDRESS].3 X X* As clinically indicated
C-peptide D [IP_ADDRESS].5 X X* X X (every 2nd
cycle)X
Pregnancy test 
(serum)D [IP_ADDRESS].7 X X* X X X X
Imaging/Other assessments
Tumor evaluation D [IP_ADDRESS] X X X (every 2nd
cycle)X X X
Bone Marrow 
biopsyD [IP_ADDRESS] Only at time of complete response
ECG D [IP_ADDRESS].1 X X* X X X X
Cardiac imaging 
(MUGA/ECHO)D [IP_ADDRESS].2 X As clinically indicated

[COMPANY_001] Confidential Page 72
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402CategoryReferenc
e to 
Section
ScreeningCycl
e 1
(28 
days
)Cycl
e 1Cycl
e 1Cycl
e 1Cycl
e 2
(28 
days
)Cycl
e 3
(28 
days
)Subsequen
t cycles
(28 day s)End of 
study  
treatmen
t (EOT)Safety  
follow
-upEfficac
y 
follow -
up (FU)Completio
n of Study
(end of 
Efficacy  
FU)Overall 
Surviva
l 
follow -
up
Visit Number 1 2 601 602 603 3 4 5 777 501 778
Day of cycle-28 
to-
1
1 2 3 4 1 1 1EOT + 
30
(+7)
days
Safety
Adverse events D 7.2.2 X Continuous
BKM120 kit 
dispensationS 6.6.1 X X X X
Drug 
administrationD [IP_ADDRESS] Continuous
Screening Log D 7.1.2 X
End of Treatment D 7.1.5 X

[COMPANY_001] Confidential Page 73
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402CategoryReferenc
e to 
Section
ScreeningCycl
e 1
(28 
days
)Cycl
e 1Cycl
e 1Cycl
e 1Cycl
e 2
(28 
days
)Cycl
e 3
(28 
days
)Subsequen
t cycles
(28 day s)End of 
study  
treatmen
t (EOT)Safety  
follow
-upEfficac
y 
follow -
up (FU)Completio
n of Study
(end of 
Efficacy  
FU)Overall 
Surviva
l 
follow -
up
Visit Number 1 2 601 602 603 3 4 5 777 501 778
Day of cycle-28 
to-
1
1 2 3 4 1 1 1EOT + 
30
(+7)
days
Study Evaluation 
CompletionD 7.1.6 X
Survival 
informationD [IP_ADDRESS] X
* Does not need to be repeated if done within 7 days before cycle 1 day 1

[COMPANY_001] Confidential Page 74
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
7.1.1 Molecular pre -screening
Not applicable.
7.1.2 Screening
After signing the main study  ICF (S-ICF) for the study , the remaining screening assessments 
will be done generally  within 7 to 28 day s prior to start of treatment (see Table 7 - 1).
Please note that the screening period must not exceed 28 day s.
[IP_ADDRESS] Eligibility  screening
Following registration for screening, patient eligibility  will be checked once all screening 
procedures are completed. The investigator will complete the Screening Log and
Inclusion/Exclusion criteria eCRF pages.
[IP_ADDRESS] Information to be collected on screening failures
Patients who sign an informed 
consent but fail to be started on treatment for any reason will 
be considered a screen failure. The reason for not being started on tr eatment will be entered on 
the Screening Log eCRF Page. The following CRFs must be completed for screen failure 
patients:
Screening failure log (including reason for not being started on treatment)
Demograph y
[IP_ADDRESS] Patient demographics and other baseline characteristics
Data will be collected on patient characteristics including demographic information (age, 
gender, race) and other background or relevant medical history , including history  of disease 
and current disease status, staging (Table 7-2), bone marrow involvement, sites of disease, 
prior anticancer therapi[INVESTIGATOR_014], prior medications/significant non-drug therapi[INVESTIGATOR_560023] i
n the study 
(i.e., ECOG Performance Status, complete physical examination (including neurological 
assessment, tumor assessment and B symptoms Table 7-2), vital signs, hematology , blood 
chemistries includ ing coagulation studies and a serum lipid profile, pregnancy  test only 
required for women of childbearing 
potential, 12-lead ECG). Furthermore the following 
assessments will be performed to assess the eligibility  of the patient:
Viral hepatitis serology  [e.g. HAAb, HBsAg, HBsAb HBcAb, HCV RNA or HDV RNA
(where needed), HEAb, CMVAb, EBcAb] and other tests (see Section 6 .3.2.2 a
nd
Section [IP_ADDRESS].8)

[COMPANY_001] Confidential Page 75
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
Table 7-2 Ann Arbor staging classification1
Stage Area of involvement
I Single lymph node group
II Multiple lymph node groups on the same side of the diaphragm
III Multiple lymph node groups on both sides of the diaphragm
IV Multiple extranodal sites or lymph nodes and extranodal disease
X Bulk disease > 10 cm
E Extranodal extension or single isolated site of extranodal disease
Class A patients who experience no B symptoms
Class B patients experience unexplained fever of ≥ 38°C; unexplained, recurrent drenching night sweats; or 
unexplained loss of >10% body weight within the previous 6 months
1 Cotswolds modification of Ann Arbor staging system adapted from 2007 NCCI guidelin es for non -Hodgkin’s 
lymphoma
7.1.[ADDRESS_736209].
Following initiation of study  treatment (Cycle 1 Day 1), the patient should visit the site every 
cycle; see Table 7 -1. Permitted visit windows for assessments within the treatment period and
at efficacy  follow -up visits: +/ -
3days of the protocol required date.
Information on drug exposure will be collected on the Dosage Administration Record eCRF. 
Concomitant medications/significant non-drug therapi[INVESTIGATOR_560024] (≤ 28days) and after 
start of study  treatment will be recorded on the appropriate eCRFs.
Compliance will be assessed by  [CONTACT_1755]/or study  personnel at each visit using box 
counts and information provided by [CONTACT_18629]. This information should be captured in the 
source document at each visit (Please also refer to Section 6.6.4).
7.1.5 End of treatment visit including study  completion and premature 
withdrawal
Patients will continue study  treatment until disease progression or until any of the study ’s 
discontinuation criteria ( Section [IP_ADDRESS]) are met.
Patients who discontinue study  treatment should be scheduled for an End-
of-Treatment visit
as early as for patient’s convenience, butit should occur within 7 days from treatment 
discontinuation, at which time all of the assessments listed for the EOT visit will be 
performed. For details of assessments, refer to Table 7 -1.
An End of Treatment eCRF page should be completed, giving the date and reason for 
discontinuation of study  treatment.

[COMPANY_001] Confidential Page 76
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
If a study  withdrawal occurs, or if the patient fails to return for visits, the investigator must 
determine the primary  reason for a patient’s premature withdrawal from the study  and record 
this information on the End of Treatment eCRF page.
Patients who discontinue study  treatment for reasons other than disease progression will enter 
the efficacy  follow -up period until disease progression or initiation of a new antineoplastic 
therap y and should not be considered withdrawn from the study .
[IP_ADDRESS] Criteria for premature patient withdrawal
Patients may voluntaril y withdraw from the study  or be dropped from it at the discretion of 
the inves tigator at any time. Patients may  be withdrawn from the study if any of the following 
occur:
Unacceptable toxicities
Protocol deviation
Lost to follow -up
Pregnancy
Discovery  of patient ineligibility
Errors in treatment compliance
Administrative problems
Death
In addition to the general study  treatment withdrawal criteria, the following study specific 
criteria will also require premature stud y treatment discontinuation:
Study  treatment modifications that result in discontinuation.
Interruption of BKM120 treatment for more than 2 8days
Use of prohibited medication.
Start of an y other anti -neoplastic therapy
If a study  treatment withdrawal occurs, or if the patient fails to return for visits, the 
investigator must determine the primary  reason for a patient’s premature withdrawal from 
study  treatment and record this information on the End of Treatment CRF page. In case of 
withdrawal from study  treatment, the patient needs to indicate on the informed consent form 
whether she is willing to continue with subsequen t follow -up procedures.
[IP_ADDRESS] Replacement policy
Not applicable.
7.1.[ADDRESS_736210] to 
follow -up, the investigator should show "due diligence" by [CONTACT_560061] 77
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
documents steps taken to contact [CONTACT_102], e.g., dates of telephone calls, registered letters, 
etc.
[IP_ADDRESS] Safety  follow  up
All patients will be followed for adverse events and serious adverse events for at least [ADDRESS_736211] dose of BKM120. At the end of this period (between day [ADDRESS_736212] dose), the inves tigator should contact [CONTACT_560062]/concomitant medication taken during this period. This could be done via either an 
office visit or a phone contact.
Patients whose treatment is interrupted or permanently  discontinued due to an adverse event 
or abnormal laboratory  value must be followed until resolution or stabilization of the event, 
whichever comes first. In case the patient has any  abnormal lab values at end of treatment that 
are considered clinically significant by [CONTACT_093], the patient needs to come to the site 
for repeat blood analysis until resolution or stabilization including at least a site visit with 
respective anal yses [ADDRESS_736213] the 
patient should be documented in the source documents (e.g., dates of telephone calls, 
registered letters, etc.) .
All new anti-cancer therapi[INVESTIGATOR_560025]-neoplastic therapi[INVESTIGATOR_560026].
[IP_ADDRESS] Efficacy  follow  up
Patients who discontinue study  treatment for reasons other than disease progression, death 
start of new anti-neoplastic therapi[INVESTIGATOR_014], lost to follow -up, or withdrawal of consent to efficacy 
follow -up will continue to have radiological tumor assessments every  8 weeks (± 7 day s) until 
[ADDRESS_736214] .
At the time the patient discontinu
es the efficacy follow -up period, the Study  Evaluation 
Completion page should be completed. In case the patient starts a new antineoplastic therapy , 
this will be recorded on the Antineoplastic therapi[INVESTIGATOR_560027].
[IP_ADDRESS] Survival follow  up
All patients who discontinue study  treatment and are no longer followed radiologicall y will be 
contact[CONTACT_560063]  12 weeks (± 7 days) from the time of the End of 
Treatment (EoT)visit or, where applicable, from the last visit in the efficacy  follow -up period 
until death. Further, patients who refuse to return for scheduled visits or are unable to do so 
should be asked to consent for survival follow -up. If applicable, the date of death should be 
captured on the End ofTreatment page, Study  Evaluation Completion , or Survival Follow Up
(whichever is applicable) page in the eCRF.

[COMPANY_001] Confidential Page 78
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
The survival follow -up period will continue for [ADDRESS_736215].
7.2 Assessment ty pes
7.2.1 Efficacy  assessments
The primary  efficacy  endpoint is the overall response rate, as defined in Section 10.4.1. 
Secondary  efficacy  endpoints are duration of response, progression
-free survival and overall 
survival as defined in Section 10.5.2 .
Response will be evaluated, using modified criteria for malignant lymphoma (adapted from 
Cheson et 
al 1999 and Cheson et al 2007). PET scan will notbe used in this study , as it is not 
yet widel y accepted by [CONTACT_560064], and it may not be available in all of the participating centers. Otherwise, response 
criteria will generally  follow the CT scan recommendations in the later publication ( Cheson et 
al 2007). Further clarification on these criteria has been published by (Cheson 2007b). MRI 
will be allowed only in those cases when CT scan cannot be performed. For complete details, 
refer to Appendix 5 .
Clinical evaluation and tumor assessments will be performed periodicall y, as is indicated in 
Table 7-1, based on physical examination, radiological evaluation and core bone marrow 
biopsy  (only to confirm complete responses in patients with bone marrow tumor involvement 
prior to stud y treatment). Tumor assessments will be performed every  2 cycles (every  8 weeks 
±7 days). Clinical suspi[INVESTIGATOR_560028] a physical 
examination and radiological confirmation to be performed promptly , rather than waiting for
the next scheduled tumor assessment. In case of an unscheduled or delay ed tumor assessment
for any reason, subsequent tumor assessments must be performed according to the originall
y
planned schedule from baseline.
[IP_ADDRESS] Physical examination
Tumor assessment by [CONTACT_560065] B symptoms 
(unexplained fever of ≥ 38°C; unexplained, recurrent drenching night sweats; or unexplained 
loss of >10% body  weight within the previous 6 months) will be performed and recorded 
following the schedule for radiological tumor assessments.
[IP_ADDRESS] Radiological tumor assessment
At screening, all patients must have a CT scan with contrast of the Chest/Abdomen and Pelvis. 
The same type of CT scan used at screening must be used for all subsequent assessm ents. 
MRI  with contrast will be allowed only  in those cases when CT scan cannot be performed and 
will be used at baseline and all subsequent assessments in these patients. No modality  change 
would be allowed during the study . Only in exceptional cases when during the study  a patient 
develops intolerance to the CT scan contrast medium, a CT scan without contrast will be 
acceptable to avoid modality  change. At screening, tumor assessments should preferabl y be 
performed ≤ [ADDRESS_736216] dose ofBKM1 20, however tumor assessments ≤ 28days 
prior to first dose of study  drug will be acceptable.

[COMPANY_001] Confidential Page 79
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
CT Scans of the Chest/Abdomen and Pelvis will be performed following completion of every 
2 cycles. It may also be performed as clinically  indicated. For visit schedule refer to 
Table 7-1. Any patient w ho has been discontinued from treatment with BKM120 for any 
reason other than death or loss to follow - up (i.e., documented disease progression by [CONTACT_1275], an AE or SAE, administrative reason, withdrawal of consent from treatment, etc.) 
will contin ue to have tumor assessments as per their current schedule until the initiation of a 
new anticancer therap y. The response CRFs are expected to continue being completed in a 
timely  fashion. The investigator or his/her designee will collect information on a new 
anticancer therap y, given after the last dose of study  drug, and record the information on the 
appropriate eCRF. All patients should have at least one site of measurable nodal disease > 2.[ADDRESS_736217] scan (MRI is allowed onl y if CT scan cannot be performed). 
Complete guidance for selecting index lesions is provided in Appendix 5. Index lesions will 
be measured and recorded at baseline and during the course of the study . They  should be 
selected on the basis of their size and suitability  for accurate repeat measurements. Skin 
lesions, if the area is ≥ [ADDRESS_736218] be histologically  conformed for 
lymphoma 
involvement (the site must document the histological confirmation (yes orno) to 
the corresponding 
CRF) and photographed (color photograph y using digital camera) 
(optional).
A sum of the product of diameters (SPD) for le sions measured prior to study  treatment will be 
calculated and reported at baseline.
Conventional CT and MRI  should be performed with contiguous cuts of 7.[ADDRESS_736219] should be performed using a 5 mm or less contiguous 
recons truction algorithm (this specification applies to tumors of the chest, abdomen and 
pelvis).
If a very small lesion can not be reliabl y measured because of its size, it is recommended to 
enter the minimum lesion size (i.e., [ADDRESS_736220]). In other cases where the lesion 
cannot be reliably  measured for reasons other than its size (i.e., borders of the lesion are 
confounded b y neighboring anatomical structures), no measurement should be entered and the 
lesion cannot be evaluated.
Any measurable extranoda l lesions (organs other than lymph nodes) that resolves from 
baseline (disappear completely ) must be assigned a size of [ADDRESS_736221] be ≥ 1 cm x 1 cm to be considered 
measurable. Refer to Appendix 5 for complete reporting guidelines.
[IP_ADDRESS] Bone marrow assessment
Information on the patient bone marrow involvement prior to study  entry must be present in 
his/her source documents. Prior tumor bone marr ow involvement should be entered on the 
corresponding eCRF.
Core bone marrow biopsy  is required to confirm Complete Responses (at the first occurrence 
of radiological and clinical evidence of CR) in patients with bone marrow tumor involvement 
prior to study treatment who achieve Complete Response based on clinical and radiological 
evidence. The biopsy  sample on which this determination is made must be adequate (with a 

[COMPANY_001] Confidential Page 80
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
goal of > 20 mm unilateral core). Bone marrow biopsy  should be obtained no later than at the 
next visit immediately  following clinical and radiological evidence of CR (i.e. < 28 days ± 7 
days from the date of the radiological assessment, on which the CR is based on).
7.2.2 Safety  and tolerability assessments
Safety  assessments will be monitored by [CONTACT_396624], concomitant 
medications, and the regular monitoring of laboratory  tests (including glucose monitoring), 
physical examinations, weight, vital signs, as well as collecting of the adverse events at every 
visit. For details on AE collection and reporting, refer to Section 8 .
[IP_ADDRESS] Physical examination
The clinical examination comprises a total body examination that should include general 
appearance, skin, neck (including thyroid), eyes,ears, nose, throat, lungs, heart, abdomen, 
back, lymph-nodes, and extremities, vascular and neurological. If indicated; rectal, external 
genitalia, breast and pelvis exams will be performed.
Clinical examinations will be performed on the scheduled day, even if study  medication is 
being withheld. More frequent examinations may  be performed at the investigator’s discretion 
and/or if medicall y indicated.
Evaluation of ocular signs and sy mptoms is recommended as part of the phy sical examination 
throughout the study . In case a patient develops symptoms such as tearing, ocular redness, 
pain, photophobia or altered vision, the possibility  of a drug-induced effect should be 
considered. To ensure appropriate diagnosis and management, and to avoid potential 
complicat ions, referral to an ophthalmologist may  be required.
Information 
about the physical examination must be present in the source documentation at 
the study  site. Significant findings those were present prior to the signing of informed consent 
must be included in the Relevant Medical History /Current Medical Conditions page on the 
patient’s eCRF. Significant new findings that begin or worsen after informed consent must be 
recorded on the Adverse Event page of the patient’s eCRF.
[IP_ADDRESS] Vital signs
Vital signs assessments include body  temperature, sitting blood pressure, and sitting pulse. 
Vital signs should be assessed on the scheduled day  even if study  treatment is being withheld. 
More frequent examinations may be performed at the investigator’s discretion, ifmedically 
indicated. If the vital signs are determined during screening ≤ [ADDRESS_736222] dose of 
study  treatment, it does not need to be repeated on Day  1 of C ycle 1.
[IP_ADDRESS] Height and weight
Weight will be performed at screening, on Day 1 Cycle 1, on D ay 1  of every  subsequent 
treatment Cycle, as clinically  indicated and at the End of treatment. Height will be measured 
and recorded at screening only. If weight is determined during screening ≤ [ADDRESS_736223] dose of study  treatment, it does not n eed to be repeated on Day  1 of Cy cle 1.

[COMPANY_001] Confidential Page 81
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
[IP_ADDRESS] Performance status
The baseline ECOG performance status will be assessed and recorded at screening, on Day 1 
Cycle 1, on Day 1 of every  subsequent treatment Cycle, and at the End of Treatment . If the 
ECOG performance status is determined during screening ≤ [ADDRESS_736224] dose of 
study  treatment, it does not need to be repeated on Day  1 of C ycle 1.
The ECOG scale and criteria allows patients to be classified, based on evaluation of patient’s 
disease progression, how the disease affects the daily living abilities of the patient, and allows 
the determination of appropriate treatment and prognosis. The definition of scores in relation 
to the performance status is given in Table 7 -3.
Table 7
-3 ECOG performance scale
Grade ECOG
0 Fully active, able to carry on all pre -disease performance without restriction
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or 
sedentary nature, e.g., light housework, office work.
2 Ambulatory and capable of all self -care but unable to carry out any work activities. Up and about more 
than 50% of waking hours.
3 Capable of only limited self -care, confined to bed or chair more than 50% of waking hours.
4 Completely disabled. Cannot carry on any self -care. Totally confined to bed or chair.
5 Death
As published by ( Oken et al 1982 ).Eastern Cooperative Oncology Group, Robert Comis M.D., Group Chair.
[IP_ADDRESS] Laboratory  evaluations
The standard clinical laboratory  analyses described below are to be performed by [CONTACT_560066]’s local laboratories according to the Visit Schedule, outlined in Table 7-1. [COMPANY_001] will 
be provided with a copy  of the laboratory  certification and tabulation of the normal ranges for 
each parameter required at study  start and should be kept apprised of any updates on an 
ongoing basis. In addition, if at any time a patient has laboratory  parameters obtained from a 
different outside laboratory , [COMPANY_001] must be provided with a copy of the cer
tification and a 
tabulation of the normal ranges for that laboratory .
The investigator is responsible for reviewing all laboratory  reports for patients in the study 
and evaluating any abnormalities for clinical significance. At any time during the study , 
abnormal laboratory  parameters that are clinically  relevant (e.g., require dose modification 
and/or interruption of study  drug, lead to clinical symptoms or signs, or require therapeutic 
intervention), whether specificall y requested in the protocol or not, must be recorded on the 
Adverse events CRF.
Laboratory  data will be summarized using the Common Terminology Criteria for Adverse 
Events (CTCAE) version 4.03.
Local laboratory  tests will be collected and analy zed on the scheduled day, even if study 
medicati on is being held. More frequent examinations may be performed at the investigator’s 
discretion if medicall y indicated; those results should be recorded on the Unscheduled Visit 
CRF.

[COMPANY_001] Confidential Page 82
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
Laboratory  assessments performed as part of the screening evaluations and within [ADDRESS_736225] be repeated until recovery  to the 
baseline value or grade 1.
Hepatotoxicity  follow -up testing will be performed when needed (refer to Section [IP_ADDRESS]).
Table [ADDRESS_736226] Name
*Viral hepatitis serologic 
tests and other tests for 
hepatotoxicity follow -up *HAAb, HBsAg, HBsAb HBcAb, HCV RNA or HDV RNA (where needed), HEAb, 
CMVAb, EBcAb, ALP, CPK, LDH, W BC (eosinophilia), and others.
* Hepatotoxicity follow -up testing/procedures will be performed locally ( refer to Section [IP_ADDRESS] and 
Section [IP_ADDRESS].8 ).
[IP_ADDRESS].1 Hematology
Hematology  includes the following parameters: complete blood count consisting of a white 
blood cell (WBC) count with differential (total neutrophils [including bands], lymphocy tes, 
monocy tes, eosinophils, basophils), hemoglobin (Hgb), and platelet counts.
Hematological tests will be performed at screening, on Cycle 1 Day 1 (prior to administration 
of the study  drug) and repeated on Day [ADDRESS_736227] may  also be pe rformed as medicall y neces sary.
[IP_ADDRESS].2 Clinical chemistry
Clinical chemistry  includes the following parameters:
Potassium, sodium, calcium, magnesium, chloride, inorganic phosphorus
ALT/SG PT, AST/SG OT, alkaline phosphatase, total bilirubin, direct bilirubin, L DH, 
Gamma GT
Serum creatinine, urea or blood urea n itrogen (BUN), lipase, albumin, uric acid
Fasting plasma glucose (fasting is defined as no calo ric intake for at least 8 hrs).
Clinical chemistry  will be performed at screening, on Cycle 1 Day 1 (prior to administration 
of study drug), repeated on D ay [ADDRESS_736228] treatment cy cle to monitor for TLS:
Uric acid, potassium, sodium, calcium, inorganic phosphorus and serum creatinine
[IP_ADDRESS].3 Coagulation
The coagulation profile includes partial thromboplastin time (PTT) and either prothrombin 
time (PT) or International normalized ratio ( INR)
.
Coagulation profile will be performed at screening, on Cycle 1 Day 1 (prior to administration 
of study  drug) and as clinically  indicated.

[COMPANY_001] Confidential Page 83
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
[IP_ADDRESS].[ADDRESS_736229] be fasting when blood is drawn for lipid panel. Lipid panel includes total-, 
LDL -and HDL -cholesterol and trigl ycerides.
Lipid panel will be performed at screening, on Cycle 1 Day 1 (prior to administration of study 
drug, on Day  1 of Cy cle 3, every  2ndcycle thereafter (i.e. Day  1 of Cy cle 5, Day  1 of Cy cle 7, 
etc.) and at End of Treatment.
[IP_ADDRESS].[ADDRESS_736230] be fasting when blood is drawn for C-peptide and HbA1c analysis. Analysis 
should be performed prior to BKM120 administration.
C-peptide and HbA1c testing will be performed at screening, on Cycle 1 Day 1  (prior to 
administration of study  drug), on Day 1 of Cycle 3, every  2ndcycle thereafter (i.e. Day 1 of 
Cycle 5, Day  1 of C ycle 7, etc.) and at End of Treatment.
[IP_ADDRESS].6 Urinalysis
Not applicable.
[IP_ADDRESS].7 Pregnancy and assessments of fertility
Pregnancy  tests are indicated for all females of childbearing potential. Serum tests are 
required at screening, on Cycle 1 Day 1 (prior to administration of study  drug) and repeated 
on Day [ADDRESS_736231] be reported to the sponsor within 24 hours of 
learning of its occurrence. See Section 8.4 for detailed reporting and follow up procedures.
Note: Women are considered post-menopausal and not of child bearing potential if any of the 
following conditions is fulfilled:
Prior surgical bilateral oophorectom y (with or wi thout hy sterectom y) or tubal l igation at 
least six weeks ago.
Age ≥60
Age < 60 and amenorrhea for 12 or more months (in the absence of chemotherap y), and 
FSH and estradiol in the postmenopausal range (serum FSH > 40 mIU/mL and estradiol 
<20 pg/mL or accord ing to the postmenopausal range definition for the laboratory  
involved).

[COMPANY_001] Confidential Page 84
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
[IP_ADDRESS].8 Viral hepatitis serology and other tests for hepatotoxicity follow -up
Viral hepatitis serologic tests are performed confirm patient’s eligibility  when needed per 
clinical judgment and specific pa tient’s clinical circumstances.
During study  treatment, viral hepatitis serologic and other tests will be performed as per the 
guidelines of management of hepatotoxicity  (ALT or AST >3.0x ULN and total bilirubin > 
2.0x ULN) in patients receivin g BKM120, refer to Section [IP_ADDRESS] for details.
Viral hepatitis serology  includes the following:
Hepatitis A IgM antibody and hepatitis A serology total
Hepatitis B surface antigen, Hepatitis B Core Antibody  (IgM) and viral D NA
Hepatitis C serology  and viral RNA
Hepatitis D RNA (where needed)
Hepatitis E IgM and IgG antibody  and viral RNA
Obtain fractionated bilirubin, serum Alkaline Phosphatase (ALP), creatine phosphokinase 
(CPK), lactate deh ydrogenase (LDH), and blood count with differential to assess eosinophilia.
Additional viral serology tests may  include:
Cytomegalovirus IgM antibody
Epstein- Barr viral capsid antigen IgM antibod y (or if unavailable , obtain heterophile 
antibody  or monospot testing)
Herpes Simplex Virus
[IP_ADDRESS] Radiological examinations
Not applicable.
[IP_ADDRESS] Cardiac assessments
[IP_ADDRESS].1 Electrocardiogram (ECG)
The study  requires standard 12-lead digital ECG as indicated in Table [ADDRESS_736232] be performed prior to any  study  drug administration on the respective day s.
Single ECG should generally  be done prior to an y blood draws.
ECGs will be performed at screening, on Cycle 1 Day 1 (prior to admi nistration of study  
drug), repeated on Day 1 of every  subsequent treatment cycle and at End of Treatment. ECGs 
may be repeated more frequentl y at the investigator’s discretion if signs and symptoms of 
cardio -toxicity  exist. If an ECG is performed for scree ning ≤ [ADDRESS_736233] be recorded on the Adverse Events CRF page.

[COMPANY_001] Confidential Page 85
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
[IP_ADDRESS].2 Cardiac imaging - MUGA (multiple gated acquisition) scan or 
echocardiogram
MUGA (multiple gated acquisitions) scan or echocardiogram (ECHO) will be used to asses s 
LVEF at screening.
LVEF assessment may be performed as clinically indicated at the investigator’s discretion if 
there are signs or symptoms of cardiotoxicity . In case of clinicall y significant abnormalities, 
they should be reported on the Adverse Events CRF.
[IP_ADDRESS] Patient self -rating mood questionnaire
The Patient Health Questionnaire -9 (PHQ -9) and General Anxiety  Disorder -7 (GAD -7) will 
be collected to screen patients for study eligibility and to aid in the identification and severit y 
assessment of potential m ood alterations. The PHQ -9 and GAD -7 are validated ( Kroenke et al 
2001, Spi[INVESTIGATOR_72443] 2006 ,Spi[INVESTIGATOR_72443] 1999 ), patient self-administered questionnaires 
developed for use in clinical practices.
The GAD-7 ( Table 7-6) is a one - dimensional questionna ire consisting of [ADDRESS_736234] been bothered by [CONTACT_560067] y 
disorder as referenced in the DSM IV. Response options are ‘‘not at all,’’ ‘‘several days,’’ 
‘‘more than half the days,’’ and ‘‘nearl y every  day,’’ scored as0, 
1, 2, and 3, respectivel y. 
The sum of all seven questions calculate the total GAD-7 score. Therefore, GAD-7 scores 
range from 0 to 21.
The PHQ -9 (Table 7-7) consists of [ADDRESS_736235] been bothered by [CONTACT_4167]. Scoring 
of the PHQ -9 is based on 
a Likert -type scale from 0 to 3 (0 indicates not at all; 1, several days; 2, more than half the 
days; 3, nearl y every  day). The sum ofall nine questions is used to determine a total PHQ -[ADDRESS_736236] complete two different mood questionnaires, (PHQ -9 and GAD -7) at 
Screening, Cycle 1 Day  1,and Day 1 of each subsequent cy cle in addition to the EOT visit. If 
the questionnaires are completed as part of screening ≤ [ADDRESS_736237] patients 
to complete the mood questionnaires prior to administration of any study-
related treatment or 
clinical assessments or procedure. Additional assessments may be done according to the 
clinical judgment of the investigator.
All questionnaires should be administered in the patient’s local language at the beginning of 
the study visit prior to any interaction with the study  investigator including any tests, 
treatments or receipt of results from any tests to avoid biasing the patient’s perspective. This 
is to avoid potentially biasing patients or their responses to study  questi onnaires.
Patients should be given sufficient space and time to complete all study  questionnaires and all 
administered questionnaires should be reviewed for completeness. If missing responses are 
noted, patients should be encouraged to complete any missing responses . Attempts should be 

[COMPANY_001] Confidential Page 86
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
made to collect responses to all questionnaires for all patients, including from those who 
discontinue prior to the study  evaluation completion visit, however, if patients refuse to 
complete questionnaires, this should be documented in study  source records.
Completed questionnaires, including both responses to the questions and any unsolicited 
comments written by  [CONTACT_102], must be reviewed and assessed by  [CONTACT_560068]. This review 
should be documented in study  source records.
If an AE or SAE is confirmed then the physician should record the event as instructed in 
Section 8 of this protocol. Investigators should not encourage the patients to change responses 
reported in questionnaires.
The severit y classification table described in Table 7-5for the PHQ -9 and GAD -7 will be 
used inthis study to increase the sensitivity  of identify ing potential anxie ty and/or depression 
disorders. During the study , questionnaire scores and corresponding severity  classification can 
be used to aid the investigator in identify ing new or worsen ing of events. Importantly , grading 
must be based on the clinical interpretation of severity  accor ding to the NCI -CTCAE (v 4.03).
Table 7-5 Classification of severity  based o n mood questionnaire scores
PHQ -9 (depression) GAD -7 (anxiety )
Score Severit y Score Severit y
0-4 None 0-4 None
5-9 Mild 5-9 Mild
10-19 Moderate 10-14 Moderate
20-27 Severe ≥ [ADDRESS_736238] to be ineligible 
based on medical mental health history  as listed in the exclusion criteria. Alternativel y, 
patients who score ≥ 12 on the PHQ -9 or ≥ [ADDRESS_736239] a positive response of ‘1, 2, or 3’ to question number [ADDRESS_736240] etion is recommended.
During the treatment phase, patients who indicate a positive response by [CONTACT_20683] ‘1, 
2, or 3’ 
to question number 9inthe PHQ -9 and/or present with suicidal ideation must interrupt
treatment with study  drug and must be referred for psychiatric consultation for appropriate 
psychotropic management regardless of the total questi onnaire score or CTCAE grading and 
to confirm if study  drug should be interrupted or permanently  discontinued. In this specific 
case, the psychiat ric advice can overrule the patient PHQ -[ADDRESS_736241] the patient to complete the questionnaires as well as how to 
determine the scores will beprovided with each instrument. Dosing modification guidelines 

[COMPANY_001] Confidential Page 87
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
for BKM120 are provided in Table 6-3. For additional information on AE reporting, please 
refer to Section 8.1.
Table [ADDRESS_736242] y ou 
been bothered by  [CONTACT_9443]?
(Use “ ✔” to indicate y our answer”Not at 
allSeveral 
daysMore than
half the 
daysNearly  
every  
day
1. Feeling nervous, anxious or on edge [ADDRESS_736243] to sit still 0 1 2 3
6. Becoming easily annoyed or irritable 0 1 2 3
7. Feeling afraid as if something awful might 
happen 0 1 2 3
Column totals: + + +
= Total Score
Table 7-[ADDRESS_736244] y ou been 
bothered by  [CONTACT_33687]?
(Use “ ✔” to indicate y our answer”Not at 
allSeveral 
daysMore 
than half 
the day sNearly  
every
day
1. Little interest or pleasure in doing things [ADDRESS_736245] noticed? Or the opposite -being so fidgety or 
restless that you have been moving around a lot more 
than usual0 1 2 3
9. Thoughts that you would be better off dead or of 
hurting yourself in some way0 1 2 3
Column totals: + + +
= Total Score _____
If you checked off any problems, how difficult have these problems made it for you to do your work, take care of 
things at home, or get along with other people?
Not difficult
atallSomewhat
difficultVery
DifficultExtremely
Difficult

[COMPANY_001] Confidential Page 88
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402

[COMPANY_001] Confidential Page 89
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402

[COMPANY_001] Confidential Page 90
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
7.2.4 Other assessments
No additional tests will be performed on patients entered into this study .
8 Safety  monitoring and reporting
8.1 Adverse events
8.1.1 Definitions and reporting
An adverse event is defined as the appearance of (or worsening of any pre-existing) 
undesirable sign(s), symptom(s), or medical condition(s) that occur after patient’s signed 
informed consent has been obtained. Abnormal laboratory  values or test results occurring 
after informed consent constitute adverse events only if they induce clinical signs or 
symptoms, are considered clinicall y significant, require therapy  (e.g., hematologic 
abnormality  that requires transfusion or hematological stem cell support), or require changes 
in study  medication(s).

[COMPANY_001] Confidential Page 91
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
Adverse events that begin or worsen after informed consent should be recorded in the Adverse 
Events CRF. Conditions that were alread y present at the time of informed consent should be 
recorded in the Medical History  CRF. Adverse event monitoring should be continued for at 
least [ADDRESS_736246] dose of study  treatment. Adverse events (including lab 
abnormalities that constitute AEs) should be described using a diagnosis whenever possible, 
rather than individual underly ing signs and symptoms. When a clear diagnosis cannot be 
identified, each sign or symptom should be reported as a separate Adverse Event.
Adverse events will be assessed according to the Common Terminology  Criteria for Adverse 
Events (CTCAE) version 4.03. If CTCAE grading does not exist for an adverse event, the 
severit y of mild, moderate, severe, and life-threatening, corresponding togrades 1 - 4, will be 
used. CTCAE grade 5 (death) will not be used in this study ; rather, information about deaths 
will be collected th rough the EOT/SEC/Survival Information eCRF pages.
The occurrence of adverse events should be sought by  [CONTACT_105]-directive questioning of the patient 
(subject) during the screening process after signing informed consent and at each visit during 
the study . Adverse events also may be detected when they are volunteered by [CONTACT_102] 
(subject) during the screening process or between visits, or through physical examination, 
laboratory  test, or other assessments. As far as possible, each adverse event should be 
evaluated to determine:
1.The severit y grade (CTCAE grade 1 - 4)
2.Its duration (Start and end dates)
3.Its relationship to the study  treatment (Reasonable possibility  that AE is related: No, Yes)
or
Its relationship to the stud y treatment (Reasonable possibility  that AE is related: No,
Yes, investigational treatment, Yes, the study  treatment (non -investigational), Yes, both 
and/or indistinguishable)
4.Action taken with respect to study  or investigational treatment (none, dose adju sted, 
temporaril y interrupted, permanentl y discontinued, unknown, not applicable)
5.Whether medication or therap y taken (no concomitant medication/non- drug therap y, 
concomitant medication/non -drug therap y)
6. Outcome (not recovered/not resolved, recovered/resol ved, recovering/resolving, 
recovered/resolved with sequalae, fatal, unknown)
7.Whether it is serious, where a serious adverse event (SAE) is defined as in Section 8.2.1
All adverse events should be treated appropriately . If a concomitant medication or non-drug 
therap y is given, this action should be recorded on the Adverse Event CRF.
Once an adverse event is detected, it should be followed until its resolution or until it is 
judged to be permanent, and assessmen t should be made at each visit (or more frequently , if 
necessary ) of any changes in severit y, the suspected relationship to the study  treatment, the 
interventions required to treat it, and the outcome.
Progression of malignancy  (including fatal outcomes), if documented by [CONTACT_15039] (Cheson criteria), should not be reported as a serious adverse event.
Adverse events separate from the progression of malignancy  (example, deep vein thrombosis 
at the time of progression or hemopty sis concurrent with finding of disease progression) will 

[COMPANY_001] Confidential Page 92
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
be reported as per usual guidelines used for such events with proper attribution regarding 
relatedness to the drug.
8.1.[ADDRESS_736247] abnormalities
[IP_ADDRESS] Definitions and reporting
Laboratory  abnormalities that constitute anAdverse event in their own right (are considered 
clinically  significant, induce clinical signs or symptoms, require concomitant therapy  or 
require changes in study  treatment), should be recorded on the Adverse Events CRF. 
Whenever possible, a diagnosis, rather than a symptom should be provided (e.g. anemia 
instead of low hemoglobin). Laboratory  abnormalities that meet the criteria for Adverse 
Events should be followed until they have returned to normal or an adequate explanation of 
the abnormality  is found . When an abnormal laboratory  or test result corresponds to a 
sign/sy mptom of an already  reported adverse event, it is not necessary  to separately  record the 
lab/test result as an additional event.
Laboratory  abnormalities, that do not meet the definition of an adverse event, should not be 
reported as adverse events. A grade 3 or 4 event (severe) as per CTCAE does not 
automatically  indicate a SAE unless it meets the definition of serious as defined below and/or 
as per investigator’s discretion. A dose hold or medication for the lab abnormality  may be 
required by [CONTACT_64103], by [CONTACT_108], be an 
adverse event and must be reported as such.
8.2 Serious adverse events
8.2.1 Definitions
Serious adverse event (SAE) is defined as one of the following:
Is fatal or life -threatening
Results in persistent or significant disability /incapacity
Constitutes a congenital anomaly /birth defect
Is medicall y significant, i.e., defined as an event that jeopardizes the patient or may 
require m edical or surgical intervention to prevent one of the outcomes listed above
Requires inpatient hospi[INVESTIGATOR_3850],
Note that hospi[INVESTIGATOR_560029] s:
Routine treatment or monitoring of the studied indication, not associated with any 
deterioration in condition
Elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study  and has not worsened since signi ng the informed consent
Social reasons and respi[INVESTIGATOR_5316]’s 
general condition
Note that treatment on an emergency outpatient basis that does not result in hospi[INVESTIGATOR_560030] y of the definitions of a SAE given above 
is not a serious a dverse event

[COMPANY_001] Confidential Page 93
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
Protocol specific SAE: any  Hy’s law case of drug-induced liver toxicity  should be reported as 
an SAE, even when assessed non-serious by [CONTACT_093]. These reports will alwa ys be 
assessed as medically  significant by  [CONTACT_560069].
Protocol exempt SAEs: 
Progression of malignancy (including fatal outcomes), if 
documented b y use of appropriate method (Cheson criteria), should not be re ported as a 
serious adverse event.
8.2.[ADDRESS_736248] be reported as follow -up to the original 
epi[INVESTIGATOR_5319] 24 hours of the investigator receiving the follow -up information. An SAE 
occurring at a different time interval or otherwise considered completely  unrelated to a 
previously  reported one should be reported separately  as a new event.
Information about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form ; all applicable sections of the form must be completed in order to provide a clinicall y 
thorough report. The investigator must assess and record the relationship of each SAE to each 
specific study  treatment (if there is more than one study  treatment), complete the SAE Report 
Form in English, and send the completed, signed form by  [CONTACT_87109] [ADDRESS_736249] persons in the local department of Drug 
Safety  and Epi[INVESTIGATOR_623]  (DS&E), specific to the site, are listed in the investigator folder 
provided to each site. The original copy of the SAE Report Form and the fax confirmation 
sheet must be kept with the case report form documentation at the study  site.
Follow -up information is sent to the same contact(s) to whom the original SAE Report Form 
was sent, using a new SAE Report Form stating that thisis a follow -up to the previously  
reported SAE and giving the date of the original report. Each re-occurrence, complication, or 
progression of the original event should be reported as a follow -up to that event regardless of 
when it occurs. The follow -up information should describe whether the event has resolved or 
continues, if and how it was treated, whether the blind was broken or not, and whether the 
patient continued or withdrew from study  participation.
If the SAE is not previously  documented in the [Investigator’s Brochure ]or Package Insert 
(new occurrence) and is thought to be related to the [COMPANY_001] study  treatment, an oncology 
[COMPANY_001] Drug Safet y and Epi[INVESTIGATOR_623]  (DS&E) department associate may urgently  require 
further information from the investi gator for Health Authority  reporting. [COMPANY_001] may  need to 
issue an Investigator Notification (IN), to inform all investigators involved in any study with 
the same drug that this SAE has been reported. Suspected Unexpected Serious Adverse 
Reactions (S[LOCATION_003]Rs ) will be collected and reported to the competent authorities and relevant 
ethics committees in accordance with Directive 2001/20/EC or as per national regulatory 
requirements in participating countries.

[COMPANY_001] Confidential Page 94
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
8.[ADDRESS_736250] be reported to [COMPANY_001] within 24 hours of learning of its occurrence. The pregnancy 
should be followed up to determine outcome, including spontaneous or voluntary  termination, 
details of the birth, and the presence or absence of any  birth defects, congenital abnormalities, 
or maternal and/or newborn complications.
Pregnancy  should be recorded on a Clinical Trial Pregnancy  Form and reported by [CONTACT_5373][INVESTIGATOR_18540] (DS&E). 
Pregnancy  follow -up should be recorded on the same form and should include an assessment 
of the possible relationship to the [COMPANY_001] study  treatment of any pregnan cy outcome. Any 
SAE experienced during pregnancy  must be reported on the SAE Report Form.
Pregnancy  outcomes must be collected for the female partners of any males who took study
drug in this study . Consent to report information regarding these pregnancy  outcomes should 
be obtained from the female partner.
8.5 Warnings and precautions
No evidence available at the time of the approval of this study  protocol indicated that special 
warnings or precautions were appropriate, other than those noted in the provided 
[Investigator ’sBrochure ]. Additional safet y information collected between IB updates will be 
communicated in the form of Investigator Notifications. This information will be included in 
the patient informed consent and should be discussed with the patient during the study  as 
needed.
8.6 Data Monitoring Committee
Not a pplicable.
8.7 Steering Committee
The 
Steering Committee will be established comprising investigators participating in the trial, 
i.e. not being [COMPANY_001] representative s from the Clinical Trial Team.
The Steering Committee will ensure transparent management of the study  according to the 
protocol through recommending and approving modifications as circumstances require. The 
Steering Committee will review protocol amendments as appropriate. Together with the 
clinical trial team, the Steering Committee will also develop recommendations for 
publications of study  results including authorship rules. The details of the role of the Steering 
Committee will be defined in a Steering Committee charter.

[COMPANY_001] Confidential Page 95
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
[ADDRESS_736251] of the following:
What protected health information (PHI) will be collected from subjects in this study
Who will have access to that information and wh y
Who will use or disclose that information
The rights of a research subject to revoke their authorization for use of their PHI .
In the event that a subject revokes authorization to collect or use PHI, the investigator, by 
[CONTACT_5151], retains the ability  to use all information collected prior to the revocation of subject 
authorization. For subjects that have revoked authorization to collect or use PHI, attempts 
should be made to obtain permission to collect at least vital status (i.e. that the subject is alive) 
at the end of their scheduled study  period.
The data collection system for this study  uses built-in security  features to encrypt all data for 
transmission in both directions, preventing unauthorized access to confidential participant 
information. Access to the system will be controlled by a sequence of individually  assigned 
user identification codes and passwords, made availab le only to authorized personnel who 
have completed prerequisite training.
Prior to entering key sensitive personally  identifiable information (Subject Initials and exact 
Date of Birth), the system will prompt site to verify  that this data is allowed to be collected. If 
the site indicates that country  rules or ethics committee standards do not permit collection of 
these items, the system will not solicit Subject Initials. Year of birth will be solicited (in the 
place of exact date of birth) to establish thatthe subject satisfies protocol age requirements 
and to enable appropriate age-related normal ranges to be used in assessing laboratory  test 
results.
9.2 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, Novar tis 
personnel (or designated CRO) will review the protocol and CRFs with the investigators and 
their staff. During the study , the field monitor will visit the site regularly to check the 
completeness of patient records, the accuracy  of entries on the CRFs, the adherence to the 
protocol to Good Clinical Practice, the progress of enrollment, and to ensure that study 
treatment is being stored, dispensed, and accounted for according to specifications. Key study 
personnel must be available to assist the field mo nitor during these visits.
The investigator must maintain source documents for each patient in the study , consisting of 
case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical 
information, laboratory data, electrocardio grams, and the results of any other tests or 
assessments. All information recorded on CRFs must be traceable to source documents in the 
patient's file. The investigator must also keep the original signed informed consent form (a 
signed cop y is given to the patient).

[COMPANY_001] Confidential Page 96
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
The investigator must give the monitor access to all relevant source documents to confirm 
their consistency  with the CRF entries. [COMPANY_001] monitoring standards require full verification 
for the presence of informed consent, adherence to the incl usion/exclusion criteria and 
documentation of SAEs. Additional checks of the consistency  of the source data with the 
CRFs are performed according to the stud y-specific monitoring plan.
9.3 Data collection
This study  will be using Electronic Data Capture (EDC), the designated investigator staff will 
enter the data required by [CONTACT_5374] (eCRF). The 
eCRFs have been built using fully validated secure web-enabled software that conforms to [ADDRESS_736252] been trained. Automatic validation programs check for data discrepancies in 
the eCRFs and, allow modification or verification of the entered data b y the investigator staff.
The Principal Investigator [INVESTIGATOR_217914], accurate, and that entry  and updates are performed in a timely  manner.
9.4 Database management and quality  control
[COMPANY_001] personnel (or designated CRO) will review the data entered by [CONTACT_49432] . Electronic data queries stating the nature of the problem and 
requesting clarification will be created for discrepancies and missing values and sent to the 
investigational site via the EDC system. Designated investigator site staff are required to 
respond promptly  to queries and to make any  necessary  changes to the data.
Concomitant treatments entered into the database will be coded using the WHO Drug 
Reference List, which employ s the Anatomical Therapeutic Chemical classification system. 
Medical history /current medical conditions and adverse events will be coded using the 
Medical dictionary  for regulatory  activities (MedDRA) terminology .
Biomarker samples and/or data will be processed centrally  and the results will be sent 
electronically  to [COMPANY_001] (or a designated CRO).
After database lock, the investigator will receive a CD-ROM or paper copi[INVESTIGATOR_268253].
[ADDRESS_736253] N = 66 subjects, i.e. N = 22 patients in each of the three
histologically  defined cohorts: mantle cell lymphoma, follicular lymphoma anddiffuse large 
B-cell lymphoma. Maximum number of patients per cohort will be capped at N = [ADDRESS_736254] deviation, median, minimum, and max imum will be presented.

[COMPANY_001] Confidential Page 97
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
If not specified otherwise, all statistical tests will use a significance level of 5% and 95% 
confidence intervals will be calculated.
10.1 Analysis sets
10.1.1 Full A nalysis Set
The Full Anal ysis Set (FAS) comprises all included patients who r eceived at least one dose of 
study  treatment. As a consequence, the FAS excludes screened patients who were not 
administered study  treatment b ut were intended to be treated.
10.1.[ADDRESS_736255] baseline safet y assessment.
Note: The statement that a patient had no adverse events (on the Adverse Event CRF page) 
constitutes a safet y assessmen t.
10.1.3 Per Protocol Set
The Per-Protocol Set (PPS) consists of a subset of the patients in the FAS who received at 
least one dose of the study treatment and who hav e no major protocol deviations.
Oncology  standards for major protocol deviations potentially leading to exclusion from the 
PPS are:
type of indication differ ent from those required b y the clinical study  protocol ( CSP)(e.g. 
incorrect histology /cytology , not refractory , not metastatic, different grade of cancer, etc.),
if prior therap y does not match with CSP requirements in terms of number and types of 
previous therap y regimens,
missing or incomplete documentation of stage of disease (as required in the CSP),
if ECOG performance status at least 2 categories worse than protocol- defined inclusion 
criteria,
another anti -neoplastic therap y administered after start of study  treatment and prior to first 
tumor assessment.
All protocol deviations leading to exclusion from the PPS will be detailed in the report and 
analysis plan (RAP) and validation anal ysis plan (VAP).
10.1.4 Dose -determining analy sis set
Not applicable .
10.1.5 Pharmacokinetic analy sis set
Not applicable .

[COMPANY_001] Confidential Page 98
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
10.2 Patient demographics/other baseline characteristics
Demographic and other baseline data including disease characteristics will be summarized 
descriptivel y by [CONTACT_560070]. Categorical data will be presented as frequencies and 
percentages. For continuous data, mean, standard deviation, median, 25th and 75th percentiles, 
minimum, and maximum will be presented.
10.3 Treatments (study  treatment, concomitant therapi[INVESTIGATOR_014], compliance)
The actual dose and duration in days of BKM120 as well as the dose intensity  (computed as 
the ratio of actual dose received and actual duration) and the relative dose intensity  (computed 
as the ratio of dose intensity  and planned dose received/planned duration), will be listed and 
summarized by [CONTACT_560071]. Dose reductions, 
interruptions/delay s and increases (including the reasons for these) will be listed and 
summarized by  [CONTACT_9084].
Concomitant medications and significant non-drug therapi[INVESTIGATOR_560031].
10.4 Primary  objective
The primary  objective of the trial is to determine the efficacy  of BKM120 in patients with 
relapsed/refractory  Non-Hodgkin Lym phoma in the three histological subgroups (cohorts): 
mantle cell ly mphoma, follicular ly mphoma anddiffuse large B -cell l ymphoma.
10.4.1 Variable
Overall response rate (ORR) is defined as the proportion of patients with a best overall 
response of CR or PR according to Cheson criteria ( Cheson et al 2007).
The ORR is the number of patients in a cohort who experience either complete response (CR) 
or partial response (PR) during their follow -up after treatment start divided by [CONTACT_560072]. Patients for whom the best response 
after treatment start is missing, ‘UNK’ or ‘PD’ will be considered as non-responders and will 
be counted in the denominator for the estimation of the ORR.
10.4.[ADDRESS_736256] comparing the ORR to 
the reference level of 10% (null hypothesis) in the FAS. The test for each cohort will use a 
significance level of 5%. The ORR will be presented together with an exact 95% Clopper -
Pearson confidence interval.
10.4.3 Handling of missing values/censoring/discontinuations
For the primary  analysis of the ORR, patients without any efficacy  assessment after treatment 
start will be coun ted as failures for the FAS analysis. These patients will be excluded from the 
PPS analy sis.

[COMPANY_001] Confidential Page 99
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
10.4.4 Supportive analy ses
The primary  anal ysis will be repeated on the PPS instead of the FAS.
10.5 Secondary  objectives
10.5.1 Key secondary  objective(s)
Not applicable .
10.5.2 Other seco ndary  efficacy  objectives
Progression -free survival
Progression- free survival (PFS) is defined as the time from the date of treatment start to the 
date of the first documented progressive disease (PD) or death due to any  cause. If a patient is 
not known tohave progressed or died at the date of the analy sis cut-off of the corresponding 
cohort or when he/she receives any further anti-cancer therapy , PFS is censored at the time of 
the last tumor assessment before the cut-off date and before the anti -cancer therapy date. PFS 
will be based on the investigator’s assessment.
PFS will be described using Kaplan -Meier curves with appropriate summary  statistics.
Duration of response
Duration of response is defined as the time from the date of first occurrence of CR orPR to 
the date of the first documented progressive disease (PD) or death due tolymphoma . If a 
patient is not known to have progressed or died at the date of the analysis cut-off for the 
corresponding cohort ,or when he/she receives any further anti-cance r therap y, duration of 
response is censored at the time of the last tumor assessment before the cut-off date and 
befor e the anti -cancer therapy  date.
Duration of response will be described using Kaplan -Meier curves with appropriate summary 
statistics.
Over all survival
Overall survival (OS) is defined as the time from treatment start to the date of death due to 
any cause. Patients not known to have died will be censored at the date of their last available 
assessment or at the analy sis cut -off date whichever comes earlier.
OS will be described using Kaplan -Meier curves with appropriate summary  statistics.
10.5.3 Safety  objectives
[IP_ADDRESS] Analysis set and groupi[INVESTIGATOR_63964] y analyses, the safet y set will be used. All listings and tables will be presented by 
[CONTACT_9084].
The overall observation period will be divided into three mutually  exclusive segments:

[COMPANY_001] Confidential Page 100
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
1.pre-treatment period: from day  of patient’s informed consent to the day  before first dose 
of study  medication
2. on- treatment period: from day  of first dose of study  medication to 30days after last dose 
of study  medication
3.post-treatment period: starting at day  [ADDRESS_736257]-treatment period 
cannot be made, then the respective data will be assigned to the on -treatment period.
[IP_ADDRESS] Adverse events (A Es)
Summary  tables for adverse events (AEs) have to include only AEs that started or worsened 
during the on-treatment period, the treatment -emergent AEs. However, all safet y data 
(including those from the pre and post-treatment periods) will be listed and those collected 
during the pre -treatment and post -treatment period are to be flagged.
The incidence of treatment- emergent adverse events (new or worsening from baseline) will be 
summarized by [CONTACT_30826], severit y (based on CTCAE grades), 
type of adverse event, relation to study  treatment by [CONTACT_9084] . Deaths reportable as SAEs and 
non-fatal serious adverse events will be listed by [CONTACT_560073] .
Specific safet y event categories (SEC) will be considered. Such categories consist of one or 
more well-defined safet y events 
which are similar in nature and for which there is a specific 
clinical interest in connection with the study  treatment.
For each specified SEC, number and percentage of patients with at least one event part of the 
SEC will be reported.
[IP_ADDRESS] Laboratory  abnormalities
For laboratory  tests covered by [CONTACT_15059] 
(CTCAE) version 4.03 (see NCI 2009) ,the study ’s biostatistical and reporting team will grade 
laboratory  data accordingl y. For laboratory  tests covered by [CONTACT_3989], a grade 0 will be 
assigned for all non- missin g values not graded as 1 or higher. Grade 5 will not be used.
In cases (e.g. white blood cell differentials) the lower limits of normal ranges used in CTCAE 
definition have to be replaced b y a clinical meaningful limit expressed in absolute counts.
For laboratory  tests where grades are not defined by [CONTACT_3989], results will be graded by [CONTACT_15060]/normal/high classifications based on laboratory  normal ranges.
The following by-treatment summaries will be generated separately  for hematology , 
biochemistry  and urinary laboratory  tests:
frequency  table for newly  occurring on -treatment grades 3 or 4 (see below for details)
shift tables using CTCAE grades to compare baseline to the worst on -treatment value
for laboratory  tests where CTCAE grades are not defined, shift tab les using the 
low/normal/high/(low and high) classification to compare baseline to the worst on-
treatment value.

[COMPANY_001] Confidential Page 101
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
listing of all laboratory  data with values flagged to show the corresponding CTCAE 
grades and the classifications relative to the laboratory no rmal ranges.
In addition to the above mentioned tables and listings, other exploratory  analy ses, for example 
figures plotting time course of raw or change in laboratory  tests over time or box plots might 
be specified in the MAP and/or RAP.
[IP_ADDRESS] Other safety  data
ECG
shift table baseline to worst on- treatment result for overall assessments
listing of ECG evaluations for all patients with at least one abnormality .
Vital signs
Definitions of notably abnormal results have to be part of the CDP, MAP, CSP and RAP.
shift table baseline to worst on-treatment result
table with descriptive statistics at baseline, one or several post -baseline time points and 
change from baseline to this/these post -baseline time points.
Data from other tests will be listed, notable values flagged, and any other information 
collected will be listed as appropriate. Any statistical tests performed to explore the data will 
be used onl y to highlight any interesting comparisons that may warrant further consideration.
Mood scales
Mood assessment includes two self-reported mood questionnaires, the GAD -[ADDRESS_736258] -
baseline severity  score for each questionnaire will be provided.
[IP_ADDRESS] Supportive analy ses for se condary  objectives
Not applicable.
[IP_ADDRESS] Tolerability
Not applicable.
10.5.4 Pharmacokinetics
Not applicable.

[COMPANY_001] Confidential Page 102
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402

[COMPANY_001] Confidential Page 103
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
10.[ADDRESS_736259] comparing the ORR to 
the reference level of 10% (null hypothesis). The test for each cohort will use a significance 
level of 5%. Sample size is determined in order to detect a true ORR of 35% with a 
probability  of at least 80%. N=[ADDRESS_736260] 6 responses are 
observed among the 22 patients corresponding to aminimal observed ORR of 27.3%.
Maximum number of patients per cohort will capped at N = 28 patients, in case of over 
enrollment. The following table provides the minimum number of respo nses (k) to be 
observed along with the corresponding number of patients enrolled (N) to achieve significant 
test result with corresponding power and observed ORR:

[COMPANY_001] Confidential Page 104
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
Table 10-1 Rejection criteria and power for different sample sizes
N kPower
(%)Observed
ORR (%)
22 6 83.7 27.3
23 6 86.9 26.1
24 7 78.9 29.2
25 7 82.7 28.0
26 7 85.8 26.9
27 7 88.5 25.9
28 7 90.8 25.0
10.9 Power for analy sis of key secondary  variables
Not applicable .
11 Ethical considerations and administrative procedures
11.1 Regulatory  and ethical compliance
This clinical study  was designed, shall be implemented and reported in accordance with the 
ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local 
regulations (including European Directive 2001/20/EC and US Code of Federal Regulations 
Title 21), and with the ethical principles laid down in the Declaration of Helsinki.
11.2 Responsibilities of the investigator and IRB/IEC/REB
The protocol and the proposed informed consent form must be reviewed and approved by a 
properl y constituted Institutional Review Board/I ndependent 
Ethics Committee/Research 
Ethics Board (IRB/IEC/REB) before study  start. A signed and dated statement that the 
protoc ol and informed consent have been approved by [CONTACT_1201]/IEC/REB must be given to 
[COMPANY_001] before study  initiation. Prior to study start, the investigator is required to sign a 
protocol signature [CONTACT_5389]/her agreement to conduct the study  in accor dance with 
these documents and all of the instructions and procedures found in this protocol and to give 
access to all relevant data and records to [COMPANY_001] monitors, auditors, [COMPANY_001] Clinical 
Quality  Assurance representatives, designated agents of Novar tis, IRBs/IECs/REBs and 
regulatory  authorities as required.
11.3 Informed consent procedures
Eligible patients may only be included in the study  after providing written (witnessed, where 
required by [CONTACT_6617]), IRB/IEC/REB -approved informed consent or, if incapable of 
doing so, after such consent has been provided by a legally  acceptable representative of the 
patient. In cases where the patient’s representative gives consent, the patient should be 
informed about the study  to the extent possible given his/her understanding. If the patient is 
capable of doing so, he/she should indicate assent by  [CONTACT_230792] a separate assent form . Informed consent must be obtained 
before conducting any study -specifi c procedures (i.e. all of the procedures described in the 
protocol). The process of obtaining informed consent should be documented in the patient 

[COMPANY_001] Confidential Page 105
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
source documents. The date when a subject’s Informed Consent was actually  obtained will be 
captured in their CRFs.
[COMPANY_001] will provide to investigators ,in a separate document , a proposed informed consent 
form (ICF) that is considered appropriate for this study  and complies with the ICH GCP 
guideline and regulatory  requirements. Any changes to this ICF suggested by [CONTACT_5381]/IEC/REB, and a copy of the 
approved version must be provided to the [COMPANY_001] monitor after IRB/ IEC/REB approval.
Women of child bearing potential should be informed that taking the study  medication may 
involve unknown risks to the fetus if pregnancy  were to occur during the study  and agree that 
in order to participate in the study  they must adhere to the contraception requirement for the 
duration of the study . If there is any question that the patient will not reliably compl y, they 
should not be entered in the study .
11.4 Discontinuation of the study
[COMPANY_001] reserves the right to discontinue this study  under the conditions specified in the 
clinical study  agreement. Specific conditio
ns for terminating the study  are outlined in 
Section 4.
11.5 Publication of study  protocol and results
[COMPANY_001] assures that the key design elements of this protocol will be posted in a publicl y 
accessible database such as clinicaltrials.gov. In addition, upon study  completion and 
finalization of the study  report the results of this study  will be either submitted for publication 
and/or posted in a publicly  accessible database of clinical study  results.
11.[ADDRESS_736261] keepi[INVESTIGATOR_5324], in 
compliance with Section 
4.9 of the ICH E6 GCP, and regulatory and institutional 
requirements for the protection of confidentiality of subjects. As part of participating in a 
[COMPANY_001] -sponsored study , each site will permit 
authorized representatives of the sponsor(s) 
and regulatory  agencies to examine (and when required by [CONTACT_1289], to copy) clinical 
records forthe purposes of qualit y assurance reviews, audits and evaluation of the study 
safet y and progress.
Source data are all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary  for the reconstructi on and evaluation of the trial. 
Examples of these original documents and data records include, but are not limited to, hospi[INVESTIGATOR_2553], clinical and office charts, laboratory notes, memoranda, subjects’ diaries or 
evaluation checklists, pharmacy  dispensin g records, recorded data from automated 
instruments, copi[INVESTIGATOR_10379], 
microfiches, photographic negatives, microfilm or magnetic media, x-rays, and subject files 
and records kept at the pharmacy , at the laboratories, and medico -technical departments 
involved in the clinical trial.

[COMPANY_001] Confidential Page 106
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
Data collection is the responsibility  of the clinical trial staff at the site under the supervision of 
the site Principal I nvestigator. The study  case report for m (CRF) is the primary  data collection 
instrument for the study . The investigator should ensure the accuracy , completeness, legibility, 
and timeliness of the data reported in the CRFs and all other required reports. Data reported 
on the CRF, that are deriv ed from source documents, should be consistent with the source 
documents or the discrepancies should be explained. All data requested on the CRF must be 
recorded. Any missing data must be explained. Any change or correction to a paper CRF 
should be dated, initialed, and explained (if necessary ) and should not obscure the original 
entry . For electronic CRFs an audit trail will be maintained by [CONTACT_1190]. The investigator 
should retain records of the changes and corrections to paper CRFs.
The investigator/in stitution should maintain the trial documents as specified in Essential 
Documents for the Conduct of a Clinical Trial (ICH E6 Section 8) and as required by 
[CONTACT_64122]/or guidelines. The investigator/institution should take measures to 
preve nt accidental or premature destruction of these documents.
Essential documents (written and electronic) should be retained for a period of not less than 
fifteen (15) years from the completion of the Clinical Trial unless Sponsor provides written 
permission to dispose of them or, requires their retention for an additional period of time 
because of applicable laws, regulations and/or guidelines.
11.[ADDRESS_736262] ensure anon ymity of the patients; patients must not be identified by 
[CONTACT_64123]. Signed informed consent forms and patient 
enrollment log must be kept strictly  confidential to enable patient identification at the site.
11.8 Audits and inspections
Source data/docume nts must be available to inspections by [CONTACT_5385].
11.[ADDRESS_736263] 
be considered a protocol amendment, and unless such an amendment is agreed upon by 
[CONTACT_560074]/IEC/REB it cannot be implemented. All significant 
protocol deviations will be recorded and reported in the CSR.

[COMPANY_001] Confidential Page 107
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
12.[ADDRESS_736264] be approved by [CONTACT_5343], Health Authorities where required, and the IRB/IEC/REB. 
Only  amendments that are required for patient safety  may be implemented prior to 
IRB/IEC/REB approval. Notwithstanding the need for approval of formal protocol 
amendments, the investigator is expected to take any immediate action required for the safet y 
of any patient included in this study , even if this action represents a deviation from the 
protocol. In such cases, [COMPANY_001] should be notified of this action and the IRB/IEC at the study 
site should be informed according to local regulations (e.g. [LOCATION_006] requires the notification of 
urgent safet y measures within 3 days) but not later than 10 working day s.

[COMPANY_001] Confidential Page 108
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
13 References (available upon request)
Abubaker J Bavi PP, Al -Harbi S et al. PIK3CA mu tations are mutually  exclusive with PTEN 
loss in diffuse large B- cell ly mphoma. Leukemia 2007; 21: 2368-2370
American Cancer Society (2012 ) SEER fact sheet Non-Hodgkin Ly mphoma Available from: 
http://seer.can cer.gov/statfacts/html/nhl.html
Armitage JO (1993) Treatment of non -Hodgkin’s lymphoma. N Engl J Med. 238: 1023-1030
Baohua Y, Xiao yan Z, Tiecheng Z et al (2008). Mutations of the PI K3CA gene in diffuse 
large B cell l ymphoma. Diagn Mol Pathol; 17: 159-165
Beaulieu J -M, Gainetdinov RR, Caron MG (2009 ) AKT/[COMPANY_004]3 signaling in the action of 
psychotropic drugs. Annual Review of Pharmacology  and Toxicology  49; 327 -347
Bendell JC, Rodon J, Burris HA, et al. Phase I, dose -escalation study  of BKM120, an oral 
pan-class I PI3K inhibitor, in patients with advance d solid tumors. J Clin Oncol. 2012; 282-
290.
Benson AB 3rd, Ajani JA, Catalano RB, et al (2004). Recommended guidelines for the 
treatment of cancer treatment -induced diarrhea. J Clin Oncol ; 22(14):2918 -26.
Busaid y N, Farooki A, Dowlati A, et al. (2012) Management of metabolic effects associated 
with anticancer agents targeting the PI3K -Akt-mTOR pathway . J Clin Oncol 30 (23):2919 -28
Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an international workshop to 
standardize response criteria for non -Hodgkin’s ly mphoma. J Clin Oncol; 17(4):1244 -1253.
Cheson BD, Pf istner B, Juweid ME et al (2007) Revised response criteria for malignant 
lymphoma. J Clin Oncol; 25(5):579 -86.
Cheson BD (2007b) The International Harmonization Project for response criteria i n 
lymphoma clinical trials. Hematol Oncol Clin North Am; 21(5):841-54.
Cheson BD (2011) New agents in follicular l ymphoma. Best Practice & Research Clinical 
Haematology . 24: 305
–312
Chiorean EG, Mahadevan D, Harris WB, et al. Phase I evaluation of SF1126, a vascular 
targeted PI3K inhibitor, administered twice weekly  IV in patients with refractory  solid tumors. 
ASCO Meeting Abstracts 2009: 2558. (Abstr.)
Chow L , Baker S (2006) PTEN function in normal and neoplastic growth. Cancer Lett. 
241(2):184- 96. Epub 2006 Jan 18.
Cully  M, You H, Levine AJ, et al (2006) Bey ond PTEN mutations: the PI 3K pathway  as an 
integrator of multiple inputs during tumorigenesis. Nat Rev Cancer; 6(3):184 -92.
Dal Col J, Zan cai P, Terrin L , et al (2008). Distinct functional significance of Akt and mTOR 
constitutive activation in ma ntle cell ly mphoma. Blood; 111: 5142
-5151.
Doi T, Ando Y, Bando H, et al (2011) Phase I dose -escalation study  of BKM120, an oral 
panclass I PI3K inhibitor, in Japanese patients with advanced solid tumors. Molecu lar Cancer 
Therapeutics: Volume 10, I ssue 11 (Supplement 1, Abstract B159).
Flinn I W, By [CONTACT_9063], Furman RR et al (2009). Evidence of Clinical Activity  in a Phase 1 Study  
of CAL -101, An Oral P110{Delta} Isoform -Selective I nhibitor of Phosphatidylinositol 3 -

[COMPANY_001] Confidential Page 109
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
Kinase, in Patients with Relapsed or Refractory  B-Cell Malignancies. Blood (ASH Annual 
Meeting Abstracts) 114:922.
Fisher RI, Bernstein SH, Kahl BS et al (2006). Multicenter Phase II stud y of bortezomib in 
patients with relapsed or refractory  mantle cell lym phoma. J Clin Oncol; 24(30):4867 -4874.
Graña -Suárez B, Burris HA, Ahnert JR , et al (2011) Oral Pan- Class I PI3 Kinase Inhibitor 
BKM120 Monotherap y in Patients With Advanced Solid Tumors: An Update on Safet y and 
Efficacy . ASCO Annual Meeting; Poster.
Kahl B, By [CONTACT_9063], Flinn IW et al (2010) Clinical Safet y and Activity In a Phase 1 Study of 
CAL -101, An Isoform- Selective Inhibitor of Phosphatidy linositol 3 -Kinase P110, I n Patients 
with Relapsed or Refractory  Non -Hodgkin Ly mphoma. Blood (ASH Annual Meeting 
Abst racts) 2010 116: Abstract 1777.
Katso R, Okkenhaug K, Ahmadi K, et al (2001) Cellular function of phosphoinositide 3 -
kinases: implications for development, homeostasis, and cancer. Cell Dev Biol; 17:615-75.
Kroenke K, Spi[INVESTIGATOR_4280] , Williams JBW. The PHQ -9: Validity  of a brief depression severit y 
measure. J Gen Intern Med 2001;16:606 -613.
Lannutti BJ, Meadows SA, Herman SEM, et al. CAL -101, a p110δ selective 
phophatidy linositol-3- kinase inhibitor for the treatment of B -cell malignancies, inhibits PI 3K 
signali ng and cellular viability . Blood. 2011; 117(2): 591-594.
Liu, Cheng, Roberts & Zhao (2009). Targeting the phosphoinositide 3- kinase pathway  in 
cancer; Nature review drug discovery ; 8:627 -644
Mahadvan D, Qi W, Stejskal A et al (2011) SF1126, a Pan- PI3K Inh ibitor Has Superior 
Preclinical Activity  to CAL -101 a PI3K Delta -Specific Inhibitor in Aggressive B -Cell Non-
Hodgkin's Lymphoma. Blood (ASH Annual Meeting Abstracts) 2011 118 (21): 1170
McCubrey  JA, Steelman LS, Abrams SL , et al (2006) Roles of the RAF/MEK /ERK and 
PI3K/PTEN/AKT pathway s in malignant transformation and drug resistance. Adv Enzy me 
Regul. Jul 17.
Mead ows SA, Kashishian A, Johnson D (2011) CAL -101 (GS -1101), a Specific Inhibitor of 
Phosphatidy linositol-3- Kinase -Delta (PI3K), Disrupts Signals From the Microenvironment, 
Induces Apoptosis, and Enhances the Antitumor Activity  of Everolimus (RAD001), An 
Inhibitor of Mammalian Target of Rapam ycin (mTOR), in Mantle Cell Lymphoma (MCL ). 
Blood (ASH Annual Meeting Abstracts) 2011 118(21):1593.
National Cancer Institution (2012) Estimated new cases and deaths from non -Hodgkin 
lymphoma in the [LOCATION_002] in 2012 http://cancer.gov/cancertopi[INVESTIGATOR_1102]/t ypes/no n-hodgkin
Oken MM, Creech RH, Tormey  DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) 
Toxicity  and response criteria of the Eastern Cooperative Oncology  Group. Am J Clin 
Oncology . 5: 649 -
55
Papadopoulos KP, Abrisqueta P, Chambers G et al(2011) A Phase I Dose Expansion Cohort 
Study  of the Safety , Pharmacokinetics and Pharmacody namics of SAR245409 (S09), An 
Orally  Administered PI3K/mTOR I nhibitor, in Patients with Ly mphoma. Blood (ASH Annual 
Meeting Abs tracts) 2011 118: Abstract 1608

[COMPANY_001] Confidential Page 110
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
Reeder CB, Gornet M K,Habermann TM et al (2007) A Phase II Trial of the Oral mTOR 
Inhibitor Everolimus (RAD001) in Relapsed Aggressive Non -Hodgkin Lymphoma (NHL).
Blood (ASH Annual Meeting Abstracts) 110:121
Renner C, Zinzani P, Gressin R et al (2012) A multicenter phase II trial (SAKK 36/06) of 
single -agent everolimus (RAD001) in patients with relapsed or refractory  mantle cell 
lymphoma. Haematologica 2012:Epub ahead of print. Rudelius M, Pi [INVESTIGATOR_61818] S, Nishizuka S, et 
al. Constitutive activation of Aktcontributes to the patho genesis and sur vival of mantle cell 
lymphoma. Blood. 2006; 108: 1668-1676.
Saura C, Bendell J, Jerusalem G, et al (2011). Phase I /II Study  of BKM120 in Combination 
with Trastuzumab in Patients with HER2 Overexpressing Metastatic Breast Cancer Resistant 
to Trastuzumab
-Containing Therap y; CTRC -AACR, San Antonio Breast Cancer S ymposium, 
Poster.
Smith SM, van Besien K, Karrison T, Dancey  J, McLaughlin P, Younes A, et al. 
Temsirolimus has activity  in non -mantle cell non -Hodgkin's l ymphoma subty pes: The 
University  of Chicago phase II consortium. J Clin Oncol. 2010;28(31):4740-6
Spi[INVESTIGATOR_4280] , Kroenke K, Williams JBW, L öwe B. A brief measure for assessing generalized 
anxiety  disorder: the GAD -7. Arch Intern Med 2006;166:1092 -1097.
Spi[INVESTIGATOR_4280] , Kroenke K, Williams JBW, for the Patient Health Questionnaire Primary  Care 
Study  Group. Validation and utility  of a self -report version of PRI ME-MD: the PHQ Primary  
Care Study . JAMA 1999;282:1737-1744
Uddin S Hussain AR, Siraj AK et al. Role of phosphatidylinositol 3 ′-kinase/AKT pathway  in 
diffuse large B -cell l ymphoma survival. Blood 2006; 108: 4178-4186Von Hoff DD, LoRusso 
P, Demetri GD et al (2011). A phase I dose -escalation study  to evaluate GDC -0941, a pan-
PI3K inhibitor, administered QD or BID in patients with advanced or metastatic solid tumors. 
ASCO Meeting Abstracts; 3052 (Abstr.)
Walsh, KJ, Fan S, Patel A et al (2009) . PI3K inhibitors inhibit ly mphoma growth by  
[CONTACT_121701] m yc-dependent proliferation. Blood. 2009; 114: 1697. (Abstr.)
Witzig TE, Gey er SM, Ghobrial I et al (2005) Phase II trial of single -agent temsirolimus 
(CCI -779) for relapsed mantle cell ly mphoma. J Clin Oncol; 23(23):5347 -5356.
Witzig TE, Reeder CB, LaPlan BR et al (2011) A phase II trial of the oral mTOR inhibitor 
everolimus in relapsed aggressive l ymphoma. Leukemia. 25: 341 –347
Zha H, Raffeld M, Carboneau L et al (2004) . Similarities of prosurvival signals in Bcl - 2-
positive and Bcl -2-negative follicular l ymphomas identified by  [CONTACT_560075] .Laboratory  Investigation .84: 235- 244.
Zhou, Y, Jin L , Pi[INVESTIGATOR_61818] S, et al (2010) . PI3K, a selective inhibitor induces growth inhibition 
in mantle cell ly mphoma. A SH Annual Meeting Abstracts
. 116: 1812. (Abstr.)

[COMPANY_001] Confidential Page 111
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
[ADDRESS_736265] of prohibited CYP3A  inhibitors and inducers
Strong CYP3A 
inhibitorsModerate CYP3A inhibitorsStrong CYP3A
inducersModerate CYP3A
inducers
clarithromycin amprenavir carbamazepi[INVESTIGATOR_050] * felbamate *
conivaptan aprepi[INVESTIGATOR_539381] * topi[INVESTIGATOR_052] * (>200 mg/day)
indinavir atazanavir phenytoin * oxcarbazepin *
itraconazole cimetidine fosphenytoin * eslicarbazepin *
ketoconazole ciprofloxacin primidone * rufinamide *
lopi[INVESTIGATOR_560032]. John's W ort modafenil
posaconazole fluconazole nafcillin
ritonavir grapefruit juice ritonavir
saquinavir schisandra sphenanthera talviraline
telithromycin tipranavir tipranavir
troleandomycin tofisopam
voriconazole verapamil
* These drugs are Enzyme Inducing Anti -Epi[INVESTIGATOR_560033]’s 
“Clinically Relevant” Table, from the University of Washington’s Drug Interaction Database based on in vitro 
studies and from the FDA’s “Guidance for Industry, Drug Interaction Stu dies;” and from (
Pursche 2008 ).

[COMPANY_001] Confidential Page 112
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
14.[ADDRESS_736266] of CYP450 substrates to be used with caution
CYP2C8 CYP2C9 CYP2C19 CYP3A**
amodiaquine celecoxib amitriptyline adinazolam felodipi[INVESTIGATOR_050]1
cerivastatin diclofenac citalopram alfentanil1,2fentanyl2
pi[INVESTIGATOR_235996] -
dihydroergocryptine1flunitrazepam
repaglinide fluvastatin clomipramine alprazolam fluticasone1
rosiglitazone glibenclamide 
(glyburide)clopi[INVESTIGATOR_539383]1
torasemide gliclazide diazepam aripi[INVESTIGATOR_539384]1
troglitazone glimepi[INVESTIGATOR_539385]1
glipi[INVESTIGATOR_560034]1nisoldipi[INVESTIGATOR_560035]1nitrendipi[INVESTIGATOR_560036]1perospi[INVESTIGATOR_5331]1
lornoxicam omeprazole capravirine quinine
losartan pantoprazole cerivastatin sildenafil1
meloxicam progesterone chlorpheniramine simvastatin1
naproxen quazepam cyclosporine2sirolimus1,2
nateglinide rabeprazole darifenacin1tolvaptan
pi[INVESTIGATOR_560037] S-mephenytoin diergotamine2triazolam1
S-ibuprofen ebastine1
sulfamethoxazole eletriptan1
tenoxicam eplerenone1
tolbutamide ergotamine2
torasemide estazolam
valdecoxib everolimus1
This database of CYP substrates was compi[INVESTIGATOR_11993]’s “Clinically 
Relevant” Table, and from ( Zhou 2009 )
** CYP3A substrates were compi[INVESTIGATOR_560038] o f Medicine’s “Clinically Relevant” Table; 
and supplemented by [CONTACT_1622]’s “Guidance for Industry, Drug Interaction Studies” and the University of 
Washington’s Drug Interaction Database.
1 Sensitive substrates: Drugs whose plasma AUC values have been shown t o increase 5 -fold or higher when co -
administered with a potent inhibitor of the respective enzyme.
2 Substrates with narrow therapeutic index (NTI): Drugs whose exposure -response indicates that increases in their 
exposure levels by [CONTACT_64128] (e.g., Torsades 
de Pointes).

[COMPANY_001] Confidential Page 113
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
14.[ADDRESS_736267] of prohibited QT prolonging drugs
Drug QT risk(*) Comment
Amiodarone known risk for TdP TdP risk regarded as low
Arsenic trioxide known risk for TdP
Astemizole known risk for TdP CYP3A4 substrate with narrow therapeutic index.
Bepridil known risk for TdP
Chloroquine known risk for TdP
Chlorpromazine known risk for TdP
Cisapride known risk for TdP CYP3A substrate with narrow therapeutic index.
Disopyramide known risk for TdP
Dofetilide known risk for TdP
Domperidone known risk for TdP
Droperidol known risk for TdP
Halofantrine known risk for TdP
Haloperidol known risk for TdP When given intravenously or at higher -than -
recommended doses, risk of sudden death, QT 
prolongation and torsades increases.
Ibutilide known risk for TdP
Levomethadyl known risk for TdP Sensitive CYP3A substrate
Mesoridazine known risk for TdP
Methadone known risk for TdP
Pentamidine known risk for TdP
Pi[INVESTIGATOR_560039]3A substrate with narrow therapeutic index
Probucol known risk for TdP
Procainamide known risk for TdP
Quetiapi[INVESTIGATOR_560040]3A substrate
Quinidine known risk for TdP Sensitive CYP3A substrate 
Sotalol known risk for TdP
Sparfloxacin known risk for TdP
Tacrolimus possible risk for TdP Sensitive CYP3A substrate with narrow therapeutic index
Terfenadine Known risk for TdP Sensitive CYP3A substrate with narrow therapeutic index
Thioridazine Known risk for TdP
Vardenafil possible risk for TdP Sensitive CYP3A substrate
(*) Classification according to the QTdrugs.org Advisory Board of the Arizona CERT
Sensitive substrates: Drugs whose plasma AUC values have been shown to increase 5 -fold or higher when co -
administered with a potent inhibitor of the respective enzyme.
Please also refer to http://crediblemeds.org/ for a comprehensive list of agents that prolong the QT interval

[COMPANY_001] Confidential Page 114
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
14.[ADDRESS_736268] of QT prolonging drugs to be used with caution
Drug QT risk
Alfuzosin possible risk for Torsades de Pointes
Amantadine possible risk for Torsades de Pointes
Amitriptyline conditional risk for Torsades de Pointes
Azithromycin possible risk for Torsades de Pointes
Chloral hydrate possible risk for Torsades de Pointes
Citalopram conditional risk for Torsades de Pointes
Clomipramine conditional risk for Torsades de Pointes
Clozapi[INVESTIGATOR_560041]/HCTZ possible risk for Torsades de Pointes
Moxifloxacin possible risk for Torsades de Pointes
Nicardipi[INVESTIGATOR_560042] 115
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
Drug QT risk
Ranolazine possible risk for Torsades de Pointes
Risperidone possible risk for Torsades de Pointes
Roxithromycin* possible risk for Torsades de Pointes
Sertindole possible risk for Torsades de Pointes
Sertraline conditional risk for Torsades de Pointes
Solifenacin conditional risk for Torsades de Pointes
Tizanidine possible risk for Torsades de Pointes
Trazodone conditional risk for Torsades de Pointes
Trimethoprim -Sulfa conditional risk for Torsade s de Pointes
Trimipramine conditional risk for Torsades de Pointes
Venlafaxine possible risk for Torsades de Pointes
Ziprasidone possible risk for Torsades de Pointes
(*) Classification according to the QTdrugs.org Advisory Board of the Arizona CERT
Please also refer to http://crediblemeds.org/ for a comprehensive list of agents that prolong the QT interval.

[COMPANY_001] Confidential Page 116
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
14.5 Appendix 5 -Guideline for efficacy  evaluation in ly mphoma 
studies (based on Cheson response criteria )
14.5.[ADDRESS_736269] y.
This document is based on the International Workin g Group response criteria (Cheson et al 
1999), and the International Harmonization Project revised response criteria (Cheson et al 
2007b). Further clarification on these criteria has been published b y (Cheson 2007a ).
As Positron emission tomograph y (PET) is not yet widel y accepted (Cheson 
2009) for 
assessing response t
o treatment in lymphoma it is not considered for standard use in [COMPANY_001] 
Oncology  Lymphoma studies and therefore it is n ot considered in this document.
In general, this document is intended for studies where patients currently  have measurable 
disease to be assessed, and therefore does not specificall y address studies when the eligible 
patient population has no measurable disease (such as studies in patients who achieved 
complete response to first line treatment, or in post-transplantation settings). Howeve r, this 
guidance should be readily  adaptable to these settings (see Appendix E ).
As these are general guidelines, the following adjustments will apply  to this trial:
Randomization is not applicable to the study  since it is a non -
randomized trial. All 
responses will be calculated from start of treatment.
If a lesion splits during the study , the sub -lesions will not be measured separatel y. Instead, 
such lesion swhich have split into sub -lesions will be me asured as one lesion with all sub -
lesions contributing to the overall SPD.
Central Blinded Review of radiological response will not be used for this study . 
Responses will be assessed by  [CONTACT_737].
14.5.2 Definitions and criteria for normalization
[IP_ADDRESS] Definitio ns
Throughout this document, the following definitions will apply (See also Appendix A ).
Nodal vs extranodal lesion
A lesion is categorized based on the location as:
Nodal lesion ,
Extranodal lesion , if it is located in organs other than lymph node or nodal mass, but 
including spleen and liver.

[COMPANY_001] Confidential Page 117
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
Measurability
Throughout this document, a lesion will be called measurable if it can be measured 
accuratel y in 2 perpendicular dimensions and:
For nodal lesion, if the long axis is > 15 mm, regardless of the length of the short axis,
For extranodal lesion, if the long and short axes are ≥ 10 mm.
Classification of ly mph nodes
Lym ph nodes are classified according to their size and/ or relationship to the disease:
A lymph node meeting the measurability  requirement above will constitute a measurable 
nodal lesion .
A lymph node not meeting the measurabilit y requirement but with long axis > 15 mm (e.g. 
short axis can not be measured accurately ) will constitute a non-measurable nodal lesion .
A lymph node not meeting the measurabilit y criteria but with a size of 11 mm to 15 mm in 
the long axis and > 10 mm in the short axis will be check ed for relationship to disease:
If it is thought to be disease related, it will constitu te a non-measurable nodal lesion 
(referred to as “involved node” in Cheson et al 2007b
).
If it is not thought to be disease related, it will constitute an abnormal lymph node 
but not a lesion.
All other ly mph nodes will be considered normal and wil l not constitute nodal lesions.
[IP_ADDRESS] Criter ia for normalization of lesions
The normalization of lesions is defined as follow:
A measurable nodal lesion must become ≤ 15 mm in long axis to be considered 
normalized.
A non
-measurable nodal lesion must decrease to ≤ 10 mm in the short axis and be ≤ 15 
mm in long ax is to be considered normalized.
An extranodal lesion must disappear completel y (assigned a size of 0 mm x 0 m m) to be 
considered normalized.
14.5.3 Efficacy  assessments
[IP_ADDRESS] Eligibility
Studies will be intended to include pa tients with measurable disease.
Patients should have at least one measurable nodal lesion greater than [ADDRESS_736270] on e measurable extranodal lesion.

[COMPANY_001] Confidential Page 118
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
[IP_ADDRESS] Methods of disease assessment
All radiological measurements should be taken in two perpendicular dimensions and recorded 
in metric notat ion, using a ruler or calipers.
All baseline evaluations should be performed as closely  as possible to the randomization/start 
of treatment (preferabl y within 7 days) and never more than 3 weeks (21 days) before the 
randomization/start of treatment.
[IP_ADDRESS].1 CT scan (or MRI)
For optim al evaluation of patients, the same methods of assessment and technique should be 
used to characterize each identified and reported lesion at baseline and during follow -up. 
Contrast -enhanced CT of chest, 
abdomen and pelvis should preferabl y be performed using a 
5mm slice thickness with a contiguous reconstruction algorithm. CT/MRI scan slice thickness 
should not exceed [ADDRESS_736271] or develops allergy  during the trial, the 
following change in imaging modality  will be accepted for follow up: a non-contrast CT of 
chest (MRI not recommended due to respi[INVESTIGATOR_14943]) plus contrast -enha nced MRI of 
abdomen and pelvis.
A change in methodology  can 
be defined as either a change in contrast use (e.g. keepi[INVESTIGATOR_111796], like CT, but switching from with to without contrast use or vice-versa, 
regardless of the justification for the change) or a change in technique (eg. from CT to MRI , 
or vice-versa), or achange in any other imaging modality . A change in methodology  will 
result by [CONTACT_15074] a “Unknown” overall radiological response assessment. However, another 
overall radiological response than the [COMPANY_001] calculated “Unknown” response may be 
accepted from the investigator or the central blinded reviewer if a definitive overall 
radiological response can be justified to be based on the available information.
In order to calculate the sum of the product of the diameters (SPD) of all index lesions (or 
extran odal lesions), their size must b e entered throughout the stud y.
Actual lesion measurements should be entered on the corresponding CRFs. If, during the 
course of the study , either of the perpendicular diameters of a lesion can not be reliabl y 
measured becau se of its small size, it is recommended to enter the minimum limit of detection 
as the diameter size (e.g. [ADDRESS_736272]). In other cases when, during the course of the 
study , the diameter cannot be reliabl y measured for reasons other than its size (i.e. borders of 
the lesion are confounded by [CONTACT_15081]), no measurement should be 
entered and the lesion cannot be evaluated.
If lesions become confluent over time, it is recommended to measure them as one lesion, 
report the overall diameters to one of the lesions and assign 0 mm x 0 mm to each of the other 
previously  measured lesions. If a  lesion splits during the study , each sub-lesion should be 
measured separatel y for all subsequent assessments and all sub -lesions contribute to the SPD.

[COMPANY_001] Confidential Page 119
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
[IP_ADDRESS].[ADDRESS_736273] a goal of > 
20 mm unilateral core. If the biops y sample is indeterminate by [CONTACT_5293] 
(immunohistochemistry ), then flow cytometry  maybe performed on bone marrow aspi[INVESTIGATOR_111800].
[IP_ADDRESS].3 Physical examinati on and assessment of B -symptoms
Skin lesions, if the size is ≥ [ADDRESS_736274] be histologicall y confirmed 
for lymphoma involvement (the investigational site must document the histological 
confirmation (yes or no) on the corresponding CRF) and photographed including a ruler 
(color photography  using digital camera). Tumor assessment will be performed and results 
will be recorded on the corresponding CRF at baseline and at the time of each radiological 
assessment.
B
-symptoms are of importance in determining prognosis and should resolve completely  in 
patients who have achieved complete response. B -symptoms in ly mphoma patients are disease 
related clinical sy mptoms and are not caused by  [CONTACT_560076] y (or drug toxicity ).
B-symptoms are defined as follows:
Signific ant unexplained fever ( ≥ 38°C),
Unexplained, r ecurrent drenching night sweats
Unexplained loss of > 10% body  weigh t within the previous 6 months,
asassessed and reported (present v s. absent) by  [CONTACT_737].
[IP_ADDRESS] Documentation of disease
For the evaluation of disease at baseline and throughout the stu dy, the following are recorded.
Index nodal lesions
Index nodal lesions are selected from the measurab le nodal lesions. A minimum of one 
measurable index nodal lesion and maximum of six of the largest dominant nodal lesions 
should be documented at baseline and assessed throughout the study . If a patient has no 
measurable nodal disease at baseline, then it would be acceptable that no index nodal lesions 
be identified. Index nodal lesions should be from disparate regions of the body  including 
mediastinal and retroperitoneal areas of disease whenever these sites are involved. Two 
perpendicular dimensions must be recorded on the corresponding CRF at each assessment of a 
measurable lesion selected to be an index lesion.

[COMPANY_001] Confidential Page 120
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
Non- index nodal lesions
All other nodal lesions (both measurable and non-measurable) are considered as non-index  
lesions.
Non-index lesions shoul d be documented at baseline and assessed throughout the study . 
Measurements of these lesions are not required to be documented on the CRF. Their response 
status will be determined from investigator assessment as descr
ibed in Section [IP_ADDRESS].2 .
Spleen and liver (index and non- index) lesions
The spleen and liver will be ass essed b y CT scan (or MRI  scan).
A maximum four of the largest dominant measurable nodules representing all involved 
anatomic locations should be selected as splenic and hepatic index lesions to be measured at 
baseline and followed up during the treatment. Two perpendicular dimensions will be 
recorded i nto the CRF at each assessment.
All other splenic or hepatic nodules (both measurable and non-measurable) are considered as 
non-index lesions. They  should be documented at baseline and assessed throughout the study . 
Measurements of these lesions are not required to be documented on the CRF. Their response 
status will be determined from investigator assessment as descr
ibed in Section [IP_ADDRESS].2 .
Other extranodal (index and non- index) lesions
Organs other than lymph nodes, liver, spleen and bone marrow (such as breast and lung) can 
be occasionally  involved by [CONTACT_56927]. Determination of lymphoma involvement of these 
organs should be confirmed histologicall y.
If such organs are confirmed to be involved with measurable lesions, then index lesions 
should be selected from those organs. Up to four measurable lesions will be selected as index  
extranodal lesions from disparate regions (other than liver and spleen) at baseline and 
followed during the study.
Additional measurable lesions and all non-measurable extranodal disease will be documented 
at baseline and assessed throughout the study  as non-index lesions. Other non-measurable 
disease, such as pleural effusion or bone lesions that are documented to be due to malignant 
disease, will be recorde d at baseline as non-index lesions and followed during the study . 
Measurements of these lesions are not required to be documented on the CRF. Their response 
status will be determined from investigator assessment as descr
ibed in Section [IP_ADDRESS].2 .
Enlarged spleen or liver
The presence of enlarged spleen or liver before randomization/start of treatment on the basis 
of CT scan should be recorded on the corresponding CRF at baseline, and reassessed if the
patient has a radiological CR.
Bone marrow involvement
Status of bone marrow involvement by [CONTACT_111919]/start of treatment 
will be collected (see Section [IP_ADDRESS].2 ).

[COMPANY_001] Confidential Page 121
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
B-symptoms
B-symptoms (unexplained fever ≥ 38°C; unexplained, recurrent drenching night sweats; 
unexplained loss of > 10% body  weight within the previous 6 months) will be recorded before 
randomization/start of treatment (baseline) and reevaluated if patients have achieved 
radiological CR as well as at the end of therap y.
[IP_ADDRESS] Evaluation of radiological response
For the sake of simplicity , complete remission (as defined in Cheson et al 2007b) and 
complete response will both be refer red to as complete response in this document.
To evaluate disease response to treatment, all index and non-index lesions will be followed 
and assessed throughout the study . 
At each assessment, response is evaluated separately  for 
the index lesions (Table 14-7) and non-index lesions (Table 14 - 8) identified at baseline, then 
a combined overall radiological response is determined ( Table 14-9 ).
[IP_ADDRESS].1 Evaluation of index lesions (nodal and extranodal)
(a) When index nodal lesions are not in complete response
The response for index lesions is evaluated by [CONTACT_111922] (SPD) of all index lesions (see Table 14-5), except when there is a Complete 
Response for index nodal lesions (i.e. complete normalization of all index nodal lesions) (see 
Section b below).
Table 14-5 Radiological status based on SPD calculation for all index lesions
Response Criteria1Evaluation of index lesions
Complete Response (CR) See Table 14 -7below (not based on SPD calculation for all index lesions)
Partial Response (PR) At least 50% decrease from baseline in the SPD of all index lesions
Stable Disease (SD) Failure to attain the criteria needed for CR or PR and failure to fulfill the criteria 
for PD
Progressive Disease (PD) At least a 50% increase from nadir2in the SPD of all index lesions
1 At each assessment (if the index nodal lesions are not in CR status), the response status based on SPD 
calculation will be first assessed for meeting PD status criteria, then PR status and SD status.
2Nadir is defined as the smallest sum of the product of th e diameters of all index lesions recorded so far, at or 
after baseline.
(b) When index nodal lesions are in complete response
When there is a Complete Response for index nodal lesions (i.e. complete normalization of all 
index nodal lesions as defined in Section [IP_ADDRESS] : all index lesion ≤ 15 mm in long axis), the 
SPD for these index nodal lesions may not be equal to zero and therefore a calculation of a 
SPD for all index lesions may be misleading. Ther efore, by [CONTACT_15094], a specific response for 
extranodal index lesions needs to be evaluated, based on the SPD calculation restricted to all 
index extranodal lesions only  (see Table 14 - 6).

[COMPANY_001] Confidential Page 122
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
Table 14-6 Radiological response criteria for index extranodal lesions in case of 
CR in index nodal lesions
Response Criteria1Evaluation of index extranodal lesions
Complete Response (CR) Complete disappearance of all index extranodal lesions
Partial Response (PR) At least 50% decrease from baseline in the SPD restricted to all index 
extranodal lesions
Stable Disease (SD) Failure to attain the criteria needed for CR or PR and failure to fulfill the criteria 
for PD
Progressive Disease (PD) At least a 50% increase from nadir2in the SPD restricted to all index 
extranodal lesions
[ADDRESS_736275] of the diameters restricted to all index extranodal lesions 
recorded so far, at or after baseline.
The algorithm for evaluating the response integrating index extranodal lesions and the SPD 
calculated on all index lesions (where appropriate) provides an overall response for index  
lesions (see Table 14 -7).
(c) Evaluation of response for all index lesions
The evaluation of response for all index lesions is based on the combination of the response 
for index nodal lesions (CR or non-CR), the response for index extranodal lesions (as 
calculated in Table 14-6), and the status based on the SPD calculated on all index lesions 
(nodal and extranodal), as described in Table 14
-7and Appendix B .
Table 14-7 Radiological respons e for index lesions
Response for index 
nodal lesions1Response for index 
extranodal lesions1Status based on SPD 
calculation for all index lesionsResponse for index 
lesions
CR CR Not calculated CR
CR SD/ PR Not calculated PR
CR PD PD PD
CR PD PR PR
CR PD SD SD
Non-CR Not evaluated PD PD
Non-CR Not evaluated PR PR
Non-CR Not evaluated SD SD
1 If no index nodal lesions are present at baseline, then index lesions response is equal to the index extranodal 
lesions response. A similar rule applied if no index extranodal lesions are present at baseline, then index lesions 
response is equal to the index nodal lesions response.
In case of a missing measurements of any of the index lesions, the radiological response for 
index lesions at that assessment wi ll be “Unknown (UNK)”, unless progression was seen.
All lesions must have been measured with the same method as the one used at baseline, 
otherwise the radiological response for index lesions at that assessment will be “Unknown 
(UNK)”.

[COMPANY_001] Confidential Page 123
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
[IP_ADDRESS].2 Evaluation of non-index lesions (including nodal, splenic and/or hepatic 
nodules and other extranodal lesions)
At each reassessment, a non-index lesion (or a group of non-index lesions) will be given one 
of the following designations:
Normalization (non- index nodal lesi on has regressed to normal size; non -index extranodal 
lesion is no longer present). Normalization of non-index nodal lesions should be 
determined based on their size at baseline as described in Section [IP_ADDRESS].
Improved, stable or worsened, but without unequivocal evidence of disease progression 
(non-
index lesion is present but there is not sufficient worsening to declare PD based on 
the existing non- index lesions).
Unequivocal evidence of disease progr ession (worsening of existing non- index lesions is 
sufficient to declare PD)
Not assessed
Then, this status for each non-index lesion (or group of non -index lesions) will lead to a 
global response for non -index lesions (Table 14-8 and Appendix C ):
Table 14-8 Response criteria for non -index lesions (nodal, splenic and/or hepatic 
nodules and other extranodal lesions)
Response Criteria Evaluation of non -index lesions
Com plete Response (CR) Complete normalization of all non -index nodal and extranodal lesions: 
Radiological regression to normal size of all lymph nodes and complete 
disappearance of all extranodal (including splenic and/or hepatic nodules) lesions
Stable Disease (SD) Failure to attain the criteria needed for CR and failure to fulfill the criteria for PD
Progressive Disease (PD) Unequivocal disease progression of any existing non -index lesions (nodal or 
extranodal)
In case of a missing status of any of the non-index lesions, the radiological response for non-
index lesions at that assessment will be “Unknown (UNK)”, unless progression was seen.
All lesions must have 
been measured with the same method as the one used at baseline, 
otherwise the radiological response for non-index lesions at that assessment will be 
“Unknown (UNK)”.
[IP_ADDRESS].3 New lesions
The appearance of any new nodal lesion >15 mm in any  axis.
New nodal lesion is defined by :
either a previously  normal ly mph node becoming > 15 mm in any  axis,
or a previo
usly identified abnormal lymph node showing an increase of at least 50% in the 
long axis,
as assessed b y investigator (or Central Review if applicable)
OR
any discrete extranodal (including splenic and/or hepatic nodules) lesions reliably  
appearing on CT scan or MRI  after baseline is alway s considered as Progressive Disease 
(PD) and has to be recorded as a new lesion in the appropriate module of the CRF. 

[COMPANY_001] Confidential Page 124
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
Determination of new lymphoma involvement in organs other than l ymph nodes or liver 
or spleen should be confirmed histologicall y and the site must document that in a 
comment to the corresponding CRF.
[IP_ADDRESS].4 Overall radiological response
Overall radiological response is calculated as shown in Table 14 -9.
Table 14
-9 Overall radiol ogical response at each assessment
Index lesions Non-index lesions1New lesions Overall radiological response
CR CR No CR
CR SD No PR
PR CR or SD No PR
SD CR or SD No SD
PD Any Yes or No PD
Any PD Yes or No PD
Any Any Yes PD
1If no non -index lesions are present at baseline, then this column is not used in evaluating overall radiological 
response.
If the evaluation of any of the index or non-index lesions identified at baseline could not be 
made during follow -up or if the index or non-index response is “Unknown (UNK)”, the 
overall response status at that assessment must be “Unknown 
(UNK)” unless progression or a 
new lesion was seen.
[IP_ADDRESS] Evaluation of overall disease response
The evaluation of overall disease response at each assessment is a composite of the individual 
radiological responses (index and non-index lesions, new lesions), laboratory  test (bone 
marrow) and clinical responses (ly mphoma related clinical sy mptoms).
[IP_ADDRESS].1 Bone marrow re -assess ment at time of radiological CR
I
n order to confirm a Complete disease response (CR), bone marrow biopsy  or aspi[INVESTIGATOR_111802] a radiological CR has been achieved (see Section [IP_ADDRESS].2 ). Details are 
provided in the Study  Protocol. The infiltrate of ly mphoma in bone marrow must have cleared 
on repeat bone marrow biopsy  or aspi[INVESTIGATOR_337]. Patients who achieve a CR by [CONTACT_560077]. New or recurrent bone marrow involvement any time during the 
follow up will be considered PD. Bone marrow biopsy  or aspi[INVESTIGATOR_111803] y indicated.
The biopsy  sample of bone ma rrow must be adequate (with a goal of > 20 mm unilateral core). 
If the sample is indeterminate by  [CONTACT_5293] , it should be negative by  [CONTACT_9064] .

[COMPANY_001] Confidential Page 125
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
[IP_ADDRESS].[ADDRESS_736276] be confirmed by [CONTACT_111924][INVESTIGATOR_337] (if required as per the Study  
Protocol), presence of normal liver and spleen size, and evaluation of lymphoma related B-
symptoms. The patient’s overall response will be calculated as follows (see also Appendix D ):
A patient will be deemed to have overall disease response of CR if bone marrow biops y or 
aspi[INVESTIGATOR_560043] (if the bone marrow was involved by 
[CONTACT_66840]) and the liver and spleen are normal in size and there are no lymphoma 
related B- symptoms in addition to radiological CR.
If asse ssments of any of the following : lymphomatous infiltration of bone marrow (If required 
as per the Study  Protocol), or evaluation of B-symptoms is not done, unknown or 
indeterminate or B-symptoms are still present when the overall radiological response is 
assessed as CR or the liver or spleen are enlarged, then the overall disease response will be 
assessed as PR until evaluation of these factors have shown normalized results and recorded 
on the corresponding CRF.
For patients whose radiological response is anything other than CR, assessme nt of bone 
marrow, liver, spleen and B -symptoms will not be required in evaluating overall response and 
overall disease response is the same as radiological response. However any new or recurrent 
bone marrow involvement at any  time during f ollow -up will be considered PD.
Of note, appearance of B-symptoms or enlarged spleen or liver will not in themselves 
constitute documentation of progression. They  are however expected to be associated with 
progressive disease. Every  effort should be made to document that evidence radiologicall y 
and report the corresponding tumor assessments. Such tumor assessments are expected to be 
performed within 2 months of appearance of B- sympto ms or enlarged spleen or liver.
14.5.4 Efficacy  analy sis definitions
[IP_ADDRESS] Best overall disease response
The best overall disease response is the best disease response recorded from 
randomization/start of treatment until progressive disease or start of new anticancer therap y, 
whichever comes first.
A best overall disease response of SD will be declared when at least one SD assessment is 
available at least 6 weeks after randomization/start of treatment (and the patient would not 
qualify  for CR or PR).
A patient will have a best overall disease response of PD if the progressive disease was 
observed less than 17weeks after randomization/ start of treatment (and the patient does not 
qualify  for CR, PR or SD).
The best overall disease response for a patient is alway s calculated, based on the sequence of 
overall disease responses. However, the overall disease respo nse at a given assessment may 
be provided from different sources:

[COMPANY_001] Confidential Page 126
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
Investigator overall disease response based on local radiological assessments, clinical and 
pathological (bone marro w in patients with CR) response
Central Blinded Review of radiological res ponse, with or without blinded adjudication 
integrating clinical and pathological (bone marro w in patients with CR) response
[COMPANY_001] calculated overall disease response, based on measurements / lesion status from 
either Investigator or Central Review and clinical and pathological (bone marro w in 
patients with CR) response
Based on the patients’ best overall disease response during the study , the following rate is 
then calculated:
Overall response rate (ORR) is the proportion of patients with a best overall disease 
response of CR and PR.
[IP_ADDRESS] Time to event variables
Most of the time to event variables are defined in this section according to the International 
Working Group response criteria (Cheson et al 2007b ). Fur ther details on dates and censoring 
rules are provided respectively  in Section [IP_ADDRESS] and Section [IP_ADDRESS].
[IP_ADDRESS].1 Overall survival
Overall survival (OS) is defined as the time from the date of randomization/start of treatment 
to the date of death due to any cause. If a patient is not known to have died, survival will be 
censor ed at the date of last contact.
[IP_ADDRESS].2 Progression
-free survival
Progression -free survival (PFS) is defined as the time from the date of randomization/start 
of treatment to the date of event defined as the first documented progression or death due to 
any cause. If a patient has not had an event, progression- free survival is censored at the date 
of the last adequate assessment.
[IP_ADDRESS].3
Time to pro gression
Time to progression (TTP) is defined as the time from the date of randomization/start of 
treatment to the date of first documented progression or death due to lymphoma. If a patient 
has not had an event, time to progression is censored at the date of the last adequate 
assessment.
[IP_ADDRESS].4 Duration of response
Duration of overall response (CR or PR) applies onl y to patients whose best overall disease 
response was CR or PR. It is defined as the time from the date of first documented disease 
response (CR or PR) to the date of first documented progression or death due to ly mphoma. If 
a patient has not had an event, duration of overall response is censored at the date of the last 
adequate as
sessment.

[COMPANY_001] Confidential Page 127
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
Duration of overall complete response (CR) applies only to patients whose best overall 
disease response was CR. It is defined as the time from the date of first documented disease 
complete response to the date of first documented progression or death due to lymphoma. If a 
patient has not had an event, duration of overall complete response is censored at the date of 
the last adequate assessment.
[IP_ADDRESS].5 Time to response
Time to overall disease response (CR or PR) is defined as the time from the date of 
randomization / start of treatment to the date of first documented disease response (PR or CR). 
This analysis will include all patients/responders. If all patients are included, then patients 
who did not achie ve a PR or CR will be censored:
At maximum follow -up (i.e. FPFV to LPLV used for the analysis) for patients who had a 
PFS event (i.e. either progressed or died due to any  cause)
At the date of the last adequate assessment otherwise.
Time to overall disease complete response (CR) is defined as the time from the date of 
randomization / start of treatment to the date of first documented disease complete response 
(CR). This analy sis will include all patients/responders. If all patients are included, then 
patients who did not achieve a CR will be censored:
At m aximum follow -up (i.e. FPFV to LPLV used for the analysis) for patients who had a 
PFS event (i.e. either progr essed or died due to any  cause)
At the date of the last adequate assessment otherwise.
[IP_ADDRESS].6 Lymphoma specific survival
Lymphoma specific survival (LSS) is defined as the time from the date of randomization/ 
start of treatment to the date of death documented as a result of l ymphoma. If a patient has not 
had an event, ly mphoma spec ific survival will be censored:
at the date of last contact [CONTACT_560078] i s not known to have died,
at the date of death if the patient died for other reason than ly mphoma.
[IP_ADDRESS].7 Event free survival
Event -free survival (Time to treatment failure (TTF)) is defined as the time from the date 
of randomization to the earlies t date of any  of the following:
death
progressive disease as overall disease response assessed b y the local investigator pri
or to 
treatment discontinuation
study  treatment discontinuation due to:
disease progression
adverse event(s)
abnormal laboratory  value(s)
abnormal test procedure results
subject withdrew consent

[COMPANY_001] Confidential Page 128
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
lost to follow -up
death
new cancer therapy
Patients who discontinue study  treatment for reasons other than those listed above (i.e., as a 
result of protocol violation, administrative problems) are censored atthe date of the last 
adequate assessment prior to discontinuation. Patients with neither an event nor study  
treatment discontinuation are censored at the date o f the last adequate assessment.
[IP_ADDRESS] Definition of start and end da tes for time to event variables
Assessment date
For each assessment (i.e. evaluation number), the assessment date is calculated as:
the latest date of all radiological measurement dates (e.g. CT-scan (or MRI), and 
excluding both bone marrow biopsy  and B -symptoms assessment), if the overall disease 
response at t hat assessment is CR/PR/SD/UNK,
the earliest date of all measurement dates (e.g. CT -scan (or MRI), including bone marrow 
biopsy , but excluding B -symptoms assessments) if the overall disease res ponse at that 
assessment is PD.
Start dates
For all “time to event” variables, other than the duration of responses, the date of 
randomization /start of treatment will be used as the start date.
For the calculation of duration of responses the follo wing start date should be used:
Date of f irst documented response is the assessment date of the first overall disease 
response of CR (for duration of overall complete response) or CR / PR (for duration of 
overall response) respectively .
End dates
The end dates which are used to calculate ‘time to event’ va riables are defined as follows:
Date of death as reported on the CRF (on the treatment completion page, the study  
evaluation completion pa ge or survival follow -up page).
Date of last contact [CONTACT_560079] (see details in Section 14.5.5).
Date of progression 
is the first assessment date at which the overall d isease response was 
recorded as PD.
Date of last adequate assessment is the date the last assessment with overall disease 
response of CR, PR or SD which was made before an event or a censoring reason occurred. 
If no post -baseline assessments are available (before an event or a censoring reason 
occurred) the date of randomizat ion/start of treatment is used.

[COMPANY_001] Confidential Page 129
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
Date of next scheduled assessment is the date of the last adequate assessment plus the 
protocol specified time interval for assessments. This date may  beused if back -dating is 
considered when the event occurred bey ond the acceptable time window for the next 
radiologi cal assessment as per protocol.
Example (if protocol defined schedule of assessments is 3 months): tumor assessments at 
baseline - 3 months - 6 months -missing - missing - PD. Date of next scheduled 
assessment would then correspond to 9 months.
Date of treatment discontinuation is the last known date subject took st udy drug.
Date of secondary anti -cancer therapy is defined as the start date of first additional 
(secondary ) antineoplastic therap y or surgery (see details in Section 14.5.5)
[IP_ADDRESS] Censoring and sensitivity analy ses
[IP_ADDRESS].1 Censoring reasons
This section outlines the possible censoring reasons for each time to event variables. In order 
to summarize the various reasons for censoring, the following categories ( Table 14 -10) will be 
calculated for each time to event variable based on the informat ion reported on treatment 
completion page, the study  evaluat
ion page and the survival page.
Table 14-[ADDRESS_736277] to follow -up
Withdrew consent
Death due to reason other than lymphoma (only used for TTP and 
duration of response)
New anti -cancer therapy added (optional, see Table 14 -11)
Event documented after two or more missing tumor assessments 
(optional, see Table 14 -11)
Adequate assessment no longer available1
LSS Alive
Lost to follow -up
Death due to reason other than lymphoma
TTF Ongoing without event
Discontinuation for protocol deviation
Discontinuation for administrative problems
Study completed as per protocol
Event documented after two or more missing tumor assessments
Adequate assessment no longer available1
1 Adequate assessment is defined in Section [IP_ADDRESS] . This reason corresponds to any censoring reasons after 
two or more missing tumor assessments. This reason will also be used for censor in case of no baseline 
assessment

[COMPANY_001] Confidential Page 130
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
[IP_ADDRESS].2 Event date, censoring date and sensitivity analyses
This section outlines the possible event and censoring dates for progression (Table 14-11), as 
well as addressing the issues of missing tumor assessments during the study . It is important 
that the protocol and analy sis plan 
specify  the primary  analysis in detail with respect to the 
definition of event and censoring dates and also include a description of one or more 
sensitivity  anal yses to be performed.
Based on definitions outlined in Section [IP_ADDRESS], and using the draft FDA guideline on 
endpoints (FDA Guideline 2005) (Clinical Trial Endpoints for the Approval of Cancer Drugs 
and Biologics, April 2005 ) as a reference, the following anal yses can be considered:
Table 14
-11 Options for event dates used in PFS, TTP, duration of response
SituationOptions for end -date (progression)1
(1) = default unless specified differently  in 
the protocol or analy sis plan Outcome
A No baseline assessment (1) Date of randomization/start of treatment2Censor
B Progression at or before next scheduled 
assessment(1) Date of progression
(2) Date of next scheduled assessment1Event
Event
C1 Progression or death after exactly  one
missing assessment(1) Date of progression (or death)
(2) Date of next scheduled assessment1Event
Event
C2 Progression or death after two or more
missing assessments(1) Date of last adequate assessment1
(2) Date of next scheduled assessment1
(3) Date of progression (or death)Censor
Event
Event
D No progression (1) Date of last adequate assessment Censor
E Treatment discontinuation due to 
‘Disease progression’ without 
documented progression, i.e. clinical 
progression based on investigator claim(1) N/A
(2) Date of discontinuation (visit date at which 
clinical progression was determined)Ignored
Event
F New anticancer therapy given (1) Date of last adequate assessment
(2) Date of secondary anti -cancer therapy
(3) Date of secondary anti -cancer therapy
(4) N/ACensor
Censor
Event
Ignored
G Deaths due to reason other than 
lymphoma(1) Date of last adequate assessment Censor (only  
TTP and 
duration of 
response)
1 = Definitions can be found in Section [IP_ADDRESS] .
2 = The rare exception to this is if the patient dies no later than the time of the second scheduled assessment as 
defined in the protocol in which case this is a PFS event at the date of death.
Situations C (C1 and C2): Progression or death after one or more missing assessments: The 
primary  anal ysis is usually  using options (1) for situations C1 and C2, i.e.
(C1) taking the actual progression or death date, in the case of only  one missing 
assessment.
(C2) censoring at the date of the last adequate assessment, in the case of two or mor e 
consecutive missing assessments.
In the case of two ormore missing assessments (situation C2), option (3) may be considered 
jointly  with option (1) in situation C1 as sensitivity  analysis. A variant of this sensitivity  

[COMPANY_001] Confidential Page 131
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
analysis consists of backdating th e date of event to the next scheduled assessment as proposed 
with option (2) in situations C1 and C2.
Situation E:Treatment discontinuation due to ‘Disease progression’ without documented 
progression: By [CONTACT_15094], option (1) is used for situation E as patients without documented PD 
should be followed for progression after discontinuation of treatment. However, option (2) 
may be used as sensitivity  analysis. If progression is claimed based on clinical deterioration 
instead of tumor assessment by  e.g. CT -scan, option (2) may  be used for indications with high 
early progression rate or difficulties to assess the tumor due to clinical deterioration.
Situation F: New cancer therapy given : the handling of this situation must be specified in 
detail in the protoc ol. However, option (1), i.e. censoring at last adequate assessment may be 
used as a default in this case.
Additional suggestions for sensitivity analyses
Other suggestions for additional sensitivity  anal yses may  include analy ses to check for 
potential bia s in follow -up schedules for tumor assessments, e.g.: By  [CONTACT_560080]. The latter could be handled by  
[CONTACT_15097] 14 -11the “Date of last adequate assessment” by  [CONTACT_941] “Date of previous 
scheduled assessment (from baseline)”, with the following definition:
Date of previous scheduled assessment (from baseline) is the date when a tumor 
assessment would have taken place, if the protocol asses sment scheme was strictly  followed 
from baseline, immediately  before or on the date o f the last adequate assessment.
By [CONTACT_560081] B- symptoms or enlarged spleen/liver as a 
documented progression with a date of progression b eing the one of those symptoms.
The need for these t ypes of sensitivity  analyses will depend on the individual requirements for 
the specific study  and disease area and have to be specified in the Study Protocol or RAP 
documentation.
14.5.5 Data handling and progr amming conventions
The following could be used for programming of efficacy  results, but should be specified in 
the RAP documentation:
Calculati on of ‘time to event’ variables
Time to event = end date –start date + 1 (in day s)
When no post-baseline assessm ents are available, the date of randomization/start of treatment 
will be used as end date (duration = 1 day ) when time is to be censored at last assessment, i.e. 
time to event v ariables can never be negative.
Date of last contact
[CONTACT_111928]:

[COMPANY_001] Confidential Page 132
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
All assessment dates (e.g. vital signs assessment, performance status assessment, and also 
assessment date in third -party  data such as tumor imaging , central laboratory , ECG etc.)
Medication dates including stud y medication, concomitant medications, antineoplastic 
therapi[INVESTIGATOR_560044] s tudy treatment discontinuation.
Adverse events dates
Last contact [CONTACT_560082] t
he ‘Survival information’ eCRF.
Randomization date.
Date o f secondary  anti-cancer therapy
The date of secondary  anti-cancer therap y is the date of the 1st antineoplastic therapy  or 
surgery  reported in the concomitant medications page, further antineoplastic therap y page or 
from other sources (e.g. Dosa ge administration record page).
Incomplete assessment dates
All investigation dates (e.g. X -ray, CT scan) must be completed with day , month and y ear.
If one or more investigation dates are incomplete but other investigation dates are available, 
this/th ese incomplete date(s) are not considered for calculation of the assessment date (and 
assessment date is calculated as outlined in Section [IP_ADDRESS]). If all measurement dates have 
no day  recorded, the 1stof the month is used.
If the month is not completed, for any of the investigations, the respective 
assessment will be 
considered to be at the date which is exactly  between previous and following assessment. If a 
previous and following assessment is notavailable, this assessment will not be used for any 
calculation.
Incomplete dates for last conta ct or death
All dates must be completed with day, month and year. If the day is missing, the 15thof the 
month will be used for incomplete death dates or dates of last contact.
Study/project specific programming
The standard anal ysis programs need to be adapted for each stud y/project.

[COMPANY_001] Confidential Page 133
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
14.5.6 References (available upon request)
Cheson BD (2007a) The international harmonization project for response criteria in 
lymphoma c linical trials. Hema tol Oncol Clin N Am 21:841-854.
Cheson BD (2009) The case against heav y PETing. J Clin Oncol 27: 1742 -1743.
Cheson BD, Horning SJ, Coiffier B, et al (1999) Report of an International Workshop to 
standardize response criteria for non -Hodg kin's l ympho mas. J Clin Oncol 17:1244 -
1253.
Cheson BD, Pfistner B, Juweid ME, et al (2007b) Revised response criteria for malignant 
lymphoma. J Clin Oncol 25:579-586.
FDA Guideline (2005) Clinical Trial Endpoints for the Approval of Cancer D rugs and 
Biolog ics, April 2005.
Pursche S, Schelever E, von Bonin M, et al (2008) Influence of enzy me-inducing antiepi[INVESTIGATOR_560045]. Curr. Clin. Pharmacol; 3 (3): 198 -
203
Zhou S -F, Liu J -P, Chowbay  B (2009) Poly morphism of human cy tochrome P450 enzy mes 
and its clinical impact. Drug Metabolism Reviews; 41(2): 89-295

[COMPANY_001] Confidential Page 134
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
14.5.7 Appendices
Figure 14-1 Appendix A  -Definition of index nodal lesion, non -index nodal lesion, 
index extranodal lesion, non -index extranodal lesion

[COMPANY_001] Confidential Page 135
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
Figure 14-2 Appendix B -Calculation of the response for index lesions

[COMPANY_001] Confidential Page 136
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
Figure 14-3 Appendix C -Calculation of the response for non -index lesions

[COMPANY_001] Confidential Page 137
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
Figure 14-4 Appendix D -Calculation of the overall disease response

[COMPANY_001] Confidential Page 138
Amended Protocol Version 04 (Clean) Protocol No. CBKM120Z2402
Appendix E - Adaptation for use in maintenance/adjuvant settings
For settings in which no measurable disease is present at baseline (e.g. maintenance), this 
guideline can be adapted. In such settin g, as patients have no more measurable disease at 
baseline, the event of main interest is no more the Progressive Disease but the Relapsed 
Disease and the main endpoint is no more the Progression- free survival but the Disease -free 
survival. The definitions that need to be considered are presented below:
Relapsed Disease
The definition of Relapsed Disease can be derived from the definition of New Lesion (see 
Section [IP_ADDRESS].3) and is as follow:
Appearanc e of the following will alway s be considered as Relapsed Disease (RD)
any new nodal lesion > 15 mm in any  axis (i.e. previously  normal l ymph node becoming > 
15 mm in any  axis) on CT scan or MRI after baseline, or
any discrete extranodal lesion (including l iver or spleen) reliabl y appearing on CT
scan or 
MRI  after baseline, or
≥ 50% increase in long axis from baseline of any  residual ly mph node or mass. A residual 
lymph node or mass is defined as a previously  lymphoma -involved ly mph node or mass 
(>10 mm in short axis (without any  upper limit)) that was PET scan negative at baseline 
and only  reliabl y detected by  [CONTACT_111931].
Note : If a residual lymph node or mass at baseline decreases in size during treatment and 
becomes normal (i.e. complete disappeara nce of extranodal mass or ≤ 10 mm in short axis 
and ≤ 15 mm long axis for nodal mass), then reappearance of an extranodal lesion at the 
same site or increase of the same nodal mass to > 15 mm in the long axis, will be 
considered as Relapsed Disease and nee d to be recorded as a new lesion in the 
appropriate module of the CRF.
Disease -Free Survival
Disease -Free Survival (DFS) is the time from date of randomization/ start of treatment to the 
date of event defined as the first documented relapse of the disease or death due to any cause. 
If a patient has not had an event, disease -free survival is censored at the date of the last 
adequate assessment.
